IL-12/p40 binding proteins

ABSTRACT

The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.

CROSS-REFERENCE TO RELATED APPLICATION

This application claims the benefit of priority to U.S. provisionalapplication No. 60/695,679 filed Jun. 30, 2005.

This application is related to U.S. patent application Ser. No.09/534,717 filed on Mar. 24, 2000 (issued as U.S. Pat. No. 6,914,128)entitled “Human antibodies that bind human IL-12 and methods forproducing.” The entire contents of this patent application, and patentsissued therefrom, are hereby incorporated herein by reference.

REFERENCE TO JOINT RESEARCH AGREEMENT

Contents of this application are under a joint research agreemententered into by and between Protein Design Labs, Inc. and AbbottLaboratories on Dec. 14, 2005, and directed to recombinantly engineeredantibodies.

FIELD OF THE INVENTION

The present invention relates to IL-12p40 binding proteins, andspecifically to their uses in the prevention and/or treatment of acuteand chronic inflammatory diseases.

BACKGROUND OF THE INVENTION

Human interleukin-12 (IL-12) is a cytokine with a unique structure andpleiotropic effects (Kobayashi, et al. (1989) J Exp Med 170:827-845;Seder, et al. (1993) Proc. Natl. Acad. Sci. 90:10188-10192, Ling, et al.(1995) J Exp Med 154:116-127; Podlaski, et al. (1992) Arch. Biochem.Biophys. 294:230-237). IL-12 plays a critical role in the pathologyassociated with several diseases involving immune and inflammatoryresponses. A review of IL-12, its biological activities, and its role indisease can be found in Trinchieri, G. (2003) Nat. Rev. Immun.3:133-146. Structurally, IL-12 is a heterodimeric protein (referred toas the “p70 protein”) comprising a 35 kDa subunit (p35) and a 40 kDasubunit (p40) which are linked together by a disulfide bridge. Theheterodimeric protein is produced primarily by antigen-presenting cellssuch as monocytes, macrophages and dendritic cells. These cell typesalso secrete an excess of the p40 subunit relative to p70 subunit. Thep40 and p35 subunits are genetically unrelated and neither has beenreported to possess biological activity, although the p40 homodimer mayfunction as an IL-12 antagonist.

Functionally, IL-12 plays a central role in regulating the balancebetween antigen-specific T helper type 1 (Th1) and type 2 (Th2)lymphocytes. The Th1 and Th2 cells govern the initiation and progressionof autoimmune disorders, and IL-12 is critical in the regulation ofTh1-lymphocyte differentiation and maturation. Cytokines released by theTh1 cells are inflammatory and include interferon gamma (IFN-γ), IL-2,and lymphotoxin (LT). Th2 cells secrete IL-4, IL-5, IL-6, IL-10 andIL-13 to facilitate humoral immunity, allergic reactions, andimmunosuppression. Consistent with the preponderance of Th1 responses inautoimmune diseases and the proinflammatory activities of IFN-γ, IL-12may play a major role in the pathology associated with many autoimmuneand inflammatory diseases such as rheumatoid arthritis (RA), multiplesclerosis (MS), psoriasis (PS) and Crohn's disease (CD).

Human patients with MS have demonstrated an increase in IL-12 expressionas documented by p40 mRNA levels in acute MS plaques (Windhagen et al.,(1995) J Exp. Med. 182:1985-1996). In addition, ex vivo stimulation ofantigen-presenting cells with CD40L expressing T cells from MS patientsresulted in increased IL-12 production compared with control T cells,consistent with the observation that CD40/CD40L interactions are potentinducers of IL-12. Elevated levels of IL-12 p70 have been detected inthe synovia of RA patients compared with healthy controls (Morita et al.(1998) Arth. and Rheumat. 41:306-314). Cytokine messenger ribonucleicacid (mRNA) expression profile in the RA synovia identifiedpredominantly Th1 cytokines (Bucht et al. (1996) Clin. Exp. Immunol.103:347-367). IL-12 also appears to play a critical role in thepathology associated with Crohn's disease. Increased expression of INF-γand IL-12 has been observed in the intestinal mucosa of patients withthis disease (Fais et al. (1994) J Interferon Res. 14:235-238; Parronchiet al. (1997) Am. J. Path. 150:823-832; Monteleone et al. (1997)Gastroent. 112:1169-1178, and Berrebi et al. (1998) Am. J Path152:667-672). The cytokine secretion profile of T cells from the laminapropria of CD patients is characteristic of a predominantly Th1response, including greatly elevated IFN-γ levels (Fuss, et al. (1996) JImmunol. 157:1261-1270). Moreover, colon tissue sections from CDpatients show an abundance of IL-12 expressing macrophages and IFN-γexpressing T cells (Parronchi et al (1997) Am. J. Path. 150:823-832).

IL-23 is also a heterodimeric cytokine and belongs to a family of fivesuch heterodimeric cytokines including IL-12 and IL-27 (Trinchieri etal., (2003) Immunity 19:641-644). IL-23 shares the identical p40 subunitas IL-12, but it is associated with a p19 subunit via adisulphide-linkage. The p19 subunit is structurally related to IL-6,granulocyte-colony stimulating factor (G-CSF), and the p35 subunit ofIL-12. IL-23 is produced by similar cell types as IL-12, and itsreceptor is expressed on T cells, NK cells, and phagocytic and dendritichematopoietic cells. IL-23 mediates signaling by binding to aheterodimeric receptor, comprised of IL-23R and IL-12beta1. TheIL-12beta1 subunit is shared by the IL-12 receptor, which is composed ofIL-12beta1 and IL-12beta2. IL-23 does share overlapping functions withIL-12 (by inducing IFN-γ production, Th1 cell differentiation andactivating the antigen-presenting functions of dendritic cells) howeverit selectively induces proliferation of memory T cells (Oppmann et al.(2000) Immunity 13:715-725, Parham, et al. (2002) J. Immunol.168:5699-5708).

The role of IL-23 in autoimmune inflammation has been dissected in partthrough studies with p19 knockout mice (Murphy et al. J Exp Med198:1951-1957; Cua et al. (2003) Nature 421:744-748). Studies havedemonstrated that IL-23 modulates immune response to infection (see,e.g., Pirhonen, et al. (2002) J. Immunol. 169:5673-5678; Broberg, et al.(2002) J. Interferon Cytokine Res. 22:641-651; Elkins, et al. (2002)Infection Immunity 70:1936-1948; Cooper, et al. (2002) J. Immunol.168:1322-1327). IL-23 is thought to play a role in immune-mediatedinflammatory diseases (Langrish et. al. (2004) Immunological Reviews202: 96-105).

Due to the role of human IL-12 in a variety of human disorders,therapeutic strategies have been designed to inhibit or counteract IL-12activity. In particular, antibodies that bind to, and neutralize, IL-12have been sought as a means to inhibit IL-12 activity. Some of theearliest antibodies were murine monoclonal antibodies (mAbs), secretedby hybridomas prepared from lymphocytes of mice immunized with IL-12(see e.g., Strober et al., PCT Publication No. WO 97/15327; Gately etal., WO9937682 A2; Neurath et al., J Exp. Med 182:1281-1290 (1995);Duchmarm et al., J Immunol. 26:934-938 (1996)). These murine IL-12antibodies are limited for their use in vivo due to problems associatedwith administration of mouse antibodies to humans, such as short serumhalf life, an inability to trigger certain human effector functions andelicitation of an unwanted immune response against the mouse antibody ina human (the “human anti-mouse antibody” (HAMA) reaction).

One approach to overcome the problem problems associated with use offully murine antibodies in humans is to generate fully human antibodiessuch as those disclosed in Salfeld et al., PCT publication No. WO00/56772 A1. Other approaches to overcome the problems associated withuse of fully murine antibodies in humans have involved geneticallyengineering the antibodies to be more “human-like.” For example,chimeric antibodies, in which the variable regions of the antibodychains are murine-derived and the constant regions of the antibodychains are human-derived, have been prepared (Junghans, et al. (1990)Cancer Res. 50:1495-1502; Brown et al. (1991) Proc. Natl. Acad. Sci.88:2663-2667; Kettleborough et al. (1991) Prot. Engineer. 4:773-783).Such chimeric antibodies to IL-12 are also disclosed in Peritt et al.PCT publication No. WO2002097048A2. However, because these chimericantibodies still retain murine variable chain sequences, they still mayelicit an unwanted immune reaction, the human anti-chimeric antibody(HACA) reaction especially when administered for prolonged periods.

There is a need in the art for improved antibodies capable of bindingthe p40 subunit of IL-12 (IL-12p40). Preferably the antibodies bindIL-12 and/or IL-23. Preferably the antibodies are capable ofneutralizing IL-12 and/or IL-23. The present invention provides a novelfamily of binding proteins, CDR grafted antibodies, humanizedantibodies, and fragments thereof, capable binding IL-12p40, bindingwith high affinity, and binding and neutralizing IL-12 and/or IL-23.

SUMMARY OF THE INVENTION

This invention pertains to IL-12p40 binding proteins, particularlyantibodies capable of binding the p40 subunit of human IL-12 and the p40subunit of human IL-23. Further, the invention provides methods ofmaking and using IL-12p40 binding proteins.

One aspect of this invention pertains to a binding protein comprising anantigen binding domain capable of binding a p40 subunit of IL-12. In oneembodiment the antigen binding domain comprises at least one CDRcomprising an amino acid sequence selected from the group consisting of:

-   -   CDR-H1. X₁-X₂-X₃-X₄-X₅-X₆-X₇ (SEQ ID NO: 55), wherein;        -   X₁ is D, K, T, or S;        -   X₂ is Y, S, or T;        -   X₃ is Y, V, G, W, S, or F;        -   X₄ is I, or M;        -   X₅ is H, G, E, or V;        -   X₆ is V, or is not present; and        -   X₇ is S, or is not present;    -   CDR-H2.        X₁-X₂-X₃-X₄-X₅-X₆-X₇-X₈-X₉-X₁₀-X₁₁-X₁₂-X₁₃-X₁₄-X₁₅-X₁₆-X₁₇-X₁₈-X₁₉-X₂₀        (SEQ ID NO: 56), wherein;        -   X₁ is H, D, G, W, S, Y or R;        -   X₂ is I, or F;        -   X₃ is Y, W, L, S, N, D or G;        -   X₄ is W, P, H, T, or S;        -   X₅ is D, G, E, A, or I;        -   X₆ is D, G, S, T, or N;        -   X₇ is D, G, S, or P;        -   X₈ is K, N, S, E, T, or H;        -   X₉ is Y, T, P, I, or N;        -   X₁₀ is Y, N, T, H, K, S, or G;        -   X₁₁, is N, or Y;        -   X₁₂ is P, N, A, D, or S;        -   X₁₃ is S, E, D, or P;        -   X₁₄ is L, K, D, T, or Y;        -   X₁₅ is K, F, V, M, R, or A;        -   X₁₆ is S, K, Q, P, or is not present;        -   X₁₇ is D, G, R, or is not present;        -   X₁₈ is F, or is not present;        -   X₁₉ is Q, or is not present; and        -   X₂₀ is D, or is not present;    -   CDR-H3. X₁-X₂-X₃-X₄-X₅-X₆-X₇-X₈-X₉-X₁₀-X₁₁-X₁₂-X₁₃ (SEQ ID NO:        57), wherein;        -   X₁ is R, N, or W;        -   X₂ is G, T, R, P, or H;        -   X₃ is I, R, F, Y, or Q;        -   X₄ is R, V, Y, F, or A;        -   X₅ is S, N, G, A, or R;        -   X₆ is A, Y, L, F, or M;        -   X₇ is M, A, D, L, or F;        -   X₈ is D, M, Y, or W;        -   X₉ is Y, D, or N;        -   X₁₀ is Y, A, or is not present;        -   X₁₁ is M, or is not present;        -   X₁₂ is D, or is not present; and        -   X₁₃ is Y, or is not present;    -   CDR-L1. X₁-X₂-X₃-X₄-X₅-X₆-X₇-X₈-X₉-X₁₀-X₁₁-X₁₂-X₁₃-X₁₄-X₁₅ (SEQ        ID NO: 58), wherein;        -   X₁ is K, or R;        -   X₂ is A;        -   X₃ is S;        -   X₄ is Q, or E;        -   X₅ is S, or N;        -   X₆ is V, or I;        -   X₇ is S, G, or D;        -   X₈ is N, T, or K;        -   X₉ is D, N, or Y;        -   X₁₀ is V, G, or L;        -   X₁₁ is A, I, or H;        -   X₁₂ is S, or is not present;        -   X₁₃ is F, or is not present;        -   X₁₄ is M, or is not present; and        -   X₁₅ is N, or is not present;    -   CDR-L2. X₁-X₂-X₃-X₄-X₅-X₆-X₇-X₈ (SEQ ID NO: 59), wherein;        -   X₁ is Y, or S;        -   X₂ is A, or T;        -   X₃ is S, or A;        -   X₄ is N, H, S, or Q;        -   X₅ is R, N, or S;        -   X₆ is Y, Q, or I;        -   X₇ is T, S, or G; and        -   X₈ is S, or is not present;

and

-   -   CDR-L3. X₁-X₂-X₃-X₄-X₅-X₆-X₇-X₈-X₉ (SEQ ID NO: 60), wherein;        -   X₁ is Q;        -   X₂ is Q;        -   X₃ is D, Y, or S;        -   X₄ is Y, N, K, or I;        -   X₅ is N, T, S, or E;        -   X₆ is S, Y, V, or W;        -   X₇ is P;        -   X₈ is W, F, Y, L, or P; and        -   X₉ is T, or S.

Preferably, the antigen binding domain comprises at least one CDRcomprising an amino acid sequence selected from the group consisting ofresidues 31-37 of SEQ ID NO.:35; residues 52-67 of SEQ ID NO.:35;residues 100-108 of SEQ ID NO.:35; residues 24-34 of SEQ ID NO.:36;residues 50-56 of SEQ ID NO.:36; residues 89-97 of SEQ ID NO.:36;residues 31-37 of SEQ ID NO.:37; residues 52-67 of SEQ ID NO.:37;residues. 100-109 of SEQ ID NO.:37; residues 24-34 of SEQ ID NO.:38;residues 50-56 of SEQ ID NO.:38; residues 89-97 of SEQ ID NO.:38;residues 31-35 of SEQ ID NO.:39; residues 50-66 of SEQ ID NO.:39;residues 99-106 of SEQ ID NO.:39; residues 24-34 of SEQ ID NO.:40;residues 50-56 of SEQ ID NO.:40; residues 89-97 of SEQ ID NO.:40;residues 31-35 of SEQ ID NO.:41; residues 50-66 of SEQ ID NO.:41;residues 99-106 of SEQ ID NO.:41; residues 24-34 of SEQ ID NO.:42;residues 50-56 of SEQ ID NO.:42; residues 89-97 of SEQ ID NO.:42;residues 31-35 of SEQ ID NO.:43; residues 50-66 of SEQ ID NO.:43;residues 99-106 of SEQ ID NO.:43; residues 24-34 of SEQ ID NO.:44;residues 50-56 of SEQ ID NO.:44; residues 89-97 of SEQ ID NO.:44;residues 31-35 of SEQ ID NO.:45; residues 50-66 of SEQ ID NO.:45;residues 99-101 of SEQ ID NO.:45; residues 24-34 of SEQ ID NO.:46;residues 50-56 of SEQ ID NO.:46; residues 89-97 of SEQ ID NO.:46;residues 31-35 of SEQ ID NO.:47; residues 50-66 of SEQ ID NO.:47;residues 99-106 of SEQ ID NO.:47; residues 24-34 of SEQ ID NO.:48;residues 50-56 of SEQ ID NO.:48; residues 89-97 of SEQ ID NO.:48;residues 31-35 of SEQ ID NO.:49; residues 50-66 of SEQ ID NO.:49;residues 99-111 of SEQ ID NO.:49; residues 24-38 of SEQ ID NO.:50;residues 53-60 of SEQ ID NO.:50; residues 93-101 of SEQ ID NO.:50;residues 31-37 of SEQ ID NO.:51; residues 52-67 of SEQ ID NO.:51;residues 100-109 of SEQ ID NO.:51; residues 24-34 of SEQ ID NO.:52;residues 50-56 of SEQ ID NO.:52; residues 89-97 of SEQ ID NO.:52;residues 31-35 of SEQ ID NO.:53; residues 47-66 of SEQ ID NO.:53;residues 99-107 of SEQ ID NO.:53; residues 24-34 of SEQ ID NO.:54;residues 50-56 of SEQ ID NO.:54; and residues 89-97 of SEQ ID NO.:54. Ina preferred embodiment, the binding protein comprises at least 3 CDRsselected from the group consisting of the sequences disclosed above.More preferably the 3 CDRs selected are from sets of variable domainCDRs selected from the group consisting of:

VH 1D4 CDR Set VH 1D4 CDR-H1 Residues 31-37 of SEQ ID NO.: 35 VH 1D4CDR-H2 Residues 52-67 of SEQ ID NO.: 35 VH 1D4 CDR-H3 Residues 100-108of SEQ ID NO.: 35 VL 1D4 CDR Set VL 1D4 CDR-L1 Residues 24-34 of SEQ IDNO.: 36 VL 1D4 CDR-L2 Residues 50-56 of SEQ ID NO.: 36 VL 1D4 CDR-L3Residues 89-97 of SEQ ID NO.: 36 VH 1A6 CDR Set VH 1A6 CDR-H1 Residues31-37 of SEQ ID NO.: 37 VH 1A6 CDR-H2 Residues 52-67 of SEQ ID NO.: 37VH 1A6 CDR-H3 Residues 100-109 of SEQ ID NO.: 37 VL 1A6 CDR Set VL 1A6CDR-L1 Residues 24-34 of SEQ ID NO.: 38 VL 1A6 CDR-L2 Residues 50-56 ofSEQ ID NO.: 38 VL 1A6 CDR-L3 Residues 89-97 of SEQ ID NO.: 38 VH 1D8 CDRSet VH 1D8 CDR-H1 Residues 31-35 of SEQ ID NO.: 39 VH 1D8 CDR-H2Residues 50-66 of SEQ ID NO.: 39 VH 1D8 CDR-H3 Residues 99-106 of SEQ IDNO.: 39 VL 1D8 CDR Set VL 1D8 CDR-L1 Residues 24-34 of SEQ ID NO.: 40 VL1D8 CDR-L2 Residues 50-56 of SEQ ID NO.: 40 VL 1D8 CDR-L3 Residues 89-97of SEQ ID NO.: 40 VH 3G7 CDR Set VH 3G7 CDR-H1 Residues 31-35 of SEQ IDNO.: 41 VH 3G7 CDR-H2 Residues 50-66 of SEQ ID NO.: 41 VH 3G7 CDR-H3Residues 99-106 of SEQ ID NO.: 41 VL 3G7 CDR Set VL 3G7 CDR-L1 Residues24-34 of SEQ ID NO.: 42 VL 3G7 CDR-L2 Residues 50-56 of SEQ ID NO.: 42VL 3G7 CDR-L3 Residues 89-97 of SEQ ID NO.: 42 VH 5E8 CDR Set VH 5E8CDR-H1 Residues 31-35 of SEQ ID NO.: 43 VH 5E8 CDR-H2 Residues 50-66 ofSEQ ID NO.: 43 VH 5E8 CDR-H3 Residues 99-106 of SEQ ID NO.: 43 VL 5E8CDR Set VL 5E8 CDR-L1 Residues 24-34 of SEQ ID NO.: 44 VL 5E8 CDR-L2Residues 50-56 of SEQ ID NO.: 44 VL 5E8 CDR-L3 Residues 89-97 of SEQ IDNO.: 44 VH 8E1 CDR Set VH 8E1 CDR-H1 Residues 31-35 of SEQ ID NO.: 45 VH8E1 CDR-H2 Residues 50-66 of SEQ ID NO.: 45 VH 8E1 CDR-H3 Residues99-101 of SEQ ID NO.: 45 VL 8E1 CDR Set VL 8E1 CDR-L1 Residues 24-34 ofSEQ ID NO.: 46 VL 8E1 CDR-L2 Residues 50-56 of SEQ ID NO.: 46 VL 8E1CDR-L3 Residues 89-97 of SEQ ID NO.: 46 VH 1H6 CDR Set VH 1H6 CDR-H1Residues 31-35 of SEQ ID NO.: 47 VH 1H6 CDR-H2 Residues 50-66 of SEQ IDNO.: 47 VH 1H6 CDR-H3 Residues 99-106 of SEQ ID NO.: 47 VL 1H6 CDR SetVL 1H6 CDR-L1 Residues 24-34 of SEQ ID NO.: 48 VL 1H6 CDR-L2 Residues50-56 of SEQ ID NO.: 48 VL 1H6 CDR-L3 Residues 89-97 of SEQ ID NO.: 48VH 3A11 CDR Set VH 3A11 CDR-H1 Residues 31-35 of SEQ ID NO.: 49 VH 3A11CDR-H2 Residues 50-66 of SEQ ID NO.: 49 VH 3A11 CDR-H3 Residues 99-111of SEQ ID NO.: 49 VL 3A11 CDR Set VL 3A11 CDR-L1 Residues 24-38 of SEQID NO.: 50 VL 3A11 CDR-L2 Residues 53-60 of SEQ ID NO.: 50 VL 3A11CDR-L3 Residues 93-101 of SEQ ID NO.: 50 VH 4B4 CDR Set VH 4B4 CDR-H1Residues 31-37 of SEQ ID NO.: 51 VH 4B4 CDR-H2 Residues 52-67 of SEQ IDNO.: 51 VH 4B4 CDR-H3 Residues 100-109 of SEQ ID NO.: 51 VL 4B4 CDR SetVL 4B4 CDR-L1 Residues 24-34 of SEQ ID NO.: 52 VL 4B4 CDR-L2 Residues50-56 of SEQ ID NO.: 52 VL 4B4 CDR-L3 Residues 89-97 of SEQ ID NO.: 52VH 7G3 CDR Set VH 7G3 CDR-H1 Residues 31-35 of SEQ ID NO.: 53 VH 7G3CDR-H2 Residues 47-66 of SEQ ID NO.: 53 VH 7G3 CDR-H3 Residues 99-107 ofSEQ ID NO.: 53 And VL 7G3 CDR Set VL 7G3 CDR-L1 Residues 24-34 of SEQ IDNO.: 54 VL 7G3 CDR-L2 Residues 50-56 of SEQ ID NO.: 54 VL 7G3 CDR-L3Residues 89-97 of SEQ ID NO.: 54

In one embodiment the binding protein of the invention comprises atleast two variable domain CDR sets. More preferably, the two variabledomain CDR sets are selected from a group consisting of: VH 1D4 CDR Set& VL 1D4 CDR Set; VH 1A6 CDR Set & VL 1A6 CDR Set; VH 1D8 CDR Set & VL1D8 CDR Set; VH 3G7 CDR Set & VL 3G7 CDR Set; VH 5E8 CDR Set & VL 5E8CDR Set; VH 8E1 CDR Set & VL 8E1 CDR Set; VH 1H6 CDR Set & VL 1H6 CDRSet; VH 3A11 CDR Set & VL 3A11 CDR Set; VH 4B4 CDR Set & VL 4B4 CDR Set;and VH 7G3 CDR Set & VL 7G3 CDR Set.

In another embodiment the binding protein disclosed above furthercomprises a human acceptor framework. Preferably the human acceptorframework comprises a amino acid sequence selected from the groupconsisting of SEQ ID NO.:6; SEQ ID NO.:7; SEQ ID NO.:8; SEQ ID NO.:9;SEQ ID NO.:10; SEQ ID NO.:11; SEQ ID NO.:12; SEQ ID NO.:13; SEQ IDNO.:14; SEQ ID NO.:15; SEQ ID NO.:16; SEQ ID NO.:17; SEQ ID NO.:18; SEQID NO.:19; SEQ ID NO.:20; SEQ ID NO.:21; SEQ ID NO.:22; SEQ ID NO.:23;SEQ ID NO.:24; SEQ ID NO.:25; SEQ ID NO.:26; SEQ ID NO.:27; SEQ IDNO.:28; SEQ ID NO.:29; SEQ ID NO.:30; SEQ ID NO.:31; SEQ ID NO.:32; SEQID NO.:33; SEQ ID NO.:34, SEQ ID NO.:92, SEQ ID NO.:93, SEQ ID NO.:94,SEQ ID NO.:95, SEQ ID NO.:96, AND SEQ ID NO.:97.

In a preferred embodiment the binding protein is a CDR grafted antibodyor antigen binding portion thereof capable of binding the p40 subunit ofIL-12 or IL-23. Preferably the CDR grafted antibody or antigen bindingportion thereof comprise one or more CDRs disclosed above. Morepreferably the CDR grafted antibody or antigen binding portion thereofcomprises at least one variable domain having an amino acid sequenceselected from the group consisting of SEQ ID NO.:61; SEQ ID NO.:62; SEQID NO.:63; SEQ ID NO.:64; SEQ ID NO.:65; SEQ ID NO.:66; SEQ ID NO.:67;SEQ ID NO.:68; SEQ ID NO.:69; SEQ ID NO.:70; SEQ ID NO.:71; SEQ IDNO.:72; SEQ ID NO.:73; SEQ ID NO.:74; SEQ ID NO.:75; SEQ ID NO.:76; SEQID NO.:77; and SEQ ID NO.:78. Most preferably the CDR grafted antibodyor antigen binding portion thereof comprises two variable domainsselected from the group disclosed above. Preferably the CDR graftedantibody or antigen binding portion thereof comprises a human acceptorframework. More preferably the human acceptor framework is any one ofthe human acceptor frameworks disclosed above.

In a preferred embodiment the binding protein is a humanized antibody orantigen binding portion thereof capable of binding the p40 subunit ofIL-12 or IL-23. Preferably the humanized antibody or antigen bindingportion thereof comprise one or more CDRs disclosed above incorporatedinto a human antibody variable domain of a human acceptor framework.Preferably the human antibody variable domain is a consensus humanvariable domain. More preferably the human acceptor framework comprisesat least one Framework Region amino acid substitution at a key residue,wherein the key residue is selected from the group consisting of aresidue adjacent to a CDR; a glycosylation site residue; a rare residue;a residue capable of interacting with a p40 subunit of human IL-12; aresidue capable of interacting with a CDR; a canonical residue; acontact residue between heavy chain variable region and light chainvariable region; a residue within a Vernier zone; and a residue in aregion that overlaps between a Chothia-defined variable heavy chain CDR1and a Kabat-defined first heavy chain framework. Preferably the keyresidue is selected from the group consisting of 3H, 5H, 10H, 11H, 12H,13H, 15H, 16H, 18H, 19H, 23H, 24H, 25H, 30H, 41H, 44H, 46H, 49H, 66H,68H, 71H, 73H, 74H, 75H, 76H, 77H, 78H, 79H, 81H, 82H, 82AH, 82BH, 82CH,83H, 84H, 85H, 86H, 87H, 89H, 93H, 98H, 108H, 109H, 1L, 2L, 3L, 7L, 8L,9L, 10L, 11L, 12L, 13L, 15L, 17L, 19L, 20L, 21L, 22L, 36L, 41L, 42L,43L, 45L, 46L, 58L, 60L, 62L, 63L, 67L, 70L, 73L, 74L, 77L, 78L, 79L,80L, 83L, 85L, 87L, 104L, and 106L. Preferably the human acceptorframework human acceptor framework comprises at least one FrameworkRegion amino acid substitution, wherein the amino acid sequence of theframework is at least 65% identical to the sequence of said humanacceptor framework and comprises at least 70 amino acid residuesidentical to said human acceptor framework.

In a preferred embodiment the binding protein is a humanized antibody orantigen binding portion thereof capable of binding the p40 subunit ofIL-12 or IL-23. Preferably the humanized antibody, or antigen bindingportion, thereof comprises one or more CDRs disclosed above. Morepreferably the humanized antibody, or antigen binding portion, thereofcomprises three or more CDRs disclosed above. Most preferably thehumanized antibody, or antigen binding portion, thereof comprises sixCDRs disclosed above.

In another embodiment of the claimed invention, the humanized antibodyor antigen binding portion thereof comprises at least one variabledomain having an amino acid sequence selected from the group consistingof SEQ ID NO.:79, SEQ ID NO.:80, SEQ ID NO.:81, SEQ ID NO.:82, SEQ IDNO.:83, SEQ ID NO.:84, SEQ ID NO.:85, SEQ ID NO.:86, SEQ ID NO.:87, SEQID NO.:88, SEQ ID NO.:89, SEQ ID NO.:90, SEQ ID NO.:91, SEQ ID NO.:98,SEQ ID NO.:99, SEQ ID NO.:100, SEQ ID NO.:101, SEQ ID NO.:102, AND SEQID NO.:103, SEQ ID NO.:104, SEQ ID NO.:105, SEQ ID NO.:106, SEQ IDNO.:107, SEQ ID NO.:108, and SEQ ID NO.:109. More preferably thehumanized antibody or antigen binding portion thereof comprises twovariable domains selected from the group disclosed above. Mostpreferably humanized antibody, or antigen binding portion thereofcomprises two variable domains, wherein said two variable domains haveamino acid sequences selected from the group consisting of SEQ ID NO.:67& SEQ ID NO.:79, SEQ ID NO.:80 & SEQ ID NO.:81, SEQ ID NO.:82 & SEQ IDNO.:83, SEQ ID NO.:84 & SEQ ID NO.:85, SEQ ID NO.:86 & SEQ ID NO.:87,SEQ ID NO.:88 & SEQ ID NO.:89, SEQ ID NO.:90 & SEQ ID NO.:91, SEQ IDNO.:98 & SEQ ID NO.:99, SEQ ID NO.:100 & SEQ ID NO.:101, SEQ ID NO.:102& SEQ ID NO.:103, SEQ ID NO.:104 & SEQ ID NO.:105, SEQ ID NO.:106 & SEQID NO.:107, and SEQ ID NO.:108 & SEQ ID NO.:109.

In a preferred embodiment the binding protein disclosed above comprisesa heavy chain immunoglobulin constant domain selected from the groupconsisting of a human IgM constant domain, a human IgG1 constant domain,a human IgG2 constant domain, a human IgG3 constant domain, a human IgG4constant domain, a human IgE constant domain, and a human IgA constantdomain. More preferably, the binding protein comprises SEQ ID NO.:2; SEQID NO.:3; SEQ ID NO.:4; and SEQ ID NO.:5.

The binding protein of the invention is capable of binding a targetselected from the group consisting of IL-12 and IL-23. Preferably thebinding protein is capable of modulating a biological function of atarget selected from the group consisting of IL-12 and IL-23. Morepreferably the binding protein is capable of neutralizing a targetselected from the group consisting of IL-12 and IL-23.

In one embodiment, the binding protein of the invention has an on rateconstant (Kon) to IL-12 or IL-23 of at least about 10²M⁻¹s⁻¹; at leastabout 10³M⁻¹s⁻¹; at least about 10⁴M⁻¹s⁻¹; at least about 10⁵M⁻¹s⁻¹; orat least about 10⁶M⁻¹s⁻¹, as measured by surface plasmon resonance.Preferably, the binding protein of the invention has an on rate constant(Kon) to IL-12 or IL-23 between 10²M⁻¹s⁻¹ to 10³M⁻¹s⁻¹; between10³M⁻¹s⁻¹ to 10⁴M⁻¹s⁻¹; between 10⁴M⁻¹s⁻¹ to 10⁵M⁻¹s⁻¹; or between10⁵M⁻¹ s⁻¹ to 10⁶M⁻¹s⁻¹, as measured by surface plasmon resonance.

In another embodiment, the binding protein of the invention has an offrate constant (Koff) to IL-12 or IL-23 of at most about 10⁻³s⁻¹; at mostabout 10⁻⁴s⁻¹; at most about 10⁻⁵s⁻¹; or at most about 10⁻⁶s⁻¹, asmeasured by surface plasmon resonance. Preferably, the binding proteinof the invention has an off rate constant (Koff) to IL-12 or IL-23 of10⁻³s⁻¹ to 10⁻⁴s⁻¹; of 10⁻⁴s⁻¹ to 10⁻⁵s⁻¹; or of 10⁻⁵s⁻¹ to 10⁻⁶s⁻¹, asmeasured by surface plasmon resonance.

In another embodiment, the binding protein of the invention has adissociation constant (K_(D)) to IL-12 or IL-23 of at most about 10⁻⁷ M;at most about 10⁻⁸ M; at most about 10⁻⁹ M; at most about 10⁻¹⁰ M; atmost about 10⁻¹¹ M; at most about 10⁻¹² M; or at most 10⁻¹³ M.Preferably, the binding protein of the invention has a dissociationconstant (K_(D)) to IL-12 or IL-23 of 10⁻⁷ M to 10⁻⁸ M; of 10⁻⁸ M to10⁻⁹ M; of 10⁻⁹ M to 10⁻¹⁰ M; of 10⁻¹⁰ to 10⁻¹¹ M; of 10⁻¹¹ M to 10⁻¹²M; or of 10⁻¹² to M 10⁻¹³ M. One embodiment of the invention provides anantibody construct comprising any one of the binding proteins disclosedabove and a linker polypeptide or an immunoglobulin. In a preferredembodiment the antibody construct is selected from the group consistingof an immunoglobulin molecule, a monoclonal antibody, a chimericantibody, a CDR-grafted antibody, a humanized antibody, a Fab, a Fab′, aF(ab′)2, a Fv, a disulfide linked Fv, a scFv, a single domain antibody,a diabody, a multispecific antibody, a dual specific antibody, and abispecific antibody. In a preferred embodiment the antibody constructcomprises a heavy chain immunoglobulin constant domain selected from thegroup consisting of a human IgM constant domain, a human IgG1 constantdomain, a human IgG2 constant domain, a human IgG3 constant domain, ahuman IgG4 constant domain, a human IgE constant domain, and a human IgAconstant domain. More preferably, the antibody construct comprises SEQID NO.:2; SEQ ID NO.:3; SEQ ID NO.:4; and SEQ ID NO.:5. In anotherembodiment the invention provides an antibody conjugate comprising anthe antibody construct disclosed above and an agent an agent selectedfrom the group consisting of; an immunoadhension molecule, an imagingagent, a therapeutic agent, and a cytotoxic agent. In a preferredembodiment the imaging agent selected from the group consisting of aradiolabel, an enzyme, a fluorescent label, a luminescent label, abioluminescent label, a magnetic label, and biotin. More preferably theimaging agent is a radiolabel selected from the group consisting of: ³H,¹⁴C, ³⁵S, ⁹⁰Y, ⁹⁹Tc, ¹¹¹In, ¹²⁵I, ¹³¹I, ¹⁷⁷Lu, ¹⁶⁶Ho, and ¹⁵³Sm. In apreferred embodiment the therapeutic or cytotoxic agent is selected fromthe group consisting of; an anti-metabolite, an alkylating agent, anantibiotic, a growth factor, a cytokine, an anti-angiogenic agent, ananti-mitotic agent, an anthracycline, toxin, and an apoptotic agent.

In another embodiment the antibody construct is glycosylated. Preferablythe glycosylation is a human glycosylation pattern.

In another embodiment binding protein, antibody construct or antibodyconjugate disclosed above exists as a crystal. Preferably the crystal isa carrier-free pharmaceutical controlled release crystal. In a preferredembodiment the crystallized binding protein, crystallized antibodyconstruct or crystallized antibody conjugate has a greater half life invivo than its soluble counterpart. In another preferred embodiment thecrystallized binding protein, crystallized antibody construct orcrystallized antibody conjugate retains biological activity aftercrystallization.

One aspect of the invention pertains to an isolated nucleic acidencoding any one of the binding protein, antibody construct or antibodyconjugate disclosed above. A further embodiment provides a vectorcomprising the isolated nucleic acid disclosed above wherein said vectoris selected from the group consisting of pcDNA; pTT (Durocher et al.,Nucleic Acids Research 2002, Vol 30, No. 2); pTT3 (pTT with additionalmultiple cloning site; pEFBOS (Mizushima, S, and Nagata, S., (1990)Nucleic acids Research Vol 18, No. 17); pBV; pJV; and pBJ.

In another aspect a host cell is transformed with the vector disclosedabove. Preferably the host cell is a prokaryotic cell. More preferablythe host cell is E. Coli. In a related embodiment the host cell is aneukaryotic cell. Preferably the eukaryotic cell is selected from thegroup consisting of protist cell, animal cell, plant cell and fungalcell. More preferably the host cell is a mammalian cell including, butnot limited to, CHO and COS; or a fungal cell such as Saccharomycescerevisiae; or an insect cell such as Sf9.

Another aspect of the invention provides a method of producing a bindingprotein that binds the p40 subunit of IL-12, comprising culturing anyone of the host cells disclosed above in a culture medium underconditions sufficient to produce a binding protein that binds the p40subunit of IL-12. Another embodiment provides a binding protein producedaccording to the method disclosed above.

One embodiment provides a composition for the release of a bindingprotein wherein the composition comprises a formulation which in turncomprises a crystallized binding protein, crystallized antibodyconstruct or crystallized antibody conjugate as disclosed above and aningredient; and at least one polymeric carrier. Preferably the polymericcarrier is a polymer selected from one or more of the group consistingof: poly (acrylic acid), poly (cyanoacrylates), poly (amino acids), poly(anhydrides), poly (depsipeptide), poly (esters), poly (lactic acid),poly (lactic-co-glycolic acid) or PLGA, poly (b-hydroxybutryate), poly(caprolactone), poly (dioxanone); poly (ethylene glycol), poly((hydroxypropyl)methacrylamide, poly [(organo)phosphazene], poly (orthoesters), poly (vinyl alcohol), poly (vinylpyrrolidone), maleicanhydride-alkyl vinyl ether copolymers, pluronic polyols, albumin,alginate, cellulose and cellulose derivatives, collagen, fibrin,gelatin, hyaluronic acid, oligosaccharides, glycaminoglycans, sulfatedpolyeaccharides, blends and copolymers thereof. Preferably theingredient is selected from the group consisting of albumin, sucrose,trehalose, lactitol, gelatin, hydroxypropyl-β-cyclodextrin,methoxypolyethylene glycol and polyethylene glycol. Another embodimentprovides a method for treating a mammal comprising the step ofadministering to the mammal an effective amount of the compositiondisclosed above.

The invention also provides a pharmaceutical composition comprising abinding protein, antibody construct or antibody conjugate as disclosedabove and a pharmaceutically acceptable carrier. In a further embodimentthe pharmaceutical composition comprises at least one additionaltherapeutic agent for treating a disorder in which IL-12 and/or IL-23activity is detrimental. Preferably the additional agent is selectedfrom the group consisting of: Therapeutic agent, imaging agent,cytotoxic agent, angiogenesis inhibitors (including but not limited toanti-VEGF antibodies or VEGF-trap); kinase inhibitors (including but notlimited to KDR and TIE-2 inhibitors); co-stimulation molecule blockers(including but not limited to anti-B7.1, anti-B7.2, CTLA4-Ig,anti-CD20); adhesion molecule blockers (including but not limited toanti-LFA-1 Abs, anti-E/L selectin Abs, small molecule inhibitors);anti-cytokine antibody or functional fragment thereof (including but notlimited to anti-IL-18, anti-TNF, anti-IL-6/cytokine receptorantibodies); methotrexate; cyclosporin; rapamycin; FK506; detectablelabel or reporter; a TNF antagonist; an antirheumatic; a musclerelaxant, a narcotic, a non-steroid anti-inflammatory drug (NSAID), ananalgesic, an anesthetic, a sedative, a local anesthetic, aneuromuscular blocker, an antimicrobial, an antipsoriatic, acorticosteriod, an anabolic steroid, an erythropoietin, an immunization,an immunoglobulin, an immunosuppressive, a growth hormone, a hormonereplacement drug, a radiopharmaceutical, an antidepressant, anantipsychotic, a stimulant, an asthma medication, a beta agonist, aninhaled steroid, an epinephrine or analog, a cytokine, and a cytokineantagonist.

In another aspect, the invention provides a method for inhibiting humanIL-12 and/or human IL-23 activity comprising contacting human IL-12and/or human IL-23 with a binding protein disclosed above such thathuman IL-12 and/or human IL-23 activity is inhibited. In a relatedaspect the invention provides a method for inhibiting human IL-12 and/orhuman IL-23 activity in a human subject suffering from a disorder inwhich IL-12 and/or IL-23 activity is detrimental, comprisingadministering to the human subject a binding protein disclosed abovesuch that human IL-12 and/or human IL-23 activity in the human subjectis inhibited and treatment is achieved. Preferably the disorder isselected from the group comprising arthritis, osteoarthritis, juvenilechronic arthritis, septic arthritis, Lyme arthritis, psoriaticarthritis, reactive arthritis, spondyloarthropathy, systemic lupuserythematosus, Crohn's disease, ulcerative colitis, inflammatory boweldisease, insulin dependent diabetes mellitus, thyroiditis, asthma,allergic diseases, psoriasis, dermatitis scleroderma, graft versus hostdisease, organ transplant rejection, acute or chronic immune diseaseassociated with organ transplantation, sarcoidosis, atherosclerosis,disseminated intravascular coagulation, Kawasaki's disease, Grave'sdisease, nephrotic syndrome, chronic fatigue syndrome, Wegener'sgranulomatosis, Henoch-Schoenlein purpurea, microscopic vasculitis ofthe kidneys, chronic active hepatitis, uveitis, septic shock, toxicshock syndrome, sepsis syndrome, cachexia, infectious diseases,parasitic diseases, acquired immunodeficiency syndrome, acute transversemyelitis, Huntington's chorea, Parkinson's disease, Alzheimer's disease,stroke, primary biliary cirrhosis, hemolytic anemia, malignancies, heartfailure, myocardial infarction, Addison's disease, sporadic,polyglandular deficiency type I and polyglandular deficiency type II,Schmidt's syndrome, adult (acute) respiratory distress syndrome,alopecia, alopecia areata, seronegative arthopathy, arthropathy,Reiter's disease, psoriatic arthropathy, ulcerative colitic arthropathy,enteropathic synovitis, chlamydia, yersinia and salmonella associatedarthropathy, spondyloarthopathy, atheromatous disease/arteriosclerosis,atopic allergy, autoimmune bullous disease, pemphigus vulgaris,pemphigus foliaceus, pemphigoid, linear IgA disease, autoimmunehaemolytic anaemia, Coombs positive haemolytic anaemia, acquiredpernicious anaemia, juvenile pernicious anaemia, myalgicencephalitis/Royal Free Disease, chronic mucocutaneous candidiasis,giant cell arteritis; primary sclerosing hepatitis, cryptogenicautoimmune hepatitis, Acquired Immunodeficiency Disease Syndrome,Acquired Immunodeficiency Related Diseases, Hepatitis B, Hepatitis C,common varied immunodeficiency (common variable hypogammaglobulinaemia),dilated cardiomyopathy, female infertility, ovarian failure, prematureovarian failure, fibrotic lung disease, cryptogenic fibrosingalveolitis, post-inflammatory interstitial lung disease, interstitialpneumonitis, connective tissue disease associated interstitial lungdisease, mixed connective tissue disease associated lung disease,systemic sclerosis associated interstitial lung disease, rheumatoidarthritis associated interstitial lung disease, systemic lupuserythematosus associated lung disease, dermatomyositis/polymyositisassociated lung disease, Sjögren's disease associated lung disease,ankylosing spondylitis associated lung disease, vasculitic diffuse lungdisease, haemosiderosis associated lung disease, drug-inducedinterstitial lung disease, fibrosis, radiation fibrosis, bronchiolitisobliterans, chronic eosinophilic pneumonia, lymphocytic infiltrativelung disease, postinfectious interstitial lung disease, gouty arthritis,autoimmune hepatitis, type-1 autoimmune hepatitis (classical autoimmuneor lupoid hepatitis), type-2 autoimmune hepatitis (anti-LKM antibodyhepatitis), autoimmune mediated hypoglycaemia, type B insulin resistancewith acanthosis nigricans, hypoparathyroidism, acute immune diseaseassociated with organ transplantation, chronic immune disease associatedwith organ transplantation, osteoarthrosis, primary sclerosingcholangitis, psoriasis type 1, psoriasis type 2, idiopathic leucopaenia,autoimmune neutropaenia, renal disease NOS, glomerulonephritides,microscopic vasulitis of the kidneys, lyme disease, discoid lupuserythematosus, male infertility idiopathic or NOS, sperm autoimmunity,multiple sclerosis (all subtypes), sympathetic ophthalmia, pulmonaryhypertension secondary to connective tissue disease, Goodpasture'ssyndrome, pulmonary manifestation of polyarteritis nodosa, acuterheumatic fever, rheumatoid spondylitis, Still's disease, systemicsclerosis, Sjörgren's syndrome, Takayasu's disease/arteritis, autoimmunethrombocytopaenia, idiopathic thrombocytopaenia, autoimmune thyroiddisease, hyperthyroidism, goitrous autoimmune hypothyroidism(Hashimoto's disease), atrophic autoimmune hypothyroidism, primarymyxoedema, phacogenic uveitis, primary vasculitis, vitiligo acute liverdisease, chronic liver diseases, alcoholic cirrhosis, alcohol-inducedliver injury, choleosatatis, idiosyncratic liver disease, Drug-Inducedhepatitis, Non-alcoholic Steatohepatitis, allergy and asthma, group Bstreptococci (GBS) infection, mental disorders (e.g., depression andschizophrenia), Th2 Type and Th1 Type mediated diseases, acute andchronic pain (different forms of pain), and cancers such as lung,breast, stomach, bladder, colon, pancreas, ovarian, prostate and rectalcancer and hematopoietic malignancies (leukemia and lymphoma),Abetalipoprotemia, Acrocyanosis, acute and chronic parasitic orinfectious processes, acute leukemia, acute lymphoblastic leukemia(ALL), acute myeloid leukemia (AML), acute or chronic bacterialinfection, acute pancreatitis, acute renal failure, adenocarcinomas,aerial ectopic beats, AIDS dementia complex, alcohol-induced hepatitis,allergic conjunctivitis, allergic contact dermatitis, allergic rhinitis,allograft rejection, alpha-1-antitrypsin deficiency, amyotrophic lateralsclerosis, anemia, angina pectoris, anterior horn cell degeneration,anti cd3 therapy, antiphospholipid syndrome, anti-receptorhypersensitivity reactions, aordic and peripheral aneuryisms, aorticdissection, arterial hypertension, arteriosclerosis, arteriovenousfistula, ataxia, atrial fibrillation (sustained or paroxysmal), atrialflutter, atrioventricular block, B cell lymphoma, bone graft rejection,bone marrow transplant (BMT) rejection, bundle branch block, Burkitt'slymphoma, Burns, cardiac arrhythmias, cardiac stun syndrome, cardiactumors, cardiomyopathy, cardiopulmonary bypass inflammation response,cartilage transplant rejection, cerebellar cortical degenerations,cerebellar disorders, chaotic or multifocal atrial tachycardia,chemotherapy associated disorders, chromic myelocytic leukemia (CML),chronic alcoholism, chronic inflammatory pathologies, chroniclymphocytic leukemia (CLL), chronic obstructive pulmonary disease(COPD), chronic salicylate intoxication, colorectal carcinoma,congestive heart failure, conjunctivitis, contact dermatitis, corpulmonale, coronary artery disease, Creutzfeldt-Jakob disease, culturenegative sepsis, cystic fibrosis, cytokine therapy associated disorders,Dementia pugilistica, demyelinating diseases, dengue hemorrhagic fever,dermatitis, dermatologic conditions, diabetes, diabetes mellitus,diabetic ateriosclerotic disease, Diffuse Lewy body disease, dilatedcongestive cardiomyopathy, disorders of the basal ganglia, Down'sSyndrome in middle age, drug-induced movement disorders induced by drugswhich block CNS dopamine receptors, drug sensitivity, eczema,encephalomyelitis, endocarditis, endocrinopathy, epiglottitis,epstein-barr virus infection, erythromelalgia, extrapyramidal andcerebellar disorders, familial hematophagocytic lymphohistiocytosis,fetal thymus implant rejection, Friedreich's ataxia, functionalperipheral arterial disorders, fungal sepsis, gas gangrene, gastriculcer, glomerular nephritis, graft rejection of any organ or tissue,gram negative sepsis, gram positive sepsis, granulomas due tointracellular organisms, hairy cell leukemia, Hallerrorden-Spatzdisease, hashimoto's thyroiditis, hay fever, heart transplant rejection,hemachromatosis, hemodialysis, hemolytic uremic syndrome/thrombolyticthrombocytopenic purpura, hemorrhage, hepatitis (A), His bundlearrythmias, HIV infection/HIV neuropathy, Hodgkin's disease,hyperkinetic movement disorders, hypersensitity reactions,hypersensitivity pneumonitis, hypertension, hypokinetic movementdisorders, hypothalamic-pituitary-adrenal axis evaluation, idiopathicAddison's disease, idiopathic pulmonary fibrosis, antibody mediatedcytotoxicity, Asthenia, infantile spinal muscular atrophy, inflammationof the aorta, influenza a, ionizing radiation exposure,iridocyclitis/uveitis/optic neuritis, ischemia-reperfusion injury,ischemic stroke, juvenile rheumatoid arthritis, juvenile spinal muscularatrophy, Kaposi's sarcoma, kidney transplant rejection, legionella,leishmaniasis, leprosy, lesions of the corticospinal system, lipedema,liver transplant rejection, lymphederma, malaria, malignant Lymphoma,malignant histiocytosis, malignant melanoma, meningitis,meningococcemia, metabolic/idiopathic, migraine headache, mitochondrialmulti.system disorder, mixed connective tissue disease, monoclonalgammopathy, multiple myeloma, multiple systems degenerations (MencelDejerine-Thomas Shi-Drager and Machado-Joseph), myasthenia gravis,mycobacterium avium intracellular, mycobacterium tuberculosis,myelodyplastic syndrome, myocardial infarction, myocardial ischemicdisorders, nasopharyngeal carcinoma, neonatal chronic lung disease,nephritis, nephrosis, neurodegenerative diseases, neurogenic I muscularatrophies, neutropenic fever, non-hodgkins lymphoma, occlusion of theabdominal aorta and its branches, occulsive arterial disorders, okt3therapy, orchitis/epidydimitis, orchitis/vasectomy reversal procedures,organomegaly, osteoporosis, pancreas transplant rejection, pancreaticcarcinoma, paraneoplastic syndrome/hypercalcemia of malignancy,parathyroid transplant rejection, pelvic inflammatory disease, perennialrhinitis, pericardial disease, peripheral atherlosclerotic disease,peripheral vascular disorders, peritonitis, pernicious anemia,pneumocystis carinii pneumonia, pneumonia, POEMS syndrome(polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy,and skin changes syndrome), post perfusion syndrome, post pump syndrome,post-MI cardiotomy syndrome, preeclampsia, Progressive supranucleoPalsy, primary pulmonary hypertension, radiation therapy, Raynaud'sphenomenon and disease, Raynoud's disease, Refsum's disease, regularnarrow QRS tachycardia, renovascular hypertension, reperfusion injury,restrictive cardiomyopathy, sarcomas, scleroderma, senile chorea, SenileDementia of Lewy body type, seronegative arthropathies, shock, sicklecell anemia, skin allograft rejection, skin changes syndrome, smallbowel transplant rejection, solid tumors, specific arrythmias, spinalataxia, spinocerebellar degenerations, streptococcal myositis,structural lesions of the cerebellum, Subacute sclerosingpanencephalitis, Syncope, syphilis of the cardiovascular system,systemic anaphalaxis, systemic inflammatory response syndrome, systemiconset juvenile rheumatoid arthritis, T-cell or FAB ALL, Telangiectasia,thromboangitis obliterans, thrombocytopenia, toxicity, transplants,trauma/hemorrhage, type III hypersensitivity reactions, type IVhypersensitivity, unstable angina, uremia, urosepsis, urticaria,valvular heart diseases, varicose veins, vasculitis, venous diseases,venous thrombosis, ventricular fibrillation, viral and fungalinfections, vital encephalitis/aseptic meningitis, vital-associatedhemaphagocytic syndrome, Wernicke-Korsakoff syndrome, Wilson's disease,xenograft rejection of any organ or tissue.

In another aspect the invention provides a method of treating a patientsuffering from a disorder in which human IL-12 and/or human IL-23 isdetrimental comprising the step of administering any one of the bindingproteins disclosed above before, concurrent, or after the administrationof a second agent, as discussed above. In a preferred embodiment thesecond agent is selected from the group consisting of budenoside,epidermal growth factor, corticosteroids, cyclosporin, sulfasalazine,aminosalicylates, 6-mercaptopurine, azathioprine, metronidazole,lipoxygenase inhibitors, mesalamine, olsalazine, balsalazide,antioxidants, thromboxane inhibitors, IL-1 receptor antagonists,anti-IL-1β monoclonal antibodies, anti-IL-6 monoclonal antibodies,growth factors, elastase inhibitors, pyridinyl-imidazole compounds,antibodies or agonists of TNF, LT, IL-1, IL-2, IL-6, IL-7, IL-8, IL-15,IL-16, IL-18, EMAP-II, GM-CSF, FGF, and PDGF, antibodies of CD2, CD3,CD4, CD8, CD25, CD28, CD30, CD40, CD45, CD69, CD90 or their ligands,methotrexate, cyclosporin, FK506, rapamycin, mycophenolate mofetil,leflunomide, NSAIDs, ibuprofen, corticosteroids, prednisolone,phosphodiesterase inhibitors, adensosine agonists, antithromboticagents, complement inhibitors, adrenergic agents, IRAK, NIK, IKK, p38,MAP kinase inhibitors, IL-1β converting enzyme inhibitors, TNF

converting enzyme inhibitors, T-cell signalling inhibitors,metalloproteinase inhibitors, sulfasalazine, azathioprine,6-mercaptopurines, angiotensin converting enzyme inhibitors, solublecytokine receptors, soluble p55 TNF receptor, soluble p75 TNF receptor,sIL-1RI, sIL-1RII, sIL-6R, antiinflammatory cytokines, IL-4, IL-10,IL-11, IL-13 and TGFβ. In a preferred embodiment the pharmaceuticalcompositions disclosed above are administered to the subject by at leastone mode selected from parenteral, subcutaneous, intramuscular,intravenous, intrarticular, intrabronchial, intraabdominal,intracapsular, intracartilaginous, intracavitary, intracelial,intracerebellar, intracerebroventricular, intracolic, intracervical,intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic,intrapericardiac, intraperitoneal, intrapleural, intraprostatic,intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal,intrasynovial, intrathoracic, intrauterine, intravesical, bolus,vaginal, rectal, buccal, sublingual, intranasal, and transdermal.

One aspect of the invention provides at least one IL-12 anti-idiotypeantibody to at least one IL-12 binding protein of the present invention.The anti-idiotype antibody includes any protein or peptide containingmolecule that comprises at least a portion of an immunoglobulin moleculesuch as, but not limited to, at least one complementarily determiningregion (CDR) of a heavy or light chain or a ligand binding portionthereof, a heavy chain or light chain variable region, a heavy chain orlight chain constant region, a framework region, or; any portionthereof, that can be incorporated into a binding protein of the presentinvention.

DETAILED DESCRIPTION OF THE INVENTION

This invention pertains to IL-12p40 binding proteins, particularlyanti-IL-12p40 antibodies, or antigen-binding portions thereof, that bindIL-12p40. Various aspects of the invention relate to antibodies andantibody fragments, and pharmaceutical compositions thereof, as well asnucleic acids, recombinant expression vectors and host cells for makingsuch antibodies and fragments. Methods of using the antibodies of theinvention to detect human IL-12p40, human IL-12 and human IL-23; toinhibit human IL-12 and/or human IL-23 activity, either in vitro or invivo; and to regulate gene expression are also encompassed by theinvention.

Unless otherwise defined herein, scientific and technical terms used inconnection with the present invention shall have the meanings that arecommonly understood by those of ordinary skill in the art. The meaningand scope of the terms should be clear, however, in the event of anylatent ambiguity, definitions provided herein take precedent over anydictionary or extrinsic definition. Further, unless otherwise requiredby context, singular terms shall include pluralities and plural termsshall include the singular. In this application, the use of “or” means“and/or” unless stated otherwise. Furthermore, the use of the term“including”, as well as other forms, such as “includes” and “included”,is not limiting. Also, terms such as “element” or “component” encompassboth elements and components comprising one unit and elements andcomponents that comprise more than one subunit unless specificallystated otherwise.

Generally, nomenclatures used in connection with, and techniques of,cell and tissue culture, molecular biology, immunology, microbiology,genetics and protein and nucleic acid chemistry and hybridizationdescribed herein are those well known and commonly used in the art. Themethods and techniques of the present invention are generally performedaccording to conventional methods well known in the art and as describedin various general and more specific references that are cited anddiscussed throughout the present specification unless otherwiseindicated. Enzymatic reactions and purification techniques are performedaccording to manufacturer's specifications, as commonly accomplished inthe art or as described herein. The nomenclatures used in connectionwith, and the laboratory procedures and techniques of, analyticalchemistry, synthetic organic chemistry, and medicinal and pharmaceuticalchemistry described herein are those well known and commonly used in theart. Standard techniques are used for chemical syntheses, chemicalanalyses, pharmaceutical preparation, formulation, and delivery, andtreatment of patients.

That the present invention may be more readily understood, select termsare defined below.

The term “Polypeptide” as used herein, refers to any polymeric chain ofamino acids. The terms “peptide” and “protein” are used interchangeablywith the term polypeptide and also refer to a polymeric chain of aminoacids. The term “polypeptide” encompasses native or artificial proteins,protein fragments and polypeptide analogs of a protein sequence. Apolypeptide may be monomeric or polymeric.

The term “isolated protein” or “isolated polypeptide” is a protein orpolypeptide that by virtue of its origin or source of derivation is notassociated with naturally associated components that accompany it in itsnative state; is substantially free of other proteins from the samespecies; is expressed by a cell from a different species; or does notoccur in nature. Thus, a polypeptide that is chemically synthesized orsynthesized in a cellular system different from the cell from which itnaturally originates will be “isolated” from its naturally associatedcomponents. A protein may also be rendered substantially free ofnaturally associated components by isolation, using protein purificationtechniques well known in the art.

The term “recovering” as used herein, refers to the process of renderinga chemical species such as a polypeptide substantially free of naturallyassociated components by isolation, e.g., using protein purificationtechniques well known in the art.

The term “human IL-12” (abbreviated herein as hIL-12, or IL-12), as usedherein, includes a human cytokine that is secreted primarily by antigenpresenting cells such as monocytes macrophages and dendritic cells. Theterm includes a heterodimeric protein comprising a 35 kD subunit (p35)and a 40 kD subunit (p40) which are both linked together with adisulfide bridge. The heterodimeric protein is referred to as a “p70protein”. The structure of human IL-12 is described further in, forexample, Kobayashi, et al. (1989) J. Exp Med. 170:827-845; Seder, et al.(1993) Proc. Natl. Acad. Sci. 90:10188-10192; Ling, et al. (1995) J. ExpMed. 154:116-127; Podlaski, et al. (1992) Arch. Biochem. Biophys.294:230-237. The term human IL-12 is intended to include recombinanthuman IL-12 (rh IL-12), which can be prepared by standard recombinantexpression methods.

The term “human IL-23” (abbreviated herein as hIL-23, or IL-23), as usedherein, includes a heterodimeric human cytokine belonging to a family offive such heterodimeric cytokines including IL-12 and IL-27 (Trinchieriet al., (2003) Immunity 19:641-644). The term includes a heterodimericprotein comprising a 19 kD subunit (p19) and a 40 kD subunit (p40) whichare both linked together with a disulfide bridge. The term human IL-23is intended to include recombinant human IL-23 (rh IL-23), which can beprepared by standard recombinant expression methods.

The term “IL-12p40”, identical to “IL-23p40”, and also referred tosimply as “p40”, as used herein, includes the 40 kD subunit of the humancytokine IL-12 (p40) and the 40 kD subunit of the human cytokine IL-23.Table 1 shows the amino acid sequence of IL-12p40, SEQ ID No. 1, whichis known in the art.

TABLE 1 Sequence of p40 subunit of IL-12 and IL-23 Sequence SequenceProtein Identifier 12345678901234567890123456789012 p40 subunit of SEQID NO.:1 MCHQQLVISWFSLVFLDLVAIWELKKDVYVVE IL-12 and IL-23LDWYPDAPGEMVVLTCDTPEEDGITWTLDQSS EVLGSGKTLTIQVKEFGDAGQYTCHKGGEVLSHSLLLLHKKEDGIWSTDILKDQKEPKNKTFLR CEAKNYSGRFTCWWLTTISTDLTFSVKSSRGSSDPQGVTCGAATLSAERVRGDNKEYEYSVECQ EDSACPAAEESLPIEVMVDAVHKLKYENYTSSFFIRDIIKPDPPKNLQLKPLKNSRQVEVSWEY PDTWSTPHSYFSLTFCVQVQGKSKREKKDRVFTDKTSATVICRKNASISVRAQDRYYSSSWSEW ASVPCS

“Biological activity” as used herein, refers to all inherent biologicalproperties of the cytokine. Biological properties of IL-12 include butare not limited to binding IL-12 receptor; induction of interferon-gamma(IFN-γ) secretion and regulation of balance between antigen-specific Thelper type 1 (Th1) and type 2 (Th2) lymphocytes. Biological propertiesof IL-23 include but are not limited to binding IL-23 receptor, inducingIFN-γ production, Th1 cell differentiation and activating theantigen-presenting functions of dendritic cells, and selectivelyinducing proliferation of memory T cells.

The terms “specific binding” or “specifically binding”, as used herein,in reference to the interaction of an antibody, a protein, or a peptidewith a second chemical species, mean that the interaction is dependentupon the presence of a particular structure (e.g., an antigenicdeterminant or epitope) on the chemical species; for example, anantibody recognizes and binds to a specific protein structure ratherthan to proteins generally. If an antibody is specific for epitope “A”,the presence of a molecule containing epitope A (or free, unlabeled A),in a reaction containing labeled “A” and the antibody, will reduce theamount of labeled A bound to the antibody.

The term “antibody”, as used herein, broadly refers to anyimmunoglobulin (Ig) molecule comprised of four polypeptide chains, twoheavy (H) chains and two light (L) chains, or any functional fragment,mutant, variant, or derivation thereof, which retains the essentialepitope binding features of an Ig molecule. Such mutant, variant, orderivative antibody formats are known in the art. Nonlimitingembodiments of which are discussed below.

In a full-length antibody, each heavy chain is comprised of a heavychain variable region (abbreviated herein as HCVR or VH) and a heavychain constant region. The heavy chain constant region is comprised ofthree domains, CH1, CH2 and CH3. Each light chain is comprised of alight chain variable region (abbreviated herein as LCVR or VL) and alight chain constant region. The light chain constant region iscomprised of one domain, CL. The VH and VL regions can be furthersubdivided into regions of hypervariability, termed complementaritydetermining regions (CDR), interspersed with regions that are moreconserved, termed framework regions (FR). Each VH and VL is composed ofthree CDRs and four FRs, arranged from amino-terminus tocarboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3,CDR3, FR4. Immunoglobulin molecules can be of any type (e.g., IgG, IgE,IgM, IgD, IgA and IgY), class (e.g., IgG 1, IgG2, IgG 3, IgG4, IgA1 andIgA2) or subclass.

The term “antigen-binding portion” of an antibody (or simply “antibodyportion”), as used herein, refers to one or more fragments of anantibody that retain the ability to specifically bind to an antigen(e.g., hIL-12). It has been shown that the antigen-binding function ofan antibody can be performed by fragments of a full-length antibody.Such antibody embodiments may also be bispecific, dual specific, ormulti-specific formats; specifically binding to two or more differentantigens. Examples of binding fragments encompassed within the term“antigen-binding portion” of an antibody include (i) a Fab fragment, amonovalent fragment consisting of the VL, VH, CL and CH1 domains; (ii) aF(ab′)₂ fragment, a bivalent fragment comprising two Fab fragmentslinked by a disulfide bridge at the hinge region; (iii) a Fd fragmentconsisting of the VH and CH1 domains; (iv) a Fv fragment consisting ofthe VL and VH domains of a single arm of an antibody, (v) a dAb fragment(Ward et al., (1989) Nature 341:544-546, Winter et al., PCT publicationWO 90/05144 A1 herein incorporated by reference), which comprises asingle variable domain; and (vi) an isolated complementarity determiningregion (CDR). Furthermore, although the two domains of the Fv fragment,VL and VH, are coded for by separate genes, they can be joined, usingrecombinant methods, by a synthetic linker that enables them to be madeas a single protein chain in which the VL and VH regions pair to formmonovalent molecules (known as single chain Fv (scFv); see e.g., Bird etal. (1988) Science 242:423-426; and Huston et al. (1988) Proc. Natl.Acad. Sci. USA 85:5879-5883). Such single chain antibodies are alsointended to be encompassed within the term “antigen-binding portion” ofan antibody. Other forms of single chain antibodies, such as diabodiesare also encompassed. Diabodies are bivalent, bispecific antibodies inwhich VH and VL domains are expressed on a single polypeptide chain, butusing a linker that is too short to allow for pairing between the twodomains on the same chain, thereby forcing the domains to pair withcomplementary domains of another chain and creating two antigen bindingsites (see e.g., Holliger, P., et al. (1993) Proc. Natl. Acad. Sci. USA90:6444-6448; Poljak, R. J., et al. (1994) Structure 2:1121-1123). Suchantibody binding portions are known in the art (Konternann and Dubeleds., Antibody Engineering (2001) Springer-Verlag. New York. 790 pp.(ISBN 3-540-41354-5).

The term “antibody construct” as used herein refers to a polypeptidecomprising one or more the antigen binding portions of the inventionlinked to a linker polypeptide or an immunoglobulin constant domain.Linker polypeptides comprise two or more amino acid residues joined bypeptide bonds and are used to link one or more antigen binding portions.Such linker polypeptides are well known in the art (see e.g., Holliger,P., et al. (1993) Proc. Natl. Acad. Sci. USA 90:6444-6448; Poljak, R.J., et al. (1994) Structure 2:1121-1123). An immunoglobulin constantdomain refers to a heavy or light chain constant domain. Human IgG heavychain and light chain constant domain amino acid sequences are known inthe art and represented in Table 2.

TABLE 2 Sequence of human IgG heavy chain constant domain and lightchain constant domain Sequence Sequence Protein Identifier12345678901234567890123456789012 Ig gamma-1 SEQ ID NO.:2ASTKGPSVFFLAPSSKSTSGGTAALGCLVKDY constant regionFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS LSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPP KPKDTLMISRTPEVTCVVXTDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVL HQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFY PSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYT QKSLSLSPGK Ig gamma-1 SEQ ID NO.:3ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDY constant regionFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS mutant LSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPP KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVL HQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFY PSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYT QKSLSLSPGK Ig Kappa constant SEQ IDNO.:4 TVAAPSVFIFPPSDEQLKSGTASVVCLLNNFY regionPREAKVQWKVDNALQSGNSQESVTEQDSKDST YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Ig Lambda SEQ ID NO.:5 QPKAAPSVTLFPPSSEELQANKATLVCLISDFconstant region YPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVE KTVAPTECS

Still further, an antibody or antigen-binding portion thereof may bepart of a larger immunoadhesion molecules, formed by covalent ornoncovalent association of the antibody or antibody portion with one ormore other proteins or peptides. Examples of such immunoadhesionmolecules include use of the streptavidin core region to make atetrameric scFv molecule (Kipriyanov, S. M., et al. (1995) HumanAntibodies and Hybridomas 6:93-101) and use of a cysteine residue, amarker peptide and a C-terminal polyhistidine tag to make bivalent andbiotinylated scFv molecules (Kipriyanov, S. M., et al. (1994) Mol.Immunol. 31:1047-1058). Antibody portions, such as Fab and F(ab′)₂fragments, can be prepared from whole antibodies using conventionaltechniques, such as papain or pepsin digestion, respectively, of wholeantibodies. Moreover, antibodies, antibody portions and immunoadhesionmolecules can be obtained using standard recombinant DNA techniques, asdescribed herein.

An “isolated antibody”, as used herein, is intended to refer to anantibody that is substantially free of other antibodies having differentantigenic specificities (e.g., an isolated antibody that specificallybinds hIL-12 is substantially free of antibodies that specifically_bindantigens other than hIL-12). An isolated antibody that specificallybinds hIL-12 may, however, have cross-reactivity to other antigens, suchas IL-12 molecules from other species. Moreover, an isolated antibodymay be substantially free of other cellular material and/or chemicals.

The term “human antibody”, as used herein, is intended to includeantibodies having variable and constant regions derived from humangermiline immunoglobulin sequences. The human antibodies of theinvention may include amino acid residues not encoded by human germlineimmunoglobulin sequences (e.g., mutations introduced by random orsite-specific mutagenesis in vitro or by somatic mutation in vivo), forexample in the CDRs and in particular CDR3. However, the term “humanantibody”, as used herein, is not intended to include antibodies inwhich CDR sequences derived from the germline of another mammalianspecies, such as a mouse, have been grafted onto human frameworksequences.

The term “recombinant human antibody”, as used herein, is intended toinclude all human antibodies that are prepared, expressed, created orisolated by recombinant means, such as antibodies expressed using arecombinant expression vector transfected into a host cell (describedfurther in Section II C, below), antibodies isolated from a recombinant,combinatorial human antibody library (Hoogenboom H. R., (1997) TIB Tech.15:62-70; Azzazy H., and Highsmith W. E., (2002) Clin. Biochem.35:425-445; Gavilondo J. V., and Larrick J. W. (2002) BioTechniques29:128-145; Hoogenboom H., and Chames P. (2000) Immunology Today21:371-378), antibodies isolated from an animal (e.g., a mouse) that istransgenic for human immunoglobulin genes (see e.g., Taylor, L. D., etal. (1992) Nucl. Acids Res. 20:6287-6295; Kellermann S-A., and Green L.L. (2002) Current Opinion in Biotechnology 13:593-597; Little M. et al(2000) Immunology Today 21:364-370) or antibodies prepared, expressed,created or isolated by any other means that involves splicing of humanimmunoglobulin gene sequences to other DNA sequences. Such recombinanthuman antibodies have variable and constant regions derived from humangermline immunoglobulin sequences. In certain embodiments, however, suchrecombinant human antibodies are subjected to in vitro mutagenesis (or,when an animal transgenic for human Ig sequences is used, in vivosomatic mutagenesis) and thus the amino acid sequences of the VH and VLregions of the recombinant antibodies are sequences that, while derivedfrom and related to human germline VH and VL sequences, may notnaturally exist within the human antibody germline repertoire in vivo.

The term “chimeric antibody” refers to antibodies which comprise heavyand light chain variable region sequences from one species and constantregion sequences from another species, such as antibodies having murineheavy and light chain variable regions linked to human constant regions.

The term “CDR-grafted antibody” refers to antibodies which compriseheavy and light chain variable region sequences from one species but inwhich the sequences of one or more of the CDR regions of VH and/or VLare replaced with CDR sequences of another species, such as antibodieshaving murine heavy and light chain variable regions in which one ormore of the murine CDRs (e.g., CDR3) has been replaced with human CDRsequences.

The term “humanized antibody” refers to antibodies which comprise heavyand light chain variable region sequences from a non-human species(e.g., a mouse) but in which at least a portion of the VH and/or VLsequence has been altered to be more “human-like”, i.e., more similar tohuman germline variable sequences. One type of humanized antibody is aCDR-grafted antibody, in which human CDR sequences are introduced intonon-human VH and VL sequences to replace the corresponding nonhuman CDRsequences.

The terms “Kabat numbering”, “Kabat definitions and “Kabat labeling” areused interchangeably herein. These terms, which are recognized in theart, refer to a system of numbering amino acid residues which are morevariable (i.e. hypervariable) than other amino acid residues in theheavy and light chain variable regions of an antibody, or an antigenbinding portion thereof (Kabat et al. (1971) Ann. NY Acad, Sci.190:382-391 and, Kabat, E. A., et al. (1991) Sequences of Proteins ofImmunological Interest, Fifth Edition, U.S. Department of Health andHuman Services, NIH Publication No. 91-3242). For the heavy chainvariable region, the hypervariable region ranges from amino acidpositions 31 to 35 for CDR1, amino acid positions 50 to 65 for CDR2, andamino acid positions 95 to 102 for CDR3. For the light chain variableregion, the hypervariable region ranges from amino acid positions 24 to34 for CDR1, amino acid positions 50 to 56 for CDR2, and amino acidpositions 89 to 97 for CDR3.

As used herein, the terms “acceptor” and “acceptor antibody” refer tothe antibody or nucleic acid sequence providing or encoding at least80%, at least 85%, at least 90%, at least 95%, at least 98% or 100% ofthe amino acid sequences of one or more of the framework regions. Insome embodiments, the term “acceptor” refers to the antibody amino acidor nucleic acid sequence providing or encoding the constant region(s).In yet another embodiment, the term “acceptor” refers to the antibodyamino acid or nucleic acid sequence providing or encoding one or more ofthe framework regions and the constant region(s). In a specificembodiment, the term “acceptor” refers to a human antibody amino acid ornucleic acid sequence that provides or encodes at least 80%, preferably,at least 85%, at least 90%, at least 95%, at least 98%, or 100% of theamino acid sequences of one or more of the framework regions. Inaccordance with this embodiment, an acceptor may contain at least 1, atleast 2, at least 3, least 4, at least 5, or at least 10 amino acidresidues that does (do) not occur at one or more specific positions of ahuman antibody. An acceptor framework region and/or acceptor constantregion(s) may be, e.g., derived or obtained from a germline antibodygene, a mature antibody gene, a functional antibody (e.g., antibodieswell-known in the art, antibodies in development, or antibodiescommercially available).

As used herein, the term “CDR” refers to the complementarity determiningregion within antibody variable sequences. There are three CDRs in eachof the variable regions of the heavy chain and the light chain, whichare designated CDR1, CDR2 and CDR3, for each of the variable regions.The term “CDR set” as used herein refers to a group of three CDRs thatoccur in a single variable region capable of binding the antigen. Theexact boundaries of these CDRs have been defined differently accordingto different systems. The system described by Kabat (Kabat et al.,Sequences of Proteins of Immunological Interest (National Institutes ofHealth, Bethesda, Md. (1987) and (1991)) not only provides anunambiguous residue numbering system applicable to any variable regionof an antibody, but also provides precise residue boundaries definingthe three CDRs. These CDRs may be referred to as Kabat CDRs. Chothia andcoworkers (Chothia &Lesk, J. Mol. Biol. 196:901-917 (1987) and Chothiaet al., Nature 342:877-883 (1989)) found that certain sub-portionswithin Kabat CDRs adopt nearly identical peptide backbone conformations,despite having great diversity at the level of amino acid sequence.These sub-portions were designated as L1, L2 and L3 or H1, H2 and H3where the “L” and the “H” designates the light chain and the heavychains regions, respectively. These regions may be referred to asChothia CDRs, which have boundaries that overlap with Kabat CDRs. Otherboundaries defining CDRs overlapping with the Kabat CDRs have beendescribed by Padlan (FASEB J. 9:133-139 (1995)) and MacCallum (J MolBiol 262(5):73245 (1996)). Still other CDR boundary definitions may notstrictly follow one of the above systems, but will nonetheless overlapwith the Kabat CDRs, although they may be shortened or lengthened inlight of prediction or experimental findings that particular residues orgroups of residues or even entire CDRs do not significantly impactantigen binding. The methods used herein may utilize CDRs definedaccording to any of these systems, although preferred embodiments useKabat or Chothia defined CDRs.

As used herein, the term “canonical” residue refers to a residue in aCDR or framework that defines a particular canonical CDR structure asdefined by Chothia et al. (J. Mol. Biol. 196:901-907 (1987); Chothia etal., J. Mol. Biol. 227:799 (1992), both are incorporated herein byreference). According to Chothia et al., critical portions of the CDRsof many antibodies have nearly identical peptide backbone confirmationsdespite great diversity at the level of amino acid sequence. Eachcanonical structure specifies primarily a set of peptide backbonetorsion angles for a contiguous segment of amino acid residues forming aloop.

As used herein, the terms “donor” and “donor antibody” refer to anantibody providing one or more CDRs. In a preferred embodiment, thedonor antibody is an antibody from a species different from the antibodyfrom which the framework regions are obtained or derived. In the contextof a humanized antibody, the term “donor antibody” refers to a non-humanantibody providing one or more CDRs.

As used herein, the term “framework” or “framework sequence” refers tothe remaining sequences of a variable region minus the CDRs. Because theexact definition of a CDR sequence can be determined by differentsystems, the meaning of a framework sequence is subject tocorrespondingly different interpretations. The six CDRs (CDR-L1, -L2,and -L3 of light chain and CDR-H1, -H2, and -H3 of heavy chain) alsodivide the framework regions on the light chain and the heavy chain intofour sub-regions (FR1, FR2, FR3 and FR4) on each chain, in which CDR1 ispositioned between FR1 and FR2, CDR2 between FR2 and FR3, and CDR3between FR3 and FR4. Without specifying the particular sub-regions asFR1, FR2, FR3 or FR4, a framework region, as referred by others,represents the combined FR's within the variable region of a single,naturally occurring immunoglobulin chain. As used herein, a FRrepresents one of the four sub-regions, and FRs represents two or moreof the four sub-regions constituting a framework region.

Human heavy chain and light chain acceptor sequences are known in theart. In one embodiment of the invention the human heavy chain and lightchain acceptor sequences are selected from the sequences described inTable 3 and Table 4.

TABLE 3 HEAVY CHAIN ACCEPTOR SEQUENCES Sequence SEQ ID No. Proteinregion 12345678901234567890123456789012 6 VH2-70/JH6EVTLRESGPALVKPTQTLTLTCTFSGFSLS 7 VH2-70/JH6 FR2 WIRQPPGKALEWLA 8VH2-70/JH6 FR3 RLTISKDTSKNQVVLTMTNMDPVDTATYYCAR 9 VH2-70/JH6 FR4WGQGTTVTVSS 10 VH2-26/JH6 FR1 EVTLKESGPVLVKPTETLTLTCTVSGFSLS 7VH2-26/JH6 FR2 WIRQPPGKALEWLA 11 VH2-26/JH6 FR3RLTISKDTSKSQVVLTMTNMDPVDTATYYCAR 9 VH2-26/JH6 FR4 WGQGTTVTVSS 12VH3-72/JH6 FR1 EVQLVESGGGLVQPGGSLRLSCAASGFTFS 13 VH3-72/JH6 FR2WVRQAPGKGLEWVG 14 VH3-72/JH6 FR3 RFTISRDDSKNSLYLQMNSLKTEDTAVYYCAR 9VH3-72/JH6 FR4 WGQGTTVTVSS 15 VH3-21/JH6 FR1EVQLVESGGGLVKPGGSLRLSCAASGFTFS 16 VH3-21/JH6 FR2 WVRQAPGKGLEWVS 17VH3-21/JH6 FR3 RFTISRDNAKNSLYLQMNSLRAEDTAVYYCAR 9 VH3-21/JH6 FR4WGQGTTVTVSS 18 VH1-69/JH6 FR1 EVQLVQSGAEVKKPGSSVKVSCKASGGTFS 19VH1-69/JH6 FR2 WVRQAPGQGLEWMG 20 VH1-69/JH6 FR3RVTITADKSTSTAYMELSSLRSEDTAVYYCAR 9 VH1-69/JH6 FR4 WGQGTTVTVSS 21VH1-18/JH6 FR1 EVQLVQSGAEVKKPGASVKVSCKASGYTFT 19 VH1-18/JH6 FR2WVRQAPGQGLEWMG 22 VH1-18/JH6 FR3 RVTMTTDTSTSTAYMELRSLRSDDTAVYYCAR 9VH1-18/JH6 FR4 WGQGTTVTVSS

TABLE 4 LIGHT CHAIN ACCEPTOR SEQUENCES ID Protein Sequence No. region12345678901234567890123456789012 23 B3/JK4 FR1 DIVMTQSPDSLAVSLGERATINC24 B3/JK4 FR2 WYQQKPGQPPKLLIY 25 B3/JK4 FR3GVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC 26 B3/JK4 FR4 FGGGTKVEIKR 27 L2/JK4 FR1EIVMTQSPATLSVSPGERATLSC 28 L2/JK4 FR2 WYQQKPGQAPRLLIY 29 L2/JK4 FR3GIPARFSGSGSGTEFTLTISSLQSEDFAVYYC 26 L2/JK4 FR4 FGGGTKVEIKR 30 L15/JK4DIQMTQSPSSLSASVGDRVTITC FR1 31 L15/JK4 WYQQKPEKAPKSLIY FR2 32 L15/JK4GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC FR3 26 L15/JK4 FGGGTKVEIKR FR4 33L5/JK4 FR1 DIQMTQSPSSVSASVGDRVTITC 34 L5/JK4 FR2 WYQQKPGKAPKLLIY 32L5/JK4 FR3 GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC 26 L5/JK4 FR4 FGGGTKVEIKR

As used herein, the term “germline antibody gene” or “gene fragment”refers to an immunoglobulin sequence encoded by non-lymphoid cells thathave not undergone the maturation process that leads to geneticrearrangement and mutation for expression of a particularimmunoglobulin. (See, e.g., Shapiro et al., Crit. Rev. Immunol. 22(3):183-200 (2002); Marchalonis et al., Adv Exp Med Biol. 484:13-30 (2001)).One of the advantages provided by various embodiments of the presentinvention stems from the recognition that germline antibody genes aremore likely than mature antibody genes to conserve essential amino acidsequence structures characteristic of individuals in the species, henceless likely to be recognized as from a foreign source when usedtherapeutically in that species.

As used herein, the term “key” residues refer to certain residues withinthe variable region that have more impact on the binding specificityand/or affinity of an antibody, in particular a humanized antibody. Akey residue includes, but is not limited to, one or more of thefollowing: a residue that is adjacent to a CDR, a potentialglycosylation site (can be either N- or O-glycosylation site), a rareresidue, a residue capable of interacting with the antigen, a residuecapable of interacting with a CDR, a canonical residue, a contactresidue between heavy chain variable region and light chain variableregion, a residue within the Vernier zone, and a residue in the regionthat overlaps between the Chothia definition of a variable heavy chainCDR1 and the Kabat definition of the first heavy chain framework.

As used herein, the term “humanized antibody” is an antibody or avariant, derivative, analog or fragment thereof which immunospecificallybinds to an antigen of interest and which comprises a framework (FR)region having substantially the amino acid sequence of a human antibodyand a complementary determining region (CDR) having substantially theamino acid sequence of a non-human antibody. As used herein, the term“substantially” in the context of a CDR refers to a CDR having an aminoacid sequence at least 80%, preferably at least 85%, at least 90%, atleast 95%, at least 98% or at least 99% identical to the amino acidsequence of a non-human antibody CDR. A humanized antibody comprisessubstantially all of at least one, and typically two, variable domains(Fab, Fab′, F(ab′)2, FabC, Fv) in which all or substantially all of theCDR regions correspond to those of a non-human immunoglobulin (i.e.,donor antibody) and all or substantially all of the framework regionsare those of a human immunoglobulin consensus sequence. Preferably, ahumanized antibody also comprises at least a portion of animmunoglobulin constant region (Fc), typically that of a humanimmunoglobulin. In some embodiments, a humanized antibody contains boththe light chain as well as at least the variable domain of a heavychain. The antibody also may include the CH1, hinge, CH2, CH3, and CH4regions of the heavy chain. In some embodiments, a humanized antibodyonly contains a humanized light chain. In some embodiments, a humanizedantibody only contains a humanized heavy chain. In specific embodiments,a humanized antibody only contains a humanized variable domain of alight chain and/or humanized heavy chain.

The humanized antibody can be selected from any class ofimmunoglobulins, including IgM, IgG, IgD, IgA and IgE, and any isotype,including without limitation IgG 1, IgG2, IgG3 and IgG4. The humanizedantibody may comprise sequences from more than one class or isotype, andparticular constant domains may be selected to optimize desired effectorfunctions using techniques well-known in the art.

The framework and CDR regions of a humanized antibody need notcorrespond precisely to the parental sequences, e.g., the donor antibodyCDR or the consensus framework may be mutagenized by substitution,insertion and/or deletion of at least one amino acid residue so that theCDR or framework residue at that site does not correspond to either thedonor antibody or the consensus framework. In a preferred embodiment,such mutations, however, will not be extensive. Usually, at least 80%,preferably at least 85%, more preferably at least 90%, and mostpreferably at least 95% of the humanized antibody residues willcorrespond to those of the parental FR and CDR sequences. As usedherein, the term “consensus framework” refers to the framework region inthe consensus immunoglobulin sequence. As used herein, the term“consensus immunoglobulin sequence” refers to the sequence formed fromthe most frequently occurring amino acids (or nucleotides) in a familyof related immunoglobulin sequences (See e.g., Winnaker, From Genes toClones (Verlagsgesellschaft, Weinheim, Germany 1987). In a family ofimmunoglobulins, each position in the consensus sequence is occupied bythe amino acid occurring most frequently at that position in the family.If two amino acids occur equally frequently, either can be included inthe consensus sequence.

As used herein, “Vernier” zone refers to a subset of framework residuesthat may adjust CDR structure and fine-tune the fit to antigen asdescribed by Foote and Winter (1992, J. Mol. Biol. 224:487-499, which isincorporated herein by reference). Vernier zone residues form a layerunderlying the CDRs and may impact on the structure of CDRs and theaffinity of the antibody.

As used herein, the term “neutralizing” refers to neutralization ofbiological activity of a cytokine when a binding protein specificallybinds the cytokine. Preferably a neutralizing binding protein is aneutralizing antibody whose binding to hIL-12 and/or hIL-23 results ininhibition of a biological activity of hIL-12 and/or hIL-23. Preferablythe neutralizing binding protein binds hIL-12 and/or hIL-23 and reducesa biologically activity of IL-12 and/or hIL-23 by at least about 20%,40%, 60%, 80%, 85% or more. Inhibition of a biological activity ofhIL-12 and/or hIL-23 by a neutralizing binding protein can be assessedby measuring one or more indicators of hIL-12 and/or hIL-23 biologicalactivity well known in the art. For example inhibition of humanphytohemagglutinin blast proliferation in a PHA blast Interferon-gammaInduction Assay (see Example 1.1.C) or inhibition of receptor binding ina human IL-12 receptor binding assay, (also see Salfeld et al., PCTpublication No. WO 00/56772 A1).

The term “activity” includes activities such as the bindingspecificity/affinity of an antibody for an antigen, for example, ananti-hIL-12 antibody that binds to an IL-12 antigen and/or theneutralizing potency of an antibody, for example, an anti-hIL-12antibody whose binding to hIL-12 inhibits the biological activity ofhIL-12, e.g. inhibition of PHA blast proliferation or inhibition ofreceptor binding in a human IL-12 receptor binding assay, or PHA blastInterferon-gamma Induction Assay (see Example 1.1.C).

The term “epitope” includes any polypeptide determinant capable ofspecific binding to an immunoglobulin or T-cell receptor. In certainembodiments, epitope determinants include chemically active surfacegroupings of molecules such as amino acids, sugar side chains,phosphoryl, or sulfonyl, and, in certain embodiments, may have specificthree dimensional structural characteristics, and/or specific chargecharacteristics. An epitope is a region of an antigen that is bound byan antibody. In certain embodiments, an antibody is said to specificallybind an antigen when it preferentially recognizes its target antigen ina complex mixture of proteins and/or macromolecules.

The term “surface plasmon resonance”, as used herein, refers to anoptical phenomenon that allows for the analysis of real-time biospecificinteractions by detection of alterations in protein concentrationswithin a biosensor matrix, for example using the BIAcore system(Pharmacia Biosensor AB, Uppsala, Sweden and Piscataway, N.J.). Forfurther descriptions, see Jönsson, U., et al. (1993) Ann. Biol. Clin.51:19-26; Jönsson, U., et al. (1991) Biotechniques 11:620-627; Johnsson,B., et al. (1995) J. Mol. Recognit. 8:125-131; and Johnnson, B., et al.(1991) Anal. Biochem. 198:268-277.

The term “K_(on)”, as used herein, is intended to refer to the on rateconstant for association of an antibody to the antigen to form theantibody/antigen complex as is known in the art.

The term “K_(off)”, as used herein, is intended to refer to the off rateconstant for dissociation of an antibody from the antibody/antigencomplex as is known in the art.

The term “K_(d)”, as used herein, is intended to refer to thedissociation constant of a particular antibody-antigen interaction as isknown in the art.

The term “labeled binding protein” as used herein, refers to a proteinwith a label incorporated that provides for the identification of thebinding protein. Preferably, the label is a detectable marker, e.g.,incorporation of a radiolabeled amino acid or attachment to apolypeptide of biotinyl moieties that can be detected by marked avidin(e.g., streptavidin containing a fluorescent marker or enzymaticactivity that can be detected by optical or colorimetric methods).Examples of labels for polypeptides include, but are not limited to, thefollowing: radioisotopes or radionuclides (e.g., ³H, ¹⁴C, ³⁵S, ⁹⁰Y,⁹⁹Tc, ¹¹¹In, ¹²⁵I, ¹³¹I, ¹⁷⁷Lu, ¹⁶⁶Ho, or ¹⁵³Sm); fluorescent labels(e.g., FITC, rhodamine, lanthanide phosphors), enzymatic labels (e.g.,horseradish peroxidase, luciferase, alkaline phosphatase);chemiluminescent markers; biotinyl groups; predetermined polypeptideepitopes recognized by a secondary reporter (e.g., leucine zipper pairsequences, binding sites for secondary antibodies, metal bindingdomains, epitope tags); and magnetic agents, such as gadoliniumchelates.

The term “antibody conjugate” refers to a binding protein, such as anantibody, chemically linked to a second chemical moiety, such as atherapeutic or cytotoxic agent. The term “agent” is used herein todenote a chemical compound, a mixture of chemical compounds, abiological macromolecule, or an extract made from biological materials.Preferably the therapeutic or cytotoxic agents include, but are notlimited to, pertussis toxin, taxol, cytochalasin B, gramicidin D,ethidium bromide, emetine, mitomycin, etoposide, tenoposide,vincristine, vinblastine, colchicin, doxorubicin, daunorubicin,dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D,1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine,propranolol, and puromycin and analogs or homologs thereof.

The terms “crystal”, and “crystallized” as used herein, refer to anantibody, or antigen binding portion thereof, that exists in the form ofa crystal. Crystals are one form of the solid state of matter, which isdistinct from other forms such as the amorphous solid state or theliquid crystalline state. Crystals are composed of regular, repeating,three-dimensional arrays of atoms, ions, molecules (e.g., proteins suchas antibodies), or molecular assemblies (e.g., antigen/antibodycomplexes). These three-dimensional arrays are arranged according tospecific mathematical relationships that are well-understood in thefield. The fundamental unit, or building block, that is repeated in acrystal is called the asymmetric unit. Repetition of the asymmetric unitin an arrangement that conforms to a given, well-definedcrystallographic symmetry provides the “unit cell” of the crystal.Repetition of the unit cell by regular translations in all threedimensions provides the crystal. See Giege, R. and Ducruix, A. Barrett,Crystallization of Nucleic Acids and Proteins, a Practical Approach, 2ndea., pp. 20 1-16, Oxford University Press, New York, N.Y., (1999).”

The term “polynucleotide” as referred to herein means a polymeric formof two or more nucleotides, either ribonucleotides or deoxynucleotidesor a modified form of either type of nucleotide. The term includessingle and double stranded forms of DNA but preferably isdouble-stranded DNA.

The term “isolated polynucleotide” as used herein shall mean apolynucleotide (e.g., of genomic, cDNA, or synthetic origin, or somecombination thereof) that, by virtue of its origin, the “isolatedpolynucleotide”: is not associated with all or a portion of apolynucleotide with which the “isolated polynucleotide” is found innature; is operably linked to a polynucleotide that it is not linked toin nature; or does not occur in nature as part of a larger sequence.

The term “vector”, as used herein, is intended to refer to a nucleicacid molecule capable of transporting another nucleic acid to which ithas been linked. One type of vector is a “plasmid”, which refers to acircular double stranded DNA loop into which additional DNA segments maybe ligated. Another type of vector is a viral vector, wherein additionalDNA segments may be ligated into the viral genome. Certain vectors arecapable of autonomous replication in a host cell into which they areintroduced (e.g., bacterial vectors having a bacterial origin ofreplication and episomal mammalian vectors). Other vectors (e.g.,non-episomal mammalian vectors) can be integrated into the genome of ahost cell upon introduction into the host cell, and thereby arereplicated along with the host genome. Moreover, certain vectors arecapable of directing the expression of genes to which they areoperatively linked. Such vectors are referred to herein as “recombinantexpression vectors” (or simply, “expression vectors”). In general,expression vectors of utility in recombinant DNA techniques are often inthe form of plasmids. In the present specification, “plasmid” and“vector” may be used interchangeably as the plasmid is the most commonlyused form of vector. However, the invention is intended to include suchother forms of expression vectors, such as viral vectors (e.g.,replication defective retroviruses, adenoviruses and adeno-associatedviruses), which serve equivalent functions.

The term “operably linked” refers to a juxtaposition wherein thecomponents described are in a relationship permitting them to functionin their intended manner. A control sequence “operably linked” to acoding sequence is ligated in such a way that expression of the codingsequence is achieved under conditions compatible with the controlsequences. “Operably linked” sequences include both expression controlsequences that are contiguous with the gene of interest and expressioncontrol sequences that act in trans or at a distance to control the geneof interest. The term “expression control sequence” as used hereinrefers to polynucleotide sequences which are necessary to effect theexpression and processing of coding sequences to which they are ligated.Expression control sequences include appropriate transcriptioninitiation, termination, promoter and enhancer sequences; efficient RNAprocessing signals such as splicing and polyadenylation signals;sequences that stabilize cytoplasmic mRNA; sequences that enhancetranslation efficiency (i.e., Kozak consensus sequence); sequences thatenhance protein stability; and when desired, sequences that enhanceprotein secretion. The nature of such control sequences differsdepending upon the host organism; in prokaryotes, such control sequencesgenerally include promoter, ribosomal binding site, and transcriptiontermination sequence; in eukaryotes, generally, such control sequencesinclude promoters and transcription termination sequence. The term“control sequences” is intended to include components whose presence isessential for expression and processing, and can also include additionalcomponents whose presence is advantageous, for example, leader sequencesand fusion partner sequences.

“Transformation”, as defined herein, refers to any process by whichexogenous DNA enters a host cell. Transformation may occur under naturalor artificial conditions using various methods well known in the art.Transformation may rely on any known method for the insertion of foreignnucleic acid sequences into a prokaryotic or eukaryotic host cell. Themethod is selected based on the host cell being transformed and mayinclude, but is not limited to, viral infection, electroporation,lipofection, and particle bombardment. Such “transformed” cells includestably transformed cells in which the inserted DNA is capable ofreplication either as an autonomously replicating plasmid or as part ofthe host chromosome. They also include cells which transiently expressthe inserted DNA or RNA for limited periods of time.

The term “recombinant host cell” (or simply “host cell”), as usedherein, is intended to refer to a cell into which exogenous DNA has beenintroduced. It should be understood that such terms are intended torefer not only to the particular subject cell, but, to the progeny ofsuch a cell. Because certain modifications may occur in succeedinggenerations due to either mutation or environmental influences, suchprogeny may not, in fact, be identical to the parent cell, but are stillincluded within the scope of the term “host cell” as used herein.Preferably host cells include prokaryotic and eukaryotic cells selectedfrom any of the Kingdoms of life. Preferred eukaryotic cells includeprotist, fungal, plant and animal cells. Most preferably host cellsinclude but are not limited to the prokaryotic cell line E. Coli;mammalian cell lines CHO, HEK 293 and COS; the insect cell line Sf9; andthe fungal cell Saccharomyces cerevisiae.

Standard techniques may be used for recombinant DNA, oligonucleotidesynthesis, and tissue culture and transformation (e.g., electroporation,lipofection). Enzymatic reactions and purification techniques may beperformed according to manufacturer's specifications or as commonlyaccomplished in the art or as described herein. The foregoing techniquesand procedures may be generally performed according to conventionalmethods well known in the art and as described in various general andmore specific references that are cited and discussed throughout thepresent specification. See e.g., Sambrook et al. Molecular Cloning: ALaboratory Manual (2d ed., Cold Spring Harbor Laboratory Press, ColdSpring Harbor, N.Y. (1989)), which is incorporated herein by referencefor any purpose.

“Transgenic organism”, as known in the art and as used herein, refers toan organism having cells that contain a transgene, wherein the transgeneintroduced into the organism (or an ancestor of the organism) expressesa polypeptide not naturally expressed in the organism. A “transgene” isa DNA construct, which is stably and operably integrated into the genomeof a cell from which a transgenic organism develops, directing theexpression of an encoded gene product in one or more cell types ortissues of the transgenic organism.

The term “regulate” and “modulate” are used interchangeably, and, asused herein, refers to a change or an alteration in the activity of amolecule of interest (e.g., the biological activity of hIL-12).Modulation may be an increase or a decrease in the magnitude of acertain activity or function of the molecule of interest. Exemplaryactivities and functions of a molecule include, but are not limited to,binding characteristics, enzymatic activity, cell receptor activation,and signal transduction.

Correspondingly, the term “modulator,” as used herein, is a compoundcapable of changing or altering an activity or function of a molecule ofinterest (e.g., the biological activity of hIL-12). For example, amodulator may cause an increase or decrease in the magnitude of acertain activity or function of a molecule compared to the magnitude ofthe activity or function observed in the absence of the modulator. Incertain embodiments, a modulator is an inhibitor, which decreases themagnitude of at least one activity or function of a molecule. Exemplaryinhibitors include, but are not limited to, proteins, peptides,antibodies, peptibodies, carbohydrates or small organic molecules.Peptibodies are described, e.g., in WO01/83525.

The term “agonist”, as used herein, refers to a modulator that, whencontacted with a molecule of interest, causes an increase in themagnitude of a certain activity or function of the molecule compared tothe magnitude of the activity or function observed in the absence of theagonist. Particular agonists of interest may include, but are notlimited to, IL-12 polypeptides or polypeptides, nucleic acids,carbohydrates, or any other molecules that bind to hIL-12.

The term “antagonist” or “inhibitor”, as used herein, refer to amodulator that, when contacted with a molecule of interest causes adecrease in the magnitude of a certain activity or function of themolecule compared to the magnitude of the activity or function observedin the absence of the antagonist. Particular antagonists of interestinclude those that block or modulate the biological or immunologicalactivity of hIL-12 and/or hIL-23. Antagonists and inhibitors of hIL-12and/or hIL-23 may include, but are not limited to, proteins, nucleicacids, carbohydrates, or any other molecules, which bind to hIL-12and/or hIL-23.

As used herein, the term “effective amount” refers to the amount of atherapy which is sufficient to reduce or ameliorate the severity and/orduration of a disorder or one or more symptoms thereof, prevent theadvancement of a disorder, cause regression of a disorder, prevent therecurrence, development, onset or progression of one or more symptomsassociated with a disorder, detect a disorder, or enhance or improve theprophylactic or therapeutic effect(s) of another therapy (e.g.,prophylactic or therapeutic agent).

The term “sample”, as used herein, is used in its broadest sense. A“biological sample”, as used herein, includes, but is not limited to,any quantity of a substance from a living thing or formerly livingthing. Such living things include, but are not limited to, humans, mice,rats, monkeys, dogs, rabbits and other animals. Such substances include,but are not limited to, blood, serum, urine, synovial fluid, cells,organs, tissues, bone marrow, lymph nodes and spleen.

I. Antibodies that Bind Human IL-12p40

One aspect of the present invention provides isolated murine monoclonalantibodies, or antigen-binding portions thereof, that bind to IL-12p40with high affinity, a slow off rate and high neutralizing capacity. Asecond aspect of the invention provides chimeric antibodies that bindIL-12p40. A third aspect of the invention provides CDR graftedantibodies, or antigen-binding portions thereof, that bind IL-12p40. Afourth aspect of the invention provides humanized antibodies, orantigen-binding portions thereof, that bind IL-12p40. Preferably, theantibodies, or portions thereof, are isolated antibodies. Preferably,the antibodies of the invention are neutralizing human anti-IL-12 and/orhuman anti-IL-23 antibodies.

A. Method of Making Anti IL-12p40 Antibodies

Antibodies of the present invention may be made by any of a number oftechniques known in the art.

1. Anti-IL-12 p40 Monoclonal Antibodies Using Hybridoma Technology

Monoclonal antibodies can be prepared using a wide variety of techniquesknown in the art including the use of hybridoma, recombinant, and phagedisplay technologies, or a combination thereof. For example, monoclonalantibodies can be produced using hybridoma techniques including thoseknown in the art and taught, for example, in Harlow et al., Antibodies:A Laboratory Manual, (Cold Spring Harbor Laboratory Press, 2nd ed.1988); Hammerling, et al., in: Monoclonal Antibodies and T-CellHybridomas 563681 (Elsevier, N.Y., 1981) (said references incorporatedby reference in their entireties). The term “monoclonal antibody” asused herein is not limited to antibodies produced through hybridomatechnology. The term “monoclonal antibody” refers to an antibody that isderived from a single clone, including any eukaryotic, prokaryotic, orphage clone, and not the method by which it is produced.

Methods for producing and screening for specific antibodies usinghybridoma technology are routine and well known in the art. In oneembodiment, the present invention provides methods of generatingmonoclonal antibodies as well as antibodies produced by the methodcomprising culturing a hybridoma cell secreting an antibody of theinvention wherein, preferably, the hybridoma is generated by fusingsplenocytes isolated from a mouse immunized with an antigen of theinvention with myeloma cells and then screening the hybridomas resultingfrom the fusion for hybridoma clones that secrete an antibody able tobind a polypeptide of the invention (See Example 1.2). Briefly, mice canbe immunized with an IL-12 antigen. In a preferred embodiment, the IL-12antigen is administered with a adjuvant to stimulate the immuneresponse. Such adjuvants include complete or incomplete Freund'sadjuvant, RIBI (muramyl dipeptides) or ISCOM (immunostimulatingcomplexes). Such adjuvants may protect the polypeptide from rapiddispersal by sequestering it in a local deposit, or they may containsubstances that stimulate the host to secrete factors that arechemotactic for macrophages and other components of the immune system.Preferably, if a polypeptide is being administered, the immunizationschedule will involve two or more administrations of the polypeptide,spread out over several weeks.

After immunization of an animal with an IL-12 antigen, antibodies and/orantibody-producing cells may be obtained from the animal. An anti-IL-12antibody-containing serum is obtained from the animal by bleeding orsacrificing the animal. The serum may be used as it is obtained from theanimal, an immunoglobulin fraction may be obtained from the serum, orthe anti-IL-12 antibodies may be purified from the serum. Serum orimmunoglobulins obtained in this manner are polyclonal, thus having aheterogeneous array of properties.

Once an immune response is detected, e.g., antibodies specific for theantigen IL-12 are detected in the mouse serum, the mouse spleen isharvested and splenocytes isolated. The splenocytes are then fused bywell-known techniques to any suitable myeloma cells, for example cellsfrom cell line SP20 available from the ATCC. Hybridomas are selected andcloned by limited dilution. The hybridoma clones are then assayed bymethods known in the art for cells that secrete antibodies capable ofbinding IL-12. Ascites fluid, which generally contains high levels ofantibodies, can be generated by immunizing mice with positive hybridomaclones.

In another embodiment, antibody-producing immortalized hybridomas may beprepared from the immunized animal. After immunization, the animal issacrificed and the splenic B cells are fused to immortalized myelomacells as is well known in the art. See, e.g., Harlow and Lane, supra. Ina preferred embodiment, the myeloma cells do not secrete immunoglobulinpolypeptides (a non-secretory cell line). After fusion and antibioticselection, the hybridomas are screened using IL-12, or a portionthereof, or a cell expressing IL-12. In a preferred embodiment, theinitial screening is performed using an enzyme-linked immunoassay(ELISA) or a radioimmunoassay (RIA), preferably an ELISA. An example ofELISA screening is provided in WO 00/37504, herein incorporated byreference.

Anti-IL-12p40 antibody-producing hybridomas are selected, cloned andfurther screened for desirable characteristics, including robusthybridoma growth, high antibody production and desirable antibodycharacteristics, as discussed further below. Hybridomas may be culturedand expanded in vivo in syngeneic animals, in animals that lack animmune system, e.g., nude mice, or in cell culture in vitro. Methods ofselecting, cloning and expanding hybridomas are well known to those ofordinary skill in the art.

In a preferred embodiment, the hybridomas are mouse hybridomas, asdescribed above. In another preferred embodiment, the hybridomas areproduced in a non-human, non-mouse species such as rats, sheep, pigs,goats, cattle or horses. In another embodiment, the hybridomas are humanhybridomas, in which a human non-secretory myeloma is fused with a humancell expressing an anti-IL-12 antibody.

Antibody fragments that recognize specific epitopes may be generated byknown techniques. For example, Fab and F(ab′)2 fragments of theinvention may be produced by proteolytic cleavage of immunoglobulinmolecules, using enzymes such as papain (to produce Fab fragments) orpepsin (to produce F(ab′)2 fragments). F(ab′)2 fragments contain thevariable region, the light chain constant region and the CH1 domain ofthe heavy chain.

2. Anti-IL-12p40 Monoclonal Antibodies Using SLAM

In another aspect of the invention, recombinant antibodies are generatedfrom single, isolated lymphocytes using a procedure referred to in theart as the selected lymphocyte antibody method (SLAM), as described inU.S. Pat. No. 5,627,052, PCT Publication WO 92/02551 and Babcock, J. S.et al. (1996) Proc. Natl. Acad. Sci. USA 93:7843-7848. In this method,single cells secreting antibodies of interest, e.g., lymphocytes derivedfrom any one of the immunized animals described in Section 1, arescreened using an antigen-specific hemolytic plaque assay, wherein theantigen IL-12, a subunit of IL-12, or a fragment thereof, is coupled tosheep red blood cells using a linker, such as biotin, and used toidentify single cells that secrete antibodies with specificity forIL-12. Following identification of antibody-secreting cells of interest,heavy- and light-chain variable region cDNAs are rescued from the cellsby reverse transcriptase-PCR and these variable regions can then beexpressed, in the context of appropriate immunoglobulin constant regions(e.g., human constant regions), in mammalian host cells, such as COS orCHO cells. The host cells transfected with the amplified immunoglobulinsequences, derived from in vivo selected lymphocytes, can then undergofurther analysis and selection in vitro, for example by panning thetransfected cells to isolate cells expressing antibodies to IL-12. Theamplified immunoglobulin sequences further can be manipulated in vitro,such as by in vitro affinity maturation methods such as those describedin PCT Publication WO 97/29131 and PCT Publication WO 00/56772.

3. Anti-IL-12p40 Monoclonal Antibodies Using Transgenic Animals

In another embodiment of the instant invention, antibodies are producedby immunizing a non-human animal comprising some, or all, of the humanimmunoglobulin locus with an IL-12 antigen. In a preferred embodiment,the non-human animal is a XENOMOUSE transgenic mouse, an engineeredmouse strain that comprises large fragments of the human immunoglobulinloci and is deficient in mouse antibody production. See, e.g., Green etal. Nature Genetics 7:13-21 (1994) and U.S. Pat. Nos. 5,916,771,5,939,598, 5,985,615, 5,998,209, 6,075,181, 6,091,001, 6,114,598 and6,130,364. See also WO 91/10741, published Jul. 25, 1991, WO 94/02602,published Feb. 3, 1994, WO 96/34096 and WO 96/33735, both published Oct.31, 1996, WO 98/16654, published Apr. 23, 1998, WO 98/24893, publishedJun. 11, 1998, WO 98/50433, published Nov. 12, 1998, WO 99/45031,published Sep. 10, 1999, WO 99/53049, published Oct. 21, 1999, WO 0009560, published Feb. 24, 2000 and WO 00/037504, published Jun. 29,2000. The XENOMOUSE transgenic mouse produces an adult-like humanrepertoire of fully human antibodies, and generates antigen-specifichuman Mabs. The XENOMOUSE transgenic mouse contains approximately 80% ofthe human antibody repertoire through introduction of megabase sized,germline configuration YAC fragments of the human heavy chain loci and xlight chain loci. See Mendez et al., Nature Genetics 15:146-156 (1997),Green and Jakobovits J. Exp. Med. 188:483-495 (1998), the disclosures ofwhich are hereby incorporated by reference.

4. Anti-IL-12 Monoclonal Antibodies Using Recombinant Antibody Libraries

In vitro methods also can be used to make the antibodies of theinvention, wherein an antibody library is screened to identify anantibody having the desired binding specificity. Methods for suchscreening of recombinant antibody libraries are well known in the artand include methods described in, for example, Ladner et al. U.S. Pat.No. 5,223,409; Kang et al. PCT Publication No. WO 92/18619; Dower et al.PCT Publication No. WO 91/17271; Winter et al. PCT Publication No. WO92/20791; Markland et al. PCT Publication No. WO 92/15679; Breitling etal. PCT Publication No. WO 93/01288; McCafferty et al. PCT PublicationNo. WO 92/01047; Garrard et al. PCT Publication No. WO 92/09690; Fuchset al. (1991) Bio/Technology 9:1370-1372; Hay et al. (1992) Hum AntibodHybridomas 3:81-85; Huse et al. (1989) Science 246:1275-1281; McCaffertyet al., Nature (1990) 348:552-554; Griffiths et al. (1993) EMBO J12:725-734; Hawkins et al. (1992) J Mol Biol 226:889-896; Clackson etal. (1991) Nature 352:624-628; Gram et al. (1992) PNAS 89:3576-3580;Garrad et al. (1991) Bio/Technology 9:1373-1377; Hoogenboom et al.(1991) Nuc Acid Res 19:4133-4137; and Barbas et al. (1991) PNAS88:7978-7982, US patent application publication 20030186374, and PCTPublication No. WO 97/29131, the contents of each of which areincorporated herein by reference.

The recombinant antibody library may be from a subject immunized withIL-12 or IL-23, or a portion of IL-12 or IL-23. Alternatively, therecombinant antibody library may be from a naïve subject, i.e., one whohas not been immunized with IL-12 or IL-23, such as a human antibodylibrary from a human subject who has not been immunized with human IL-12or IL-23. Antibodies of the invention are selected by screening therecombinant antibody library with the peptide comprising human IL-12p40to thereby select those antibodies that recognize IL-12p40. Methods forconducting such screening and selection are well known in the art, suchas described in the references in the preceding paragraph. To selectantibodies of the invention having particular binding affinities forhIL-12, such as those that dissociate from human IL-12 with a particulark_(off) rate constant, the art-known method of surface plasmon resonancecan be used to select antibodies having the desired k_(off) rateconstant. To select antibodies of the invention having a particularneutralizing activity for hIL-12, such as those with a particular anIC₅₀, standard methods known in the art for assessing the inhibition ofhIL-12 activity may be used.

In one aspect, the invention pertains to an isolated antibody, or anantigen-binding portion thereof, that binds human IL-12 and/or humanIL-23. Preferably, the antibody is a neutralizing antibody. In variousembodiments, the antibody is a recombinant antibody or a monoclonalantibody.

For example, the antibodies of the present invention can also begenerated using various phage display methods known in the art. In phagedisplay methods, functional antibody domains are displayed on thesurface of phage particles which carry the polynucleotide sequencesencoding them. In a particular, such phage can be utilized to displayantigen-binding domains expressed from a repertoire or combinatorialantibody library (e.g., human or murine). Phage expressing an antigenbinding domain that binds the antigen of interest can be selected oridentified with antigen, e.g., using labeled antigen or antigen bound orcaptured to a solid surface or bead. Phage used in these methods aretypically filamentous phage including fd and M13 binding domainsexpressed from phage with Fab, Fv or disulfide stabilized Fv antibodydomains recombinantly fused to either the phage gene III or gene VIIIprotein. Examples of phage display methods that can be used to make theantibodies of the present invention include those disclosed in Brinkmanet al., J. Immunol. Methods 182:41-50 (1995); Ames et al., J. Immunol.Methods 184:177-186 (1995); Kettleborough et al., Eur. J. Immunol.24:952-958 (1994); Persic et al., Gene 187 9-18 (1997); Burton et al.,Advances in Immunology 57:191-280 (1994); PCT application No.PCT/GB91/01134; PCT publications WO 90/02809; WO 91/10737; WO 92101047;WO 92/18619; WO 93/11236; WO 95/15982; WO 95/20401; and U.S. Pat. Nos.5,698,426; 5,223,409; 5,403,484; 5,580,717; 5,427,908; 5,750,753;5,821,047; 5,571,698; 5,427,908; 5,516,637; 5,780,225; 5,658,727;5,733,743 and 5,969,108; each of which is incorporated herein byreference in its entirety.

As described in the above references, after phage selection, theantibody coding regions from the phage can be isolated and used togenerate whole antibodies including human antibodies or any otherdesired antigen binding fragment, and expressed in any desired host,including mammalian cells, insect cells, plant cells, yeast, andbacteria, e.g., as described in detail below. For example, techniques torecombinantly produce Fab, Fab′ and F(ab′)2 fragments can also beemployed using methods known in the art such as those disclosed in PCTpublication WO 92/22324; Mullinax et al., BioTechniques 12(6):864-869(1992); and Sawai et al., AJRI 34:26-34 (1995); and Better et al.,Science 240:1041-1043 (1988) (said references incorporated by referencein their entireties). Examples of techniques which can be used toproduce single-chain Fvs and antibodies include those described in U.S.Pat. Nos. 4,946,778 and 5,258,498; Huston et al., Methods in Enzymology203:46-88 (1991); Shu et al., PNAS 90:7995-7999 (1993); and Skerra etal., Science 240:1038-1040 (1988).

Alternative to screening of recombinant antibody libraries by phagedisplay, other methodologies known in the art for screening largecombinatorial libraries can be applied to the identification of dualspecificity antibodies of the invention. One type of alternativeexpression system is one in which the recombinant antibody library isexpressed as RNA-protein fusions, as described in PCT Publication No. WO98/31700 by Szostak and Roberts, and in Roberts, R. W. and Szostak, J.W. (1997) Proc. Natl. Acad. Sci. USA 94:12297-12302. In this system, acovalent fusion is created between an mRNA and the peptide or proteinthat it encodes by in vitro translation of synthetic mRNAs that carrypuromycin, a peptidyl acceptor antibiotic, at their 3′ end. Thus, aspecific mRNA can be enriched from a complex mixture of mRNAs (e.g., acombinatorial library) based on the properties of the encoded peptide orprotein, e.g., antibody, or portion thereof, such as binding of theantibody, or portion thereof, to the dual specificity antigen. Nucleicacid sequences encoding antibodies, or portions thereof, recovered fromscreening of such libraries can be expressed by recombinant means asdescribed above (e.g., in mammalian host cells) and, moreover, can besubjected to further affinity maturation by either additional rounds ofscreening of mRNA-peptide fusions in which mutations have beenintroduced into the originally selected sequence(s), or by other methodsfor affinity maturation in vitro of recombinant antibodies, as describedabove.

In another approach the antibodies of the present invention can also begenerated using yeast display methods known in the art. In yeast displaymethods, genetic methods are used to tether antibody domains to theyeast cell wall and display them on the surface of yeast. In particular,such yeast can be utilized to display antigen-binding domains expressedfrom a repertoire or combinatorial antibody library (e.g., human ormurine). Examples of yeast display methods that can be used to make theantibodies of the present invention include those disclosed Wittrup, etal. U.S. Pat. No. 6,699,658 incorporated herein by reference.

B. Production of Recombinant IL-12p40 Antibodies

Antibodies of the present invention may be produced by any of a numberof techniques known in the art. For example, expression from host cells,wherein expression vector(s) encoding the heavy and light chains is(are) transfected into a host cell by standard techniques. The variousforms of the term “transfection” are intended to encompass a widevariety of techniques commonly used for the introduction of exogenousDNA into a prokaryotic or eukaryotic host cell, e.g., electroporation,calcium-phosphate precipitation, DEAE-dextran transfection and the like.Although it is possible to express the antibodies of the invention ineither prokaryotic or eukaryotic host cells, expression of antibodies ineukaryotic cells is preferable, and most preferable in mammalian hostcells, because such eukaryotic cells (and in particular mammalian cells)are more likely than prokaryotic cells to assemble and secrete aproperly folded and immunologically active antibody.

Preferred mammalian host cells for expressing the recombinant antibodiesof the invention include Chinese Hamster Ovary (CHO cells) (includingdhfr-CHO cells, described in Urlaub and Chasin, (1980) Proc. Natl. Acad.Sci. USA 77:4216-4220, used with a DHFR selectable marker, e.g., asdescribed in R. J. Kaufman and P. A. Sharp (1982) Mol. Biol.159:601-621), NSO myeloma cells, COS cells and SP2 cells. Whenrecombinant expression vectors encoding antibody genes are introducedinto mammalian host cells, the antibodies are produced by culturing thehost cells for a period of time sufficient to allow for expression ofthe antibody in the host cells or, more preferably, secretion of theantibody into the culture medium in which the host cells are grown.Antibodies can be recovered from the culture medium using standardprotein purification methods.

Host cells can also be used to produce functional antibody fragments,such as Fab fragments or scFv molecules. It will be understood thatvariations on the above procedure are within the scope of the presentinvention. For example, it may be desirable to transfect a host cellwith DNA encoding functional fragments of either the light chain and/orthe heavy chain of an antibody of this invention. Recombinant DNAtechnology may also be used to remove some, or all, of the DNA encodingeither or both of the light and heavy chains that is not necessary forbinding to the antigens of interest. The molecules expressed from suchtruncated DNA molecules are also encompassed by the antibodies of theinvention. In addition, bifunctional antibodies may be produced in whichone heavy and one light chain are an antibody of the invention and theother heavy and light chain are specific for an antigen other than theantigens of interest by crosslinking an antibody of the invention to asecond antibody by standard chemical crosslinking methods.

In a preferred system for recombinant expression of an antibody, orantigen-binding portion thereof, of the invention, a recombinantexpression vector encoding both the antibody heavy chain and theantibody light chain is introduced into dhfr-CHO cells by calciumphosphate-mediated transfection. Within the recombinant expressionvector, the antibody heavy and light chain genes are each operativelylinked to CMV enhancer/AdMLP promoter regulatory elements to drive highlevels of transcription of the genes. The recombinant expression vectoralso carries a DHFR gene, which allows for selection of CHO cells thathave been transfected with the vector using methotrexateselection/amplification. The selected transformant host cells arecultured to allow for expression of the antibody heavy and light chainsand intact antibody is recovered from the culture medium. Standardmolecular biology techniques are used to prepare the recombinantexpression vector, transfect the host cells, select for transformants,culture the host cells and recover the antibody from the culture medium.Still further the invention provides a method of synthesizing arecombinant antibody of the invention by culturing a host cell of theinvention in a suitable culture medium until a recombinant antibody ofthe invention is synthesized. The method can further comprise isolatingthe recombinant antibody from the culture medium.

1. Anti IL-12p40 Antibodies

Table 5 is a list of amino acid sequences of VH and VL regions ofpreferred anti-hIL-12p40 antibodies of the invention.

TABLE 5 List of Amino Acid Sequences of VH and VL regions SEQ IDSequence No. Protein region 123456789012345678901234567890 35 VH 1D4QVTLKESGPGILQPSQTLSLTCSFSGFSLR KSVMGVSWIRQPSGKGLEWLAHIYWDDDKYYNPSLKSRLTISKDPSRNQVFLKITSVDTA DAATYYCTRRGIRSAMDYWGQGTSVTVSS VH 1D4 CDR-Residues 31-37 KSVMGVS H1 of SEQ ID NO.:35 VH 1D4 CDR- Residues 52-67HIYWDDDKYYNPSLKS H2 of SEQ ID NO.:35 VH 1D4 CDR- Residues 100- RGIRSAMDYH3 108 of SEQ ID NO.:35 36 VL 1D4 SVVMTQTPKFLLVSAGDRVTITCKASQSVSNDVAWYQQKPGQSPKLLIYYASNRYTGVPD RFTGSGYGTDFTFIISTVRAEDLAVYFCQQDYNSPWTFGGGTKLEIKR VL 1D4 CDR- Residues24-34 KASQSVSNDVA L1 of SEQ IDNO.:36 VL 1D4 CDR- Residues50-56 YASNRYT L2 of SEQ ID NO.:36 VL 1D4 CDR-Residues89-97 QQDYNSPWT L3 of SEQ ID NO.:36 37 VH 1A6QVTLKESGPGILKPSQTLSLTCSFSGFSLS TSGMGVSWIRQPSGKGLEWLAHIWWDGDNYYNPSLKSQLTISKDTSRNQVFLRIATVDTA DTATYYCARRTRVNYAMDYWGQGTSVTVSS VH 1A6CDR- Residues31-37 TSGMGVS H1 of SEQ ID NO.:37 VH 1A6 CDR- Residues52-67HIWWDGDNYYNPSLKS H2 of SEQ ID NO.:37 VH 1A6 CDR- Residues100- RTRVNYAMDYH3 109 of SEQ ID NO.:37 38 VH 1A6 SVVMTQTPKFLLVSAGDRVTITCKASQSVSNDVAWFQQKPGQSPKLLIYYASNRYTGVPD RFTGSGYGTDFTFTISTVQAEDLAVYFCQQDYNSPWTFGGGTKLEIKR VL 1A6 CDR- Residues24-34 KASQSVSNDVA L1 of SEQ IDNO.:38 VL 1A6 CDR- Residues50-56 YASNRYT L2 of SEQ ID NO.:38 VL 1A6 CDR-Residues89-97 QQDYNSPWT L3 of SEQ ID NO.:38 39 VH 1D8QVQLQQSGAELMKPGASVKISCKATGYTFS SYWIEWVKQRPGHGLEWIGDILPGSGSTNYNEKFKDKATFTADTSFNTAYMQLSSLTSED SAVYYCATRRFRGLDYWGQGTTLTVSS VH 1D8 CDR-Residues 31-35 SYWIE H1 of SEQ ID NO.:39 VH 1D8 CDR- Residues 50-66DILPGSGSTNYNEKFKD H2 of SEQ ID NO.:39 VH 1D8 CDR- Residues 99- RRFRGLDYH3 106 of SEQ ID NO.:39 40 VL 1D8 SIVMTQTPKFLLVSAGDRVTITCKASQSVSNDVAWYQQKSGQSPKLLIYYASNRYTGVPD RFTGSGYGTDFTFTISTVQPEDLAVYFCQQDYTSPFTFGSGTKLEIKR VL 1D8 CDR- Residues 24-34 KASQSVSNDVA L1 of SEQ IDNO.:40 VL 1D8 CDR- Residues 50-56 YASNRYT L2 of SEQ ID NO.:40 VL 1D8CDR- Residues 89-97 QQDYTSPFT L3 of SEQ ID NO.:40 41 VH 3G7QVQLQQSGAELMKPGASVKISCKATGYTFN DYWIEWVKQRPGHGLEWIGGFSHGSGSTNYNEKFKGKATFTADSSSNTAYMQLSSLTSED SAVYYCARRRFRGMDYWGQGTSVTVSS VH 3G7 CDR-Residues 31-35 DYWIE H1 of SEQ ID NO.:41 VH 3G7 CDR- Residues 50-66GFSHGSGSTNYNEKFKG H2 of SEQ ID NO.:41 VH 3G7 CDR- Residues 99- RRFRGMDYH3 106 of SEQ ID NO.:41 42 VL 3G7 SIVMTQTPKFLLVSAGDRVTITCKASQSVSNDVAWYQQKPGQSPKLLIYYASNRYTGVPD RFTGSGYGTDFTFTITTVQAEDLAVYFCQQDYSSPWSFGGGTKLEIKR VL 3G7 CDR- Residues 24-34 KASQSVSNDVA L1 of SEQ IDNO.:42 VL 3G7 CDR- Residues 50-56 YASNRYT L2 of SEQ ID NO.:42 VL 3G7CDR- Residues 89-97 QQDYSSPWS L3 of SEQ ID NO.:42 43 VH 5E8QIQLVQSGPELKKPGETVKISCKASGYSFT DYSMHWVKQAPGKGLKWMDWINTETGEPTYADDFKGRFAFSLETSASTAYLQINNLKNED TATYFCSRRRYRAFDYWGQGTTLTVSS 43 VH 5E8CDR- Residues 31-35 DYSMH H1 of SEQ ID NO.:43 VH 5E8 CDR- Residues 50-66WINTETGEPTYADDFKG H2 of SEQ ID NO.:43 VH 5E8 CDR- Residues 99- RRYRAFDYH3 106 of SEQ ID NO.:43 44 VL 5E8 SIVMTQSPKFLLVSAGDRVTITCKASQSVSNDVAWYQQKLGQSPKLLIYYASNRYTGVPD RFTGSGYGTDFTFTINTVQAEDLAVFCQQDYTSPYTFGGGTKLEIQR VL 5E8 CDR- Residues 24-34 KASQSVSNDVA L1 of SEQ IDNO.:44 VL 5E8 CDR- Residues 50-56 YASNRYT L2 of SEQ ID NO.:44 VL 5E8CDR- Residues 89-97 QQDYTSPYT L3 of SEQ ID NO.:44 45 VH 8E1EVKLVESGGGLVQPGGSRKLSCAASGFTFS DYGMVWVRQAPGKGLEWVASISSGSSNIYYADTVKGRFTISRDDPNNTLFLQMRSLRSED TAMYYCARNPYWGQGTTLTVSS VH 8E1 CDR-Residues 31-35 H1 of SEQ ID DYGMV NO.:45 VH 8E1 CDR- Residues 50-66SISSGSSNIYYADTVKG H2 of SEQ ID NO.:45 VH 8E1 CDR- Residues 99- NPY H3101 of SEQ ID NO.:45 46 VL 8E1 DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTNVAWYQQKPGQSPKGLIYSASHRYSGVPD RFAGSGSGTDFTLTISNVQSEDLAEYFCQQYNSYPLTFGGCTKLELKR VL 8E1 CDR- Residues 24-34 KASQNVGTNVA L1 of SEQ IDNO.:46 VL 8E1 CDR- Residues 50-56 SASHRYS L2 of SEQ ID NO.:46 VL 8E1CDR- Residues 89-97 QQYNSYPLT L3 of SEQ ID NO.:46 47 VH 1H6EVKLVESGGGLVQPGGSRKLSCAASGFTFS DYGMVWVRQAPGKGLEWVAYISSGSSTIHYADTMKGRFTISRDNPKNTLFLQMSSLRSED TAMYYCARRHYYAMDYWGQGTSVTVSS VH 1H6 CDR-Residues 31-35 DYGMV H1 of SEQ ID NO.:47 VH 1H6 CDR- Residues 50-66YISSGSSTIHYADTMKG H2 of SEQ ID NO.:47 VH 1H6 CDR- Residues 99- RHYYAMDYH3 106 of SEQ ID NO.:47 48 VL 1H6 SFVMTQTPKFLLVSAGDRVTITCKASQSVSNDVAWYQQKPGQSPKLLIYYASNRYTGVPD RFTGTGYGTDFTFTISTVQAEDLAVYFCQQDYTSPFTFGSGTKLEIKR VL 1H6 CDR- Residues 24-34 KASQSVSNDVA L1 of SEQ IDNO.:48 VL 1H6 CDR- Residues 50-56 YASNRYT L2 of SEQ ID NO.:48 VL 1H6CDR- Residues 89-97 QQDYTSPFT L3 of SEQ ID NO.:48 49 VH 3A11EVQLQQSGADLEKPGASVKLSCTASGFNIK DTFMHWVKQRPEQGLEWIGRIDPANGHTKYDPKFQGKATITADTSSNTAYLQLSSLTSED TAVYYCARWGQFGLLWNAMDYWGQGTSVTV SS VH 3A11CDR- Residues 31-35 DTFMH H1 of SEQ ID NO.:49 VH 3A11 CDR- Residues50-66 RIDPANGHTKYDPKFQG H2 of SEQ ID NO.:49 VH 3A11 CDR- Residues 99- H3111 of SEQ ID WGQFGLLWNAMDY NO.:49 50 VL 3A11DIVLTQSPGSLAVSLGQRATISCRASESVD NYGISFMNWFQQKPGQPPKLLIYAASNQGSGVPARFSGSGSGTDFSLDIHPMEEDDTAMY FCQQSKEVPPTFGGGTKLEIKR VL 3A11 CDR-Residues 24-38 RASESVDNYGISFM L1 of SEQ ID NO.:50 VL 3A11 CDR- Residues53-60 YAASNQGS L2 of SEQ ID NO.:50 VL 3A11 CDR- Residues 93- QQSKEVPPTL3 101 of SEQ ID NO.:50 51 VH 4B4 QVTLKESGPGILKPSQTLSLTCSLSGFSLSTSGMGVSWIRQPSGKGLEWLAHIWWDGDSY SNPSLRSRLTISRDTSRNQVFLRIATVDTADTATYYCARRTRVNYMDYWGQGTSVTVSS VH 4B4 CDR- Residues 31-37 TSGMGVS H1 ofSEQ ID NO.:51 VH 4B4 CDR- Residues 52-67 HIWWDGDSYSNPSLRS H2 of SEQ IDNO.:51 VH 4B4 CDR- Residues 100- RTRVNYAMDY H3 109 of SEQ ID NO.:51 52VL 4B4 SVVMTQTPKFLLVSAGDRVTMTCKASQSVS NDVAWFQQKPGQSPKLLIYYASNRYTGVPDRFTGSGYGTDFTFTISTVQAEDLAVYFCQQ DYNSPWTFGGGTKLEIKR VL 4B4 CDR- Residues24-34 KASQSVSNDVA L1 of SEQ ID NO.:52 VL 4B4 CDR- Residues 50-56 YASNRYTL2 of SEQ ID NO.:52 VL 4B4 CDR- Residues 89-97 QQDYNSPWT L3 of SEQ IDNO.:52 53 VH 7G3 EVQLQQSGAEFVRSGASVKLSCTASGLNIKDYYIHWVKQRPEQVLDWIGWIDPENGYSEY APRFQDKATMTADTSSNTAYLHLSSLTSEDTAVYYCNPGELARYFDYWGQGTTLTVSS VH 7G3 CDR- Residues 31-35 DYYIH H1 of SEQID NO.:53 VH 7G3 CDR- Residues 47-66 WIGWIDPENGYSEYAPRFQD H2 of SEQ IDNO.:53 VH 7G3 CDR- Residues 99- GELARYFDY H3 107 of SEQ ID NO.:53 54 VL7G3 DIVLSQSPATLSVTPGDSVSLSCRASQSIS KNLHWYQQKSHESPRLLIKYTSQSISGIPSRFSGSGSGTDFTLSINSVETEDFGMYFCQQ SISWPLTFGAGTKLELKR VL 7G3 CDR- Residues24-34 RASQSISKNLH L1 of SEQ ID NO.:54 VL 7G3 CDR- Residues 50-56 YTSQSISL2 of SEQ ID NO.:54 VL 7G3 CDR- Residues 89-97 QQSISWPLT L3 of SEQ IDNO.:54

The foregoing isolated anti-IL-12p40 antibody CDR sequences establish anovel family of IL-12p40 binding proteins, isolated in accordance withthis invention, and comprising polypeptides that include the CDRsequences listed in Table 6 below. To generate and to select CDR's ofthe invention having preferred IL-12p40 binding and/or neutralizingactivity with respect to hIL-12 and or hIL-23, standard methods known inthe art for generating binding proteins of the present invention andassessing the IL-12 and or IL-23 binding and/or neutralizingcharacteristics of those binding protein may be used, including but notlimited to those specifically described herein.

TABLE 6 Consensus IL-12p40 CDR affinity ligands (alternative residuesare listed below each amino acid position; — indicates residue may beabsent). CDR Sequence Consensus region Identifier Sequence CDR-H1 SEQ IDX₁ X₂ X₃ X₄ X₅ X₆ X₇ NO.:55 D Y Y I H — — K S V M G V S T T G E S W V SF CDR-H2 SEQ ID X₁ X₂ X₃ X₄ X₅ X₆ X₇ X₈ X₉ X₁₀ X₁₁ X₁₂ X₁₃ X₁₄ X₁₅ X₁₆X₁₇ X₁₈ X₁₉ X₂₀ NO.:56 H I Y W D D D K Y Y N P S L K — — — — — D F W P GG G N T N Y N E K F S D F Q D G L H E S S S P T A D D V K G W S T A T PE I H D P T M Q R S N S I N T N K S Y R P Y D H S A R G G CDR-H3 SEQ IDX₁ X₂ X₃ X₄ X₅ X₆ X₇ X₈ X₉ X₁₀ X₁₁ X₁₂ X₁₃ NO.:57 R G I R S A M D Y — —— — N T R V N Y A M D Y M D Y W R F Y G L D Y N A P Y F A F L W H Q A RM F CDR-L1 SEQ ID X₁ X₂ X₃ X₄ X₅ X₆ X₇ X₈ X₉ X₁₀ X₁₁ X₁₂ X₁₃ X₁₄ X₁₅NO.:58 K A S Q S V S N D V A — — — — R E N I G T N G I S F M N D K Y L HCDR-L2 SEQ ID X₁ X₂ X₃ X₄ X₅ X₆ X₇ X₈ NO.:59 Y A S N R Y T — S T A H N QS S S S I G Q CDR-L3 SEQ ID X₁ X₂ X₃ X₄ X₅ X₆ X₇ X₈ X₉ NO.:60 Q Q D Y NS P W T Y N T Y F S S K S V Y I E W L P2. Anti IL-12p40 Chimeric Antibodies

A chimeric antibody is a molecule in which different portions of theantibody are derived from different animal species, such as antibodieshaving a variable region derived from a murine monoclonal antibody and ahuman immunoglobulin constant region. Methods for producing chimericantibodies are known in the art and discussed in detail in Example 2.1.See e.g., Morrison, Science 229:1202 (1985); Oi et al., BioTechniques4:214 (1986); Gillies et al., (1989) J. Immunol. Methods 125:191-202;U.S. Pat. Nos. 5,807,715; 4,816,567; and 4,816,397, which areincorporated herein by reference in their entireties. In addition,techniques developed for the production of “chimeric antibodies”(Morrison et al., 1984, Proc. Natl. Acad. Sci. 81:851-855; Neuberger etal., 1984, Nature 312:604-608; Takeda et al., 1985, Nature 314:452-454which are incorporated herein by reference in their entireties) bysplicing genes from a mouse antibody molecule of appropriate antigenspecificity together with genes from a human antibody molecule ofappropriate biological activity can be used.

In one embodiment, the chimeric antibodies of the invention are producedby replacing the heavy chain constant region of the murine monoclonalanti human IL-12 antibodies described in section 1 with a human IgG1constant region. In a specific embodiment the chimeric antibody of theinvention comprises a heavy chain variable region (V_(H)) comprising theamino acid sequence of SEQ ID NO: 35; SEQ ID NO: 37; SEQ ID NO: 39; SEQID NO: 41; SEQ ID NO: 43; SEQ ID NO: 45; SEQ ID NO: 47; SEQ ID NO: 49;SEQ ID NO: 51; or SEQ ID NO: 53 and a light chain variable region(V_(L)) comprising the amino acid sequence of SEQ ID NO: 36; SEQ ID NO:38; SEQ ID NO: 40; SEQ ID NO: 42; SEQ ID NO: 44; SEQ ID NO: 46; SEQ IDNO: 48; SEQ ID NO: 50; SEQ ID NO: 52; or SEQ ID NO: 54.

3. Anti IL-12p40 CDR Grafted Antibodies

CDR-grafted antibodies of the invention comprise heavy and light chainvariable region sequences from a human antibody wherein one or more ofthe CDR regions of V_(H) and/or V_(L) are replaced with CDR sequences ofthe murine antibodies of the invention. A framework sequence from anyhuman antibody may serve as the template for CDR grafting. However,straight chain replacement onto such a framework often leads to someloss of binding affinity to the antigen. The more homologous a humanantibody is to the original murine antibody, the less likely thepossibility that combining the murine CDRs with the human framework willintroduce distortions in the CDRs that could reduce affinity. Therefore,it is preferable that the human variable framework that is chosen toreplace the murine variable framework apart from the CDRs have at leasta 65% sequence identity with the murine antibody variable regionframework. It is more preferable that the human and murine variableregions apart from the CDRs have at least 70% sequence identify. It iseven more preferable that the human and murine variable regions apartfrom the CDRs have at least 75% sequence identity. It is most preferablethat the human and murine variable regions apart from the CDRs have atleast 80% sequence identity. Methods for producing chimeric antibodiesare known in the art and discussed in detail in Example 2.2. (also seeEP 239,400; PCT publication WO 91/09967; U.S. Pat. Nos. 5,225,539;5,530,101; and 5,585,089), veneering or resurfacing (EP 592,106; EP519,596; Padlan, Molecular Immunology 28(4/5):489-498 (1991); Studnickaet al., Protein Engineering 7(6):805-814 (1994); Roguska et al., PNAS91:969-973 (1994)), and chain shuffling (U.S. Pat. No. 5,565,352).

In a specific embodiment the invention provides CDR grafted antibodieswith V_(H) and/or V_(L) chains as described in Table 7.

TABLE 7 CDR Grafted antibodies Sequence SEQ ID No. Protein region123456789012345678901234567890 61 VH 1D4.1  (6) (VH2-70/JH6 FR1)EVTLRESGPALVKPTQTLTLTCTFSGFSLS  (7) (VH2-70/JH6 FR2)KSVMGVSWIRQPPGKALEWLAHIYWDDDKY  (8) (VH2-70/JH6 FR3)YNPSLKSRLTISKDTSKNQVVLTMTNMDPV  (9) (VH2-70/JH6 FR4)DTATYYCARRGIRSAMDYWGQGTTVTVSS 62 VL 1D4.1 (23) (B3/JK4 FR1)DIVMTQSPDSLAVSLGERATINCKASQSVS (24) (B3/JK4 FR2)NDVAWYQQKPGQPPKLLIYYASNRYTGVPD (25) (B3/JK4 FR3)RFSGSGSGTDFTLTISSLQAEDVAVYYCQQ (26) (B3/JK4 FR4) DYNSPWTFGGGTKVEIKR 63VH 1D4.2 (10) (VH2-26/JH6 FR1) EVTLKESGPVLVKPTETLTLTCTVSGFSLS  (7)(VH2-70/JH6 FR2) KSVMGVSWIRQPPGKALEWLAHIYWDDDKY (11) (VH2-26/JH6 FR3)YNPSLKSRLTISKDTSKSQVVLTMTNMDPV  (9) (VH2-70/JH6 FR4)DTATYYCARRGIRSAMDYWGQGTTVTVSS 64 VL 1D4.2 (27) (L2/JK4 FR1)EIVMTQSPATLSVSPGERATLSCKASQSVS (28) (L2/JK4 FR2)NDVAWYQQKPGQAPRLLIYYASNRYTGIPA (29) (L2/JK4 FR3)RFSGSGSGTEFTLTISSLQSEDFAVYYCQQ (26) (B3/JK4 FR4) DYNSPWTFGGGTKVEIKR 65VH 1D4.3  (6) (VH2-70/JH6 FR1) EVTLRESGPALVKPTQTLTLTCTFSGFSLS  (7)(VH2-70/JH6 FR2) KSVMGVSWIRQPPGKALEWLAHIYWDDDKY  (8) (VH2-70/JH6 FR3)YNPSLKSRLTISKDTSKNQVVLTMTNMDPV  (9) (VH2-70/JH6 FR4)DTATYYCARRGIRSAMDYWGQGTTVTVSS 66 VL 1D4.3 (27) (L2/JK4 FR1)EIVMTQSPATLSVSPGERATLSCKASQSVS (28) (L2/JK4 FR2)NDVAWYQQKPGQAPRLLIYYASNRYTGIPA (29) (L2/JK4 FR3)RFSGSGSGTEFTLTISSLQSEDFAVYYCQQ (26) (B3/JK4 FR4) DYNSPWTFGGGTKVEIKR 67VH 1A6.1  (6) (VH2-70/JH6 FR1) EVTLRESGPALVKPTQTLTLTCTFSGFSLS  (7)(VH2-70/JH6 FR2) TSGMGVSWIRQPPGKALEWLAHIWWDGDNY  (8) (VH2-70/JH6 FR3)YNPSLKSRLTISKDTSKNQVVLTMTNMDPV  (9) (VH2-70/JH6 FR4)DTATYYCARRTRVNYAMDYWGQGTTVTVSS 68 VL 1A6.1 (23) (B3/JK4 FR1)DIVMTQSPDSLAVSLGERATINCKASQSVS (24) (B3/JK4 FR2)NDVAWYQQKPGQPPKLLIYYASNRYTGVPD (25) (B3/JK4 FR3)RFSGSGSGTDFTLTISSLQAEDVAVYYCQQ (26) (B3/JK4 FR4) DYNSPWTFGGGTKVEIKR 69VH 1A6.2 (10) (VH2-26/JH6 FR1) EVTLKESGPVLVKPTETLTLTCTVSGFSLS  (7)(VH2-70/JH6 FR2) TSGMGVSWIRQPPGKALEWLAHIWWDGDNY (11) (VH2-26/JH6 FR3)YNPSLKSRLTISKDTSKSQVVLTMTNMDPV  (9) (VH2-70/JH6 FR4)DTATYYCARRTRVNYAMDYWGQGTTVTVSS 70 VL 1A6.2 (27) (L2/JK4 FR1)EIVMTQSPATLSVSPGERATLSCKASQSVS (28) (L2/JK4 FR2)NDVAWYQQKPGQAPRLLIYYASNRYTGIPA (29) (L2/JK4 FR3)RFSGSGSGTEFTLTISSLQSEDFAVYYCQQ (26) (B3/JK4 FR4) DYNSPWTFGGGTKVEIKR 71VH 8E1.1 (12) (VH3-72/JH6 FR1) EVQLVESGGGLVQPGGSLRLSCAASGFTFS (13)(VH3-72/JH6 FR2) DYGMVWVRQAPGKGLEWVGSISSGSSNIYY (14) (VH3-72/JH6 FR3)ADTVKGRFTISRDDSKNSLYLQMNSLKTED  (9) (VH2-70/JH6 FR4)TAVYYCARNPYWGQGTTVTVSS 72 VL 8E1.1 (30) (L15/JK4 FR1)DIQMTQSPSSLSASVGDRVTITCKASQNVG (31) (L15/JK4 FR2)TNVAWYQQKPEKAPKSLIYSASHRYSGVPS (32) (L15/JK4 FR3)RFSGSGSGTDFTLTISSLQPEDFATYYCQQ (26) (B3/JK4 FR4) YNSYPLTFGGGTKVEIKR 73VH 8E1.2 (15) (VH3-21/JH6 FR1) EVQLVESGGGLVKPGGSLRLSCAASGFTFS (16)(VH3-21/JH6 FR2) DYGMVWVRQAPGKGLEWVSSISSGSSNIYY (17) (VH3-21/JH6 FR3)ADTVKGRFTISRDNAKNSLYLQMNSLRAED  (9) (VH2-70/JH6 FR4)TAVYYCARNPYWGQGTTVTVSS 74 VL 8E1.2 (33) (L15/JK4 FR1)DIQMTQSPSSVSASVGDRVTITCKASQNVG (34) (L15/JK4 FR2)TNVAWYQQKPGKAPKLLIYSASHRYSGVPS (32) (L15/JK4 FR3)RFSGSGSGTDFTLTISSLQPEDFATYYCQQ (26) (B3/JK4 FR4) YNSYPLTFGGGTKVEIKR 75VH 3G7.1 (18) (VH1-69/JH6 FR1) EVQLVQSGAEVKKPGSSVKVSCKASGGTFS (19)(VH1-69/JH6 FR2) DYWIEWVRQAPGQGLEWMGGFSHGSGSTNY (20) (VH1-69/JH6 FR3)NEKFKGRVTITADKSTSTAYMELSSLRSED  (9) (VH2-70/JH6 FR4)TAVYYCARRRFRGMDYWGQGTTVTVSS 76 VL 3G7.1 (23) (B3/JK4 FR1)DIVMTQSPDSLAVSLGERATINCKASQSVS (24) (B3/JK4 FR2)NDVAWYQQKPGQPPKLLIYYASNRYTGVPD (25) (B3/JK4 FR3)RFSGSGSGTDFTLTISSLQAEDVAVYYCQQ (26) (B3/JK4 FR4) DYSSPWSFGGGTKVEIKR 77VH 3G7.2 (21) (VH1-18/JH6 FR1) EVQLVQSGAEVKKPGASVKVSCKASGYTFT (19)(VH1-69/JH6 FR2) DYWIEWVRQAPGQGLEWMGGFSHGSGSTNY (22) (VH1-18/JH6 FR3)NEKFKGRVTMTTDTSTSTAYMELRSLRSDD  (9) (VH2-70/JH6 FR4)TAVYYCARRRFRGMDYWGQGTTVTVSS 78 VL 3G7.2 (27) (L2/JK4 FR1)EIVMTQSPATLSVSPGERATLSCKASQSVS (28) (L2/JK4 FR2)NDVAWYQQKPGQAPRLLIYYASNRYTGIPA (29) (L2/JK4 FR3)RFSGSGSGTEFTLTISSLQSEDFAVYYCQQ (26) (B3/JK4 FR4) DYSSPWSFGGGTKVEIKR 67VH 1A6.5  (6) (VH2-70/JH6 FR1) EVTLRESGPALVKPTQTLTLTCTFSGFSLS  (7)(VH2-70/JH6 FR2) TSGMGVSWIRQPPGKALEWLAHIWWDGDNY  (8) (VH2-70/JH6 FR3)YNPSLKSRLTISKDTSKNQVVLTMTNMDPV  (9) (VH2-70/JH6 FR4)DTATYYCARRTRVNYAMDYWGQGTTVTVSS 70 VL 1A6.5 (27) (L2/JK4 FR1)EIVMTQSPATLSVSPGERATLSCKASQSVS (28) (L2/JK4 FR2)NDVAWYQQKPGQAPRLLIYYASNRYTGIPA (29) (L2/JK4 FR3)RFSGSGSGTEFTLTISSLQSEDFAVYYCQQ (26) (B3/JK4 FR4) DYNSPWTFGGGTKVEIKR 69VH 1A6.6 (10) (VH2-26/JH6 FR1) EVTLKESGPVLVKPTETLTLTCTVSGFSLS  (7)(VH2-70/JH6 FR2) TSGMGVSWIRQPPGKALEWLAHIWWDGDNY (11) (VH2-26/JH6 FR3)YNPSLKSRLTISKDTSKSQVVLTMTNMDPV  (9) (VH2-70/JH6 FR4)DTATYYCARRTRVNYAMDYWGQGTTVTVSS 68 VL 1A6.6 (23) (B3/JK4 FR1)DIVMTQSPDSLAVSLGERATINCKASQSVS (24) (B3/JK4 FR2)NDVAWYQQKPGQPPKLLIYYASNRYTGVPD (25) (B3/JK4 FR3)RFSGSGSGTDFTLTISSLQAEDVAVYYCQQ (26) (B3/JK4 FR4) DYNSPWTFGGGTKVEIKR4. Anti IL-12p40 Humanized Antibodies

Humanized antibodies are antibody molecules from non-human speciesantibody that binds the desired antigen having one or morecomplementarity determining regions (CDRs) from the non-human speciesand framework regions from a human immunoglobulin molecule. Known humanIg sequences are disclosed, e.g., world wide webncbi.nlm.nih.gov/entrez-/query.fcgi; atcc.org/phage/hdb.html;sciquest.com/; abcam.com/; antibodyresource.com/onlinecomp.html;public.iastate.edu/.about.pedro/research_tools.html;mgen.uni-heidelberg.de/SD/IT/IT.html;whfreeman.com/immunology/CH-05/kuby05.htm;library.thinkquest.org/12429/Immune/Antibody.html;hhmi.org/grants/lectures/1996/vlab/;path.cam.ac.uk/.about.mrc7/m-ikeimages.html; antibodyresource.com/;mcb.harvard.edu/BioLinks/Immuno-logy.html. immunologylink.com/;pathbox.wustl.edu/.about.hcenter/index.-html;biotech.ufl.edu/.about.hcl/; www.pebio.com/pa/340913/340913.html-;nal.usda.gov/awic/pubs/antibody/;m.ehime-u.acjp/.about.yasuhito-/Elisa.html; biodesign.com/table.asp;icnet.uk/axp/facs/davies/lin-ks.html;biotech.ufl.edu/.about.fccl/protocol.html; isac-net.org/sites_geo.html;aximtl.imt.uni-marburg.de/.about.rek/AEP-Start.html;baserv.uci.kun.nl/.about.jraats/linksl.html;recab.uni-hd.de/immuno.bme.nwu.edu/;mrc-cpe.cam.ac.uk/imt-doc/pu-blic/INTRO.html;ibt.unam.mx/vir/V_mice.html; imgt.cnusc.fr:8104/;biochem.ucl.ac.uk/.about.martin/abs/index.html; antibody.bath.ac.uk/;abgen.cvm.tamu.edu/lab/wwwabgen.html;unizh.ch/.about.honegger/AHOsem-inar/Slide01.html;cryst.bbk.ac.uk/.about.ubcg07s/; nimr.mrc.ac.uk/CC/ccaewg/ccaewg.htm;path.cam.ac.uk/.about.mrc7/h-umanisation/TAHHP.html;ibt.unam.mx/vir/structure/stat_aim.html;biosci.missouri.edu/smithgp/index.html;cryst.bioc.cam.ac.uk/.abo-ut.fmolina/Web-pages/Pept/spottech.html;jerini.de/fr roducts.htm; patents.ibm.com/ibm.html.Kabat et al.,Sequences of Proteins of Immunological Interest, U.S. Dept. Health(1983), each entirely incorporated herein by reference. Such importedsequences can be used to reduce immunogenicity or reduce, enhance ormodify binding, affinity, on-rate, off-rate, avidity, specificity,half-life, or any other suitable characteristic, as known in the art.

Framework residues in the human framework regions may be substitutedwith the corresponding residue from the CDR donor antibody to alter,preferably improve, antigen binding. These framework substitutions areidentified by methods well known in the art, e.g., by modeling of theinteractions of the CDR and framework residues to identify frameworkresidues important for antigen binding and sequence comparison toidentify unusual framework residues at particular positions. (See, e.g.,Queen et al., U.S. Pat. No. 5,585,089; Riechmann et al., Nature 332:323(1988), which are incorporated herein by reference in their entireties.)Three-dimensional immunoglobulin models are commonly available and arefamiliar to those skilled in the art. Computer programs are availablewhich illustrate and display probable three-dimensional conformationalstructures of selected candidate immunoglobulin sequences. Inspection ofthese displays permits analysis of the likely role of the residues inthe functioning of the candidate immunoglobulin sequence, i.e., theanalysis of residues that influence the ability of the candidateimmunoglobulin to bind its antigen. In this way, FR residues can beselected and combined from the consensus and import sequences so thatthe desired antibody characteristic, such as increased affinity for thetarget antigen(s), is achieved. In general, the CDR residues aredirectly and most substantially involved in influencing antigen binding.Antibodies can be humanized using a variety of techniques known in theart, such as but not limited to those described in Jones et al., Nature321:522 (1986); Verhoeyen et al., Science 239:1534 (1988)), Sims et al.,J. Immunol. 151: 2296 (1993); Chothia and Lesk, J. Mol. Biol. 196:901(1987), Carter et al., Proc. Natl. Acad. Sci. U.S.A. 89:4285 (1992);Presta et al., J. Immunol. 151:2623 (1993), Padlan, Molecular Immunology28(4/5):489-498 (1991); Studnicka et al., Protein Engineering7(6):805-814 (1994); Roguska. et al., PNAS 91:969-973 (1994); PCTpublication WO 91/09967, PCT/: US98/16280, US96/18978, US91/09630,US91/05939, US94/01234, GB89/01334, GB91/01134, GB92/01755; WO90/14443,WO90/14424, WO90/14430, EP 229246, EP 592,106; EP 519,596, EP 239,400,U.S. Pat. Nos. 5,565,332, 5,723,323, 5,976,862, 5,824,514, 5,817,483,5,814,476, 5,763,192, 5,723,323, 5,766886, 5,714,352, 6,204,023,6,180,370, 5,693,762, 5,530,101, 5,585,089, 5,225,539; 4,816,567, eachentirely incorporated herein by reference, included references citedtherein.

C. Production of Antibodies and Antibody-Producing Cell Lines

Preferrably, anti-IL-12p40 antibodies of the present invention, exhibita high capacity to reduce or to neutralize IL-12 activity, e.g., asassessed by any one of several in vitro and in vivo assays known in theart (e.g., see Example 1.1.C). For example, these antibodies neutralizeIL-12-induced production of interferon gamma by PHA blasts with IC₅₀values in the range of at least about 10⁻⁸ M, about 10⁻⁹ M, or about10⁻¹⁰ M. Preferrably, anti-IL-12p40 antibodies of the present invention,also exhibit a high capacity to reduce or to neutralize IL-23 activity

In preferred embodiments, the isolated antibody, or antigen-bindingportion thereof, binds human IL-12p40, wherein the antibody, orantigen-binding portion thereof, dissociates from human IL-12p40 with ak_(off) rate constant of about 0.1s⁻¹ or less, as determined by surfaceplasmon resonance, or which inhibits human IL-12 and/or human IL-23activity with an IC₅₀ of about 1×10⁻⁶M or less. Alternatively, theantibody, or an antigen-binding portion thereof, may dissociate fromhuman IL-12p40 with a k_(off) rate constant of about 1×10⁻²s⁻¹ or less,as determined by surface plasmon resonance, or may inhibit human IL-12and/or human IL-23 activity with an IC₅₀ of about 1×10⁻⁷M or less.Alternatively, the antibody, or an antigen-binding portion thereof, maydissociate from human IL-12p40 with a k_(off) rate constant of about1×10⁻³s⁻¹ or less, as determined by surface plasmon resonance, or mayinhibit human IL-12 and/or human IL-23 with an IC₅₀ of about 1×10⁻⁸M orless. Alternatively, the antibody, or an antigen-binding portionthereof, may dissociate from human IL-12p40 with a k_(off) rate constantof about 1×10⁻⁴s⁻¹ or less, as determined by surface plasmon resonance,or may inhibit IL-12 and/or human IL-23 activity with an IC₅₀ of about1×10⁻⁹M or less. Alternatively, the antibody, or an antigen-bindingportion thereof, may dissociate from human IL-12p40 with a k_(off) rateconstant of about 1×10⁻⁵s⁻¹ or less, as determined by surface plasmonresonance, or may inhibit IL-12 and/or human IL-23 activity with an IC₅₀of about 1×10⁻¹⁰M or less. Alternatively, the antibody, or anantigen-binding portion thereof, may dissociate from human IL-12p40 witha k_(off) rate constant of about 1×10⁻⁵s⁻¹ or less, as determined bysurface plasmon resonance, or may inhibit IL-12 and/or human IL-23activity with an IC₅₀ of about 1×10⁻¹¹M or less.

In certain embodiments, the antibody comprises a heavy chain constantregion, such as an IgG1, IgG2, IgG3, IgG4, IgA, IgE, IgM or IgD constantregion. Preferably, the heavy chain constant region is an IgG1 heavychain constant region or an IgG4 heavy chain constant region.Furthermore, the antibody can comprise a light chain constant region,either a kappa light chain constant region or a lambda light chainconstant region. Preferably, the antibody comprises a kappa light chainconstant region. Alternatively, the antibody portion can be, forexample, a Fab fragment or a single chain Fv fragment.

Replacements of amino acid residues in the Fc portion to alter antibodyeffector function are known in the art (Winter, et al. U.S. Pat. Nos.5,648,260; 5,624,821). The Fc portion of an antibody mediates severalimportant effector functions e.g. cytokine induction, ADCC,phagocytosis, complement dependent cytotoxicity (CDC) andhalf-life/clearance rate of antibody and antigen-antibody complexes. Insome cases these effector functions are desirable for therapeuticantibody but in other cases might be unnecessary or even deleterious,depending on the therapeutic objectives. Certain human IgG isotypes,particularly IgG1 and IgG3, mediate ADCC and CDC via binding to FcγRsand complement C1q, respectively. Neonatal Fc receptors (FcRn) are thecritical components determining the circulating half-life of antibodies.In still another embodiment at least one amino acid residue is replacedin the constant region of the antibody, for example the Fc region of theantibody, such that effector functions of the antibody are altered.

One embodiment provides a labeled binding protein wherein an antibody orantibody portion of the invention is derivatized or linked to anotherfunctional molecule (e.g., another peptide or protein). For example, alabeled binding protein of the invention can be derived by functionallylinking an antibody or antibody portion of the invention (by chemicalcoupling, genetic fusion, noncovalent association or otherwise) to oneor more other molecular entities, such as another antibody (e.g., abispecific antibody or a diabody), a detectable agent, a cytotoxicagent, a pharmaceutical agent, and/or a protein or peptide that canmediate associate of the antibody or antibody portion with anothermolecule (such as a streptavidin core region or a polyhistidine tag).

Useful detectable agents with which an antibody or antibody portion ofthe invention may be derivatized include fluorescent compounds.Exemplary fluorescent detectable agents include fluorescein, fluoresceinisothiocyanate, rhodamine, 5-dimethylamine-1-napthalenesulfonylchloride, phycoerythrin and the like. An antibody may also bederivatized with detectable enzymes, such as alkaline phosphatase,horseradish peroxidase, glucose oxidase and the like. When an antibodyis derivatized with a detectable enzyme, it is detected by addingadditional reagents that the enzyme uses to produce a detectablereaction product. For example, when the detectable agent horseradishperoxidase is present, the addition of hydrogen peroxide anddiaminobenzidine leads to a colored reaction product, which isdetectable. An antibody may also be derivatized with biotin, anddetected through indirect measurement of avidin or streptavidin binding.

Another embodiment of the invention provides a crystallized bindingprotein. Preferably the invention relates to crystals of wholeanti-IL-12p40 antibodies and fragments thereof as disclosed herein, andformulations and compositions comprising such crystals. In oneembodiment the crystallized binding protein has a greater half-life invivo than the soluble counterpart of the binding protein. In anotherembodiment the binding protein retains biological activity aftercrystallization.

Crystallized binding protein of the invention may be produced accordingmethods known in the art and as disclosed in WO 02072636, incorporatedherein by reference.

Another embodiment of the invention provides a glycosylated bindingprotein wherein the antibody or antigen-binding portion thereofcomprises one or more carbohydrate residues. Nascent in vivo proteinproduction may undergo further processing, known as post-translationalmodification. In particular, sugar (glycosyl) residues may be addedenzymatically, a process known as glycosylation. The resulting proteinsbearing covalently linked oligosaccharide side chains are known asglycosylated proteins or glycoproteins. Antibodies are glycoproteinswith one or more carbohydrate residues in the Fc domain, as well as thevariable domain. Carbohydrate residues in the Fc domain have importanteffect on the effector function of the Fc domain, with minimal effect onantigen binding or half-life of the antibody (R. Jefferis, Biotechnol.Prog. 21 (2005), pp. 11-16). In contrast, glycosylation of the variabledomain may have an effect on the antigen binding activity of theantibody. Glycosylation in the variable domain may have a negativeeffect on antibody binding affinity, likely due to steric hindrance (Co,M. S., et al., Mol. Immunol. (1993) 30:1361-1367), or result inincreased affinity for the antigen (Wallick, S, C., et al., Exp. Med.(1988) 168:1099-1109; Wright, A., et al., EMBO J. (1991) 10:2717 2723).

One aspect of the present invention is directed to generatingglycosylation site mutants in which the O- or N-linked glycosylationsite of the binding protein has been mutated. One skilled in the art cangenerate such mutants using standard well-known technologies.Glycosylation site mutants that retain the biological activity but haveincreased or decreased binding activity are another object of thepresent invention.

In still another embodiment, the glycosylation of the antibody orantigen-binding portion of the invention is modified. For example, anaglycoslated antibody can be made (i.e., the antibody lacksglycosylation). Glycosylation can be altered to, for example, increasethe affinity of the antibody for antigen. Such carbohydratemodifications can be accomplished by, for example, altering one or moresites of glycosylation within the antibody sequence. For example, one ormore amino acid substitutions can be made that result in elimination ofone or more variable region glycosylation sites to thereby eliminateglycosylation at that site. Such aglycosylation may increase theaffinity of the antibody for antigen. Such an approach is described infurther detail in PCT Publication WO2003016466A2, and U.S. Pat. Nos.5,714,350 and 6,350,861, each of which is incorporated herein byreference in its entirety.

Additionally or alternatively, a modified antibody of the invention canbe made that has an altered type of glycosylation, such as ahypofucosylated antibody having reduced amounts of fucosyl residues oran antibody having increased bisecting GlcNAc structures. Such alteredglycosylation patterns have been demonstrated to increase the ADCCability of antibodies. Such carbohydrate modifications can beaccomplished by, for example, expressing the antibody in a host cellwith altered glycosylation machinery. Cells with altered glycosylationmachinery have been described in the art and can be used as host cellsin which to express recombinant antibodies of the invention to therebyproduce an antibody with altered glycosylation. See, for example,Shields, R. L. et al. (2002) J. Biol. Chem. 277:26733-26740; Umana etal. (1999) Nat. Biotech. 17:176-1, as well as, European Patent No: EP1,176,195; PCT Publications WO 03/035835; WO 99/54342 80, each of whichis incorporated herein by reference in its entirety.

Protein glycosylation depends on the amino acid sequence of the proteinof interest, as well as the host cell in which the protein is expressed.Different organisms may produce different glycosylation enzymes (eg.,glycosyltransferases and glycosidases), and have different substrates(nucleotide sugars) available. Due to such factors, proteinglycosylation pattern, and composition of glycosyl residues, may differdepending on the host system in which the particular protein isexpressed. Glycosyl residues useful in the invention may include, butare not limited to, glucose, galactose, mannose, fucose,n-acetylglucosamine and sialic acid. Preferably the glycosylated bindingprotein comprises glycosyl residues such that the glycosylation patternis human.

It is known to those skilled in the art that differing proteinglycosylation may result in differing protein characteristics. Forinstance, the efficacy of a therapeutic protein produced in amicroorganism host, such as yeast, and glycosylated utilizing the yeastendogenous pathway may be reduced compared to that of the same proteinexpressed in a mammalian cell, such as a CHO cell line. Suchglycoproteins may also be immunogenic in humans and show reducedhalf-life in vivo after administration. Specific receptors in humans andother animals may recognize specific glycosyl residues and promote therapid clearance of the protein from the bloodstream. Other adverseeffects may include changes in protein folding, solubility,susceptibility to proteases, trafficking, transport,compartmentalization, secretion, recognition by other proteins orfactors, antigenicity, or allergenicity. Accordingly, a practitioner mayprefer a therapeutic protein with a specific composition and pattern ofglycosylation, for example glycosylation composition and patternidentical, or at least similar, to that produced in human cells or inthe species-specific cells of the intended subject animal.

Expressing glycosylated proteins different from that of a host cell maybe achieved by genetically modifying the host cell to expressheterologous glycosylation enzymes. Using techniques known in the art apractitioner may generate antibodies or antigen-binding portions thereofexhibiting human protein glycosylation. For example, yeast strains havebeen genetically modified to express non-naturally occurringglycosylation enzymes such that glycosylated proteins (glycoproteins)produced in these yeast strains exhibit protein glycosylation identicalto that of animal cells, especially human cells (U.S patent applications20040018590 and 20020137134 and PCT publication WO2005100584 A2).

In addition to the binding proteins, the present invention is alsodirected to an anti-idiotypic (anti-Id) antibody specific for suchbinding proteins of the invention. An anti-Id antibody is an antibody,which recognizes unique determinants generally associated with theantigen-binding region of another antibody. The anti-Id can be preparedby immunizing an animal with the binding protein or a CDR containingregion thereof. The immunized animal will recognize, and respond to theidiotypic determinants of the immunizing antibody and produce an anti-Idantibody. The anti-Id antibody may also be used as an “immunogen” toinduce an immune response in yet another animal, producing a so-calledanti-anti-Id antibody.

Further, it will be appreciated by one skilled in the art that a proteinof interest may be expressed using a library of host cells geneticallyengineered to express various glycosylation enzymes, such that memberhost cells of the library produce the protein of interest with variantglycosylation patterns. A practitioner may then select and isolate theprotein of interest with particular novel glycosylation patterns.Preferably, the protein having a particularly selected novelglycosylation pattern exhibits improved or altered biologicalproperties.

D. Uses of Anti-IL-12p40 Antibodies

Given their ability to bind to human IL-12p40, the anti-human IL-12p40antibodies, or portions thereof, of the invention can be used to detectIL-12 and/or human IL-23 (e.g., in a biological sample, such as serum orplasma), using a conventional immunoassay, such as an enzyme linkedimmunosorbent assays (ELISA), an radioimmunoassay (RIA) or tissueimmunohistochemistry. The invention provides a method for detectingIL-12 and/or human IL-23 in a biological sample comprising contacting abiological sample with an antibody, or antibody portion, of theinvention and detecting either the antibody (or antibody portion) boundto IL-12 and/or human IL-23 or unbound antibody (or antibody portion),to thereby detect IL-12 and/or human IL-23 in the biological sample. Theantibody is directly or indirectly labeled with a detectable substanceto facilitate detection of the bound or unbound antibody. Suitabledetectable substances include various enzymes, prosthetic groups,fluorescent materials, luminescent materials and radioactive materials.Examples of suitable enzymes include horseradish peroxidase, alkalinephosphatase, β-galactosidase, or acetylcholinesterase; examples ofsuitable prosthetic group complexes include streptavidin/biotin andavidin/biotin; examples of suitable fluorescent materials includeumbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine,dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; anexample of a luminescent material includes luminol; and examples ofsuitable radioactive material include ³H, ¹⁴C. ³⁵S, ⁹⁰Y, ⁹⁹Tc, ¹¹¹In,¹²⁵I, ¹³¹I, ¹⁷⁷Lu, ¹⁶⁶Ho, or ¹⁵³Sm.

Alternative to labeling the antibody, human IL-12 can be assayed inbiological fluids by a competition immunoassay utilizing rhIL-12standards labeled with a detectable substance and an unlabeledanti-human IL-12p40 antibody. In this assay, the biological sample, thelabeled rhIL-12 standards and the anti-human IL-12p40 antibody arecombined and the amount of labeled rhIL-12 standard bound to theunlabeled antibody is determined. The amount of human IL-12 in thebiological sample is inversely proportional to the amount of labeledrhIL-12 standard bound to the anti-IL-12p40 antibody. Similarly, humanIL-23 can also be assayed in biological fluids by a competitionimmunoassay utilizing rhIL-23 standards labeled with a detectablesubstance and an unlabeled anti-human IL-12p40 antibody.

The antibodies and antibody portions of the invention preferably arecapable of neutralizing human IL-12 and/or human IL-23 activity both invitro and in vivo. Accordingly, such antibodies and antibody portions ofthe invention can be used to inhibit hIL-12 and/or hIL-23 activity,e.g., in a cell culture containing hIL-12 and/or hIL-23, in humansubjects or in other mammalian subjects having IL-12 and/or hIL-23 withwhich an antibody of the invention cross-reacts. In one embodiment, theinvention provides a method for inhibiting hIL-12 and/or hIL-23 activitycomprising contacting hIL-12 and/or hIL-23 with an antibody or antibodyportion of the invention such that hIL-12 and/or hIL-23 activity isinhibited. For example, in a cell culture containing, or suspected ofcontaining hIL-12 and/or hIL-23, an antibody or antibody portion of theinvention can be added to the culture medium to inhibit hIL-12 and/orhIL-23 activity in the culture.

In another embodiment, the invention provides a method for reducinghIL-12 and/or hIL-23 activity in a subject, advantageously from asubject suffering from a disease or disorder in which IL-12 or IL-23activity is detrimental. The invention provides methods for reducingIL-12 and/or IL-23 activity in a subject suffering from such a diseaseor disorder, which method comprises administering to the subject anantibody or antibody portion of the invention such that IL-12 and/orIL-23 activity in the subject is reduced. Preferably, the IL-12 is humanIL-12, the IL-23 is human IL-23, and the subject is a human subject.Alternatively, the subject can be a mammal expressing an IL-12 and/orIL-23 to which an antibody of the invention is capable of binding. Stillfurther the subject can be a mammal into which IL-12 and/or IL-23 hasbeen introduced (e.g., by administration of IL-12 and/or IL-23 or byexpression of an IL-12 and/or IL-23 transgene). An antibody of theinvention can be administered to a human subject for therapeuticpurposes. Moreover, an antibody of the invention can be administered toa non-human mammal expressing an IL-12 and/or IL-23 with which theantibody is capable of binding for veterinary purposes or as an animalmodel of human disease. Regarding the latter, such animal models may beuseful for evaluating the therapeutic efficacy of antibodies of theinvention (e.g., testing of dosages and time courses of administration).

As used herein, the term “a disorder in which IL-12 and/or IL-23activity is detrimental” is intended to include diseases and otherdisorders in which the presence of IL-12 and/or IL-23 in a subjectsuffering from the disorder has been shown to be or is suspected ofbeing either responsible for the pathophysiology of the disorder or afactor that contributes to a worsening of the disorder. Accordingly, adisorder in which IL-12 and/or IL-23 activity is detrimental is adisorder in which reduction of IL-12 and/or IL-23 activity is expectedto alleviate the symptoms and/or progression of the disorder. Suchdisorders may be evidenced, for example, by an increase in theconcentration of IL-12 and/or IL-23 in a biological fluid of a subjectsuffering from the disorder (e.g., an increase in the concentration ofIL-12 and/or IL-23 in serum, plasma, synovial fluid, etc. of thesubject), which can be detected, for example, using an anti-IL-12p40antibody as described above. Non-limiting examples of disorders that canbe treated with the antibodies of the invention include those disordersdiscussed in the section below pertaining to pharmaceutical compositionsof the antibodies of the invention.

D. Pharmaceutical Composition

The invention also provides pharmaceutical compositions comprising anantibody, or antigen-binding portion thereof, of the invention and apharmaceutically acceptable carrier. The pharmaceutical compositionscomprising antibodies of the invention are for use in, but not limitedto, diagnosing, detecting, or monitoring a disorder, in preventing,treating, managing, or ameliorating of a disorder or one or moresymptoms thereof, and/or in research. In a specific embodiment, acomposition comprises one or more antibodies of the invention. Inanother embodiment, the pharmaceutical composition comprises one or moreantibodies of the invention and one or more prophylactic or therapeuticagents other than antibodies of the invention for treating a disorder inwhich IL-12 and/or IL-23 activity is detrimental. Preferably, theprophylactic or therapeutic agents known to be useful for or having beenor currently being used in the prevention, treatment, management, oramelioration of a disorder or one or more symptoms thereof. Inaccordance with these embodiments, the composition may further compriseof a carrier, diluent or excipient.

The antibodies and antibody-portions of the invention can beincorporated into pharmaceutical compositions suitable foradministration to a subject. Typically, the pharmaceutical compositioncomprises an antibody or antibody portion of the invention and apharmaceutically acceptable carrier. As used herein, “pharmaceuticallyacceptable carrier” includes any and all solvents, dispersion media,coatings, antibacterial and antifungal agents, isotonic and absorptiondelaying agents, and the like that are physiologically compatible.Examples of pharmaceutically acceptable carriers include one or more ofwater, saline, phosphate buffered saline, dextrose, glycerol, ethanoland the like, as well as combinations thereof. In many cases, it will bepreferable to include isotonic agents, for example, sugars, polyalcoholssuch as mannitol, sorbitol, or sodium chloride in the composition.Pharmaceutically acceptable carriers may further comprise minor amountsof auxiliary substances such as wetting or emulsifying agents,preservatives or buffers, which enhance the shelf life or effectivenessof the antibody or antibody portion.

Various delivery systems are known and can be used to administer one ormore antibodies of the invention or the combination of one or moreantibodies of the invention and a prophylactic agent or therapeuticagent useful for preventing, managing, treating, or ameliorating adisorder or one or more symptoms thereof, e.g., encapsulation inliposomes, microparticles, microcapsules, recombinant cells capable ofexpressing the antibody or antibody fragment, receptor-mediatedendocytosis (see, e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)),construction of a nucleic acid as part of a retroviral or other vector,etc. Methods of administering a prophylactic or therapeutic agent of theinvention include, but are not limited to, parenteral administration(e.g., intradermal, intramuscular, intraperitoneal, intravenous andsubcutaneous), epidurala administration, intratumoral administration,and mucosal adminsitration (e.g., intranasal and oral routes). Inaddition, pulmonary administration can be employed, e.g., by use of aninhaler or nebulizer, and formulation with an aerosolizing agent. See,e.g., U.S. Pat. Nos. 6,019,968, 5,985,320, 5,985,309, 5,934,272,5,874,064, 5,855,913, 5,290,540, and 4,880,078; and PCT Publication Nos.WO 92/19244, WO 97/32572, WO 97/44013, WO 98/31346, and WO 99/66903,each of which is incorporated herein by reference their entireties. Inone embodiment, an antibody of the invention, combination therapy, or acomposition of the invention is administered using Alkermes AIR®pulmonary drug delivery technology (Alkermes, Inc., Cambridge, Mass.).In a specific embodiment, prophylactic or therapeutic agents of theinvention are administered intramuscularly, intravenously,intratumorally, orally, intranasally, pulmonary, or subcutaneously. Theprophylactic or therapeutic agents may be administered by any convenientroute, for example by infusion or bolus injection, by absorption throughepithelial or mucocutaneous linings (e.g., oral mucosa, rectal andintestinal mucosa, etc.) and may be administered together with otherbiologically active agents. Administration can be systemic or local.

In a specific embodiment, it may be desirable to administer theprophylactic or therapeutic agents of the invention locally to the areain need of treatment; this may be achieved by, for example, and not byway of limitation, local infusion, by injection, or by means of animplant, said implant being of a porous or non-porous material,including membranes and matrices, such as sialastic membranes, polymers,fibrous matrices (e.g., Tissuel®), or collagen matrices. In oneembodiment, an effective amount of one or more antibodies of theinvention antagonists is administered locally to the affected area to asubject to prevent, treat, manage, and/or ameliorate a disorder or asymptom thereof. In another embodiment, an effective amount of one ormore antibodies of the invention is administered locally to the affectedarea in combination with an effective amount of one or more therapies(e.g., one or more prophylactic or therapeutic agents) other than anantibody of the invention of a subject to prevent, treat, manage, and/orameliorate a disorder or one or more symptoms thereof.

In another embodiment, the prophylactic or therapeutic agent can bedelivered in a controlled release or sustained release system. In oneembodiment, a pump may be used to achieve controlled or sustainedrelease (see Langer, supra; Sefton, 1987, CRC Crit. Ref. Biomed. Eng.14:20; Buchwald et al., 1980, Surgery 88:507; Saudek et al., 1989, N.Engl. J. Med. 321:574). In another embodiment, polymeric materials canbe used to achieve controlled or sustained release of the therapies ofthe invention (see e.g., Medical Applications of Controlled Release,Langer and Wise (eds.), CRC Pres., Boca Raton, Fla. (1974); ControlledDrug Bioavailability, Drug Product Design and Performance, Smolen andBall (eds.), Wiley, New York (1984); Ranger and Peppas, 1983, J.,Macromol. Sci. Rev. Macromol. Chem. 23:61; see also Levy et al., 1985,Science 228:190; During et al., 1989, Ann. Neurol. 25:351; Howard etal., 1989, J. Neurosurg. 7 1:105); U.S. Pat. No. 5,679,377; U.S. Pat.No. 5,916,597; U.S. Pat. No. 5,912,015; U.S. Pat. No. 5,989,463; U.S.Pat. No. 5,128,326; PCT Publication No. WO 99/15154; and PCT PublicationNo. WO 99/20253. Examples of polymers used in sustained releaseformulations include, but are not limited to, poly(2-hydroxy ethylmethacrylate), poly(methyl methacrylate), poly(acrylic acid),poly(ethylene-co-vinyl acetate), poly(methacrylic acid), polyglycolides(PLG), polyanhydrides, poly(N-vinyl pyrrolidone), poly(vinyl alcohol),polyacrylamide, poly(ethylene glycol), polylactides (PLA),poly(lactide-co-glycolides) (PLGA), and polyorthoesters. In a preferredembodiment, the polymer used in a sustained release formulation isinert, free of leachable impurities, stable on storage, sterile, andbiodegradable. In yet another embodiment, a controlled or sustainedrelease system can be placed in proximity of the prophylactic ortherapeutic target, thus requiring only a fraction of the systemic dose(see, e.g., Goodson, in Medical Applications of Controlled Release,supra, vol. 2, pp. 115-138 (1984)).

Controlled release systems are discussed in the review by Langer (1990,Science 249:1527-1533). Any technique known to one of skill in the artcan be used to produce sustained release formulations comprising one ormore therapeutic agents of the invention. See, e.g., U.S. Pat. No.4,526,938, PCT publication WO 91/05548, PCT publication WO 96/20698,Ning et al., 1996, “Intratumoral Radioimmunotheraphy of a Human ColonCancer Xenograft Using a Sustained-Release Gel,” Radiotherapy &Oncology39:179-189, Song et al., 1995, “Antibody Mediated Lung Targeting ofLong-Circulating Emulsions,” PDA Journal of Pharmaceutical Science&Technology 50:372-397, Cleek et al., 1997, “Biodegradable PolymericCarriers for a bFGF Antibody for Cardiovascular Application,” Pro.Int'l. Symp. Control. Rel. Bioact. Mater. 24:853-854, and Lam et al.,1997, “Microencapsulation of Recombinant Humanized Monoclonal Antibodyfor Local Delivery,” Proc. Int'l. Symp. Control Rel. Bioact. Mater.24:759-760, each of which is incorporated herein by reference in theirentireties.

In a specific embodiment, where the composition of the invention is anucleic acid encoding a prophylactic or therapeutic agent, the nucleicacid can be administered in vivo to promote expression of its encodedprophylactic or therapeutic agent, by constructing it as part of anappropriate nucleic acid expression vector and administering it so thatit becomes intracellular, e.g., by use of a retroviral vector (see U.S.Pat. No. 4,980,286), or by direct injection, or by use of microparticlebombardment (e.g., a gene gun; Biolistic, Dupont), or coating withlipids or cell-surface receptors or transfecting agents, or byadministering it in linkage to a homeobox-like peptide which is known toenter the nucleus (see, e.g., Joliot et al., 1991, Proc. Natl. Acad.Sci. USA 88:1864-1868). Alternatively, a nucleic acid can be introducedintracellularly and incorporated within host cell DNA for expression byhomologous recombination.

A pharmaceutical composition of the invention is formulated to becompatible with its intended route of administration. Examples of routesof administration include, but are not limited to, parenteral, e.g.,intravenous, intradermal, subcutaneous, oral, intranasal (e.g.,inhalation), transdermal (e.g., topical), transmucosal, and rectaladministration. In a specific embodiment, the composition is formulatedin accordance with routine procedures as a pharmaceutical compositionadapted for intravenous, subcutaneous, intramuscular, oral, intranasal,or topical administration to human beings. Typically, compositions forintravenous administration are solutions in sterile isotonic aqueousbuffer. Where necessary, the composition may also include a solubilizingagent and a local anesthetic such as lignocamne to ease pain at the siteof the injection.

If the compositions of the invention are to be administered topically,the compositions can be formulated in the form of an ointment, cream,transdermal patch, lotion, gel, shampoo, spray, aerosol, solution,emulsion, or other form well known to one of skill in the art. See,e.g., Remington's Pharmaceutical Sciences and Introduction toPharmaceutical Dosage Forms, 19th ed., Mack Pub. Co., Easton, Pa.(1995). For non-sprayable topical dosage forms, viscous to semi-solid orsolid forms comprising a carrier or one or more excipients compatiblewith topical application and having a dynamic viscosity preferablygreater than water are typically employed. Suitable formulationsinclude, without limitation, solutions, suspensions, emulsions, creams,ointments, powders, liniments, salves, and the like, which are, ifdesired, sterilized or mixed with auxiliary agents (e.g., preservatives,stabilizers, wetting agents, buffers, or salts) for influencing variousproperties, such as, for example, osmotic pressure. Other suitabletopical dosage forms include sprayable aerosol preparations wherein theactive ingredient, preferably in combination with a solid or liquidinert carrier, is packaged in a mixture with a pressurized volatile(e.g., a gaseous propellant, such as freon) or in a squeeze bottle.Moisturizers or humectants can also be added to pharmaceuticalcompositions and dosage forms if desired. Examples of such additionalingredients are well known in the art.

If the method of the invention comprises intranasal administration of acomposition, the composition can be formulated in an aerosol form,spray, mist or in the form of drops. In particular, prophylactic ortherapeutic agents for use according to the present invention can beconveniently delivered in the form of an aerosol spray presentation frompressurized packs or a nebuliser, with the use of a suitable propellant(e.g., dichlorodifluoromethane, trichlorofluoromethane,dichlorotetrafluoroethane, carbon dioxide or other suitable gas). In thecase of a pressurized aerosol the dosage unit may be determined byproviding a valve to deliver a metered amount. Capsules and cartridges(composed of, e.g., gelatin) for use in an inhaler or insufflator may beformulated containing a powder mix of the compound and a suitable powderbase such as lactose or starch.

If the method of the invention comprises oral administration,compositions can be formulated orally in the form of tablets, capsules,cachets, gelcaps, solutions, suspensions, and the like. Tablets orcapsules can be prepared by conventional means with pharmaceuticallyacceptable excipients such as binding agents (e.g., pregelatinised maizestarch, polyvinylpyrrolidone, or hydroxypropyl methylcellulose); fillers(e.g., lactose, microcrystalline cellulose, or calcium hydrogenphosphate); lubricants (e.g., magnesium stearate, talc, or silica);disintegrants (e.g., potato starch or sodium starch glycolate); orwetting agents (e.g., sodium lauryl sulphate). The tablets may be coatedby methods well-known in the art. Liquid preparations for oraladministration may take the form of, but not limited to, solutions,syrups or suspensions, or they may be presented as a dry product forconstitution with water or other suitable vehicle before use. Suchliquid preparations may be prepared by conventional means withpharmaceutically acceptable additives such as suspending agents (e.g.,sorbitol syrup, cellulose derivatives, or hydrogenated edible fats);emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles(e.g., almond oil, oily esters, ethyl alcohol, or fractionated vegetableoils); and preservatives (e.g., methyl or propyl-p-hydroxybenzoates orsorbic acid). The preparations may also contain buffer salts, flavoring,coloring, and sweetening agents as appropriate. Preparations for oraladministration may be suitably formulated for slow release, controlledrelease, or sustained release of a prophylactic or therapeutic agent(s).

The method of the invention may comprise pulmonary administration, e.g.,by use of an inhaler or nebulizer, of a composition formulated with anaerosolizing agent. See, e.g., U.S. Pat. Nos. 6,019,968, 5,985,320, 5,985,309, 5,934,272, 5,874,064, 5,855,913, 5,290,540, and 4,880,078; andPCT Publication Nos. WO 92/19244, WO 97/32572, WO 97/44013, WO 98/31346,and WO 99/66903, each of which is incorporated herein by reference theirentireties. In a specific embodiment, an antibody of the invention,combination therapy, and/or composition of the invention is administeredusing Alkermes AIR® pulmonary drug delivery technology (Alkermes, Inc.,Cambridge, Mass.).

The method of the invention may comprise administration of a compositionformulated for parenteral administration by injection (e.g., by bolusinjection or continuous infusion). Formulations for injection may bepresented in unit dosage form (e.g., in ampoules or in multi-dosecontainers) with an added preservative. The compositions may take suchforms as suspensions, solutions or emulsions in oily or aqueousvehicles, and may contain formulatory agents such as suspending,stabilizing and/or dispersing agents. Alternatively, the activeingredient may be in powder form for constitution with a suitablevehicle (e.g., sterile pyrogen-free water) before use. The methods ofthe invention may additionally comprise of administration ofcompositions formulated as depot preparations. Such long actingformulations may be administered by implantation (e.g., subcutaneouslyor intramuscularly) or by intramuscular injection. Thus, for example,the compositions may be formulated with suitable polymeric orhydrophobic materials (e.g., as an emulsion in an acceptable oil) or ionexchange resins, or as sparingly soluble derivatives (e.g., as asparingly soluble salt).

The methods of the invention encompasse administration of compositionsformulated as neutral or salt forms. Pharmaceutically acceptable saltsinclude those formed with anions such as those derived fromhydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., andthose formed with cations such as those derived from sodium, potassium,ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine,2-ethylamino ethanol, histidine, procaine, etc.

Generally, the ingredients of compositions are supplied eitherseparately or mixed together in unit dosage form, for example, as a drylyophilized powder or water free concentrate in a hermetically sealedcontainer such as an ampoule or sachette indicating the quantity ofactive agent. Where the mode of administration is infusion, compositioncan be dispensed with an infusion bottle containing sterilepharmaceutical grade water or saline. Where the mode of administrationis by injection, an ampoule of sterile water for injection or saline canbe provided so that the ingredients may be mixed prior toadministration.

In particular, the invention also provides that one or more of theprophylactic or therapeutic agents, or pharmaceutical compositions ofthe invention is packaged in a hermetically sealed container such as anampoule or sachette indicating the quantity of the agent. In oneembodiment, one or more of the prophylactic or therapeutic agents, orpharmaceutical compositions of the invention is supplied as a drysterilized lyophilized powder or water free concentrate in ahermetically sealed container and can be reconstituted (e.g., with wateror saline) to the appropriate concentration for administration to asubject. Preferably, one or more of the prophylactic or therapeuticagents or pharmaceutical compositions of the invention is supplied as adry sterile lyophilized powder in a hermetically sealed container at aunit dosage of at least 5 mg, more preferably at least 10 mg, at least15 mg, at least 25 mg, at least 35 mg, at least 45 mg, at least 50 mg,at least 75 mg, or at least 100 mg. The lyophilized prophylactic ortherapeutic agents or pharmaceutical compositions of the inventionshould be stored at between 2° C. and 8° C. in its original containerand the prophylactic or therapeutic agents, or pharmaceuticalcompositions of the invention should be administered within 1 week,preferably within 5 days, within 72 hours, within 48 hours, within 24hours, within 12 hours, within 6 hours, within 5 hours, within 3 hours,or within 1 hour after being reconstituted. In an alternativeembodiment, one or more of the prophylactic or therapeutic agents orpharmaceutical compositions of the invention is supplied in liquid formin a hermetically sealed container indicating the quantity andconcentration of the agent. Preferably, the liquid form of theadministered composition is supplied in a hermetically sealed containerat least 0.25 mg/ml, more preferably at least 0.5 mg/ml, at least 1mg/ml, at least 2.5 mg/ml, at least 5 mg/ml, at least 8 mg/ml, at least10 mg/ml, at least 15 mg/kg, at least 25 mg/ml, at least 50 mg/ml, atleast 75 mg/ml or at least 100 mg/ml. The liquid form should be storedat between 2° C. and 8° C. in its original container.

The antibodies and antibody-portions of the invention can beincorporated into a pharmaceutical composition suitable for parenteraladministration. Preferably, the antibody or antibody-portions will beprepared as an injectable solution containing 0.1-250 mg/ml antibody.The injectable solution can be composed of either a liquid orlyophilized dosage form in a flint or amber vial, ampule or pre-filledsyringe. The buffer can be L-histidine (1-50 mM), optimally 5-10 mM, atpH 5.0 to 7.0 (optimally pH 6.0). Other suitable buffers include but arenot limited to, sodium succinate, sodium citrate, sodium phosphate orpotassium phosphate. Sodium chloride can be used to modify the toxicityof the solution at a concentration of 0-300 mM (optimally 150 mM for aliquid dosage form). Cryoprotectants can be included for a lyophilizeddosage form, principally 0-10% sucrose (optimally 0.5-1.0%). Othersuitable cryoprotectants include trehalose and lactose. Bulking agentscan be included for a lyophilized dosage form, principally 1-10%mannitol (optimally 24%). Stabilizers can be used in both liquid andlyophilized dosage forms, principally 1-50 mM L-Methionine (optimally5-10 mM). Other suitable bulking agents include glycine, arginine, canbe included as 0-0.05% polysorbate-80 (optimally 0.005-0.01%).Additional surfactants include but are not limited to polysorbate 20 andBRIJ surfactants. The pharmaceutical composition comprising theantibodies and antibody-portions of the invention prepared as aninjectable solution for parenteral administration, can further comprisean agent useful as an adjuvant, such as those used to increase theabsorption, or dispersion of a therapeutic protein (e.g., antibody). Aparticularly useful adjuvant is hyaluronidase, such as Hylenex®(recombinant human hyaluronidase). Addition of hyaluronidase in theinjectable solution improves human bioavailability following parenteraladministration, particularly subcutaneous administration. It also allowsfor greater injection site volumes (i.e. greater than 1 ml) with lesspain and discomfort, and minimum incidence of injection site reactions.(see WO2004078140, US2006104968 incorporated herein by reference).

The compositions of this invention may be in a variety of forms. Theseinclude, for example, liquid, semi-solid and solid dosage forms, such asliquid solutions (e.g., injectable and infusible solutions), dispersionsor suspensions, tablets, pills, powders, liposomes and suppositories.The preferred form depends on the intended mode of administration andtherapeutic application. Typical preferred compositions are in the formof injectable or infusible solutions, such as compositions similar tothose used for passive immunization of humans with other antibodies. Thepreferred mode of administration is parenteral (e.g., intravenous,subcutaneous, intraperitoneal, intramuscular). In a preferredembodiment, the antibody is administered by intravenous infusion orinjection. In another preferred embodiment, the antibody is administeredby intramuscular or subcutaneous injection.

Therapeutic compositions typically must be sterile and stable under theconditions of manufacture and storage. The composition can be formulatedas a solution, microemulsion, dispersion, liposome, or other orderedstructure suitable to high drug concentration. Sterile injectablesolutions can be prepared by incorporating the active compound (i.e.,antibody or antibody portion) in the required amount in an appropriatesolvent with one or a combination of ingredients enumerated above, asrequired, followed by filtered sterilization. Generally, dispersions areprepared by incorporating the active compound into a sterile vehiclethat contains a basic dispersion medium and the required otheringredients from those enumerated above. In the case of sterile,lyophilized powders for the preparation of sterile injectable solutions,the preferred methods of preparation are vacuum drying and spray-dryingthat yields a powder of the active ingredient plus any additionaldesired ingredient from a previously sterile-filtered solution thereof.The proper fluidity of a solution can be maintained, for example, by theuse of a coating such as lecithin, by the maintenance of the requiredparticle size in the case of dispersion and by the use of surfactants.Prolonged absorption of injectable compositions can be brought about byincluding, in the composition, an agent that delays absorption, forexample, monostearate salts and gelatin.

The antibodies and antibody-portions of the present invention can beadministered by a variety of methods known in the art, although for manytherapeutic applications, the preferred route/mode of administration issubcutaneous injection, intravenous injection or infusion. As will beappreciated by the skilled artisan, the route and/or mode ofadministration will vary depending upon the desired results. In certainembodiments, the active compound may be prepared with a carrier thatwill protect the compound against rapid release, such as a controlledrelease formulation, including implants, transdermal patches, andmicroencapsulated delivery systems. Biodegradable, biocompatiblepolymers can be used, such as ethylene vinyl acetate, polyanhydrides,polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Manymethods for the preparation of such formulations are patented orgenerally known to those skilled in the art. See, e.g., Sustained andControlled Release Drug Delivery Systems, J. R. Robinson, ed., MarcelDekker, Inc., New York, 1978.

In certain embodiments, an antibody or antibody portion of the inventionmay be orally administered, for example, with an inert diluent or anassimilable edible carrier. The compound (and other ingredients, ifdesired) may also be enclosed in a hard or soft shell gelatin capsule,compressed into tablets, or incorporated directly into the subject'sdiet. For oral therapeutic administration, the compounds may beincorporated with excipients and used in the form of ingestible tablets,buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers,and the like. To administer a compound of the invention by other thanparenteral administration, it may be necessary to coat the compoundwith, or co-administer the compound with, a material to prevent itsinactivation.

Supplementary active compounds can also be incorporated into thecompositions. In certain embodiments, an antibody or antibody portion ofthe invention is coformulated with and/or coadministered with one ormore additional therapeutic agents that are useful for treatingdisorders in which IL-12 activity is detrimental. For example, ananti-hIL-12 antibody or antibody portion of the invention may becoformulated and/or coadministered with one or more additionalantibodies that bind other targets (e.g., antibodies that bind othercytokines or that bind cell surface molecules). Furthermore, one or moreantibodies of the invention may be used in combination with two or moreof the foregoing therapeutic agents. Such combination therapies mayadvantageously utilize lower dosages of the administered therapeuticagents, thus avoiding possible toxicities or complications associatedwith the various monotherapies.

In certain embodiments, an antibody to IL-12 or fragment thereof islinked to a half-life extending vehicle known in the art. Such vehiclesinclude, but are not limited to, the Fc domain, polyethylene glycol, anddextran. Such vehicles are described, e.g., in U.S. application Ser. No.09/428,082 and published PCT Application No. WO 99/25044, which arehereby incorporated by reference for any purpose.

In a specific embodiment, nucleic acid sequences comprising nucleotidesequences encoding an antibody of the invention or another prophylacticor therapeutic agent of the invention are administered to treat,prevent, manage, or ameliorate a disorder or one or more symptomsthereof by way of gene therapy. Gene therapy refers to therapy performedby the administration to a subject of an expressed or expressiblenucleic acid. In this embodiment of the invention, the nucleic acidsproduce their encoded antibody or prophylactic or therapeutic agent ofthe invention that mediates a prophylactic or therapeutic effect.

Any of the methods for gene therapy available in the art can be usedaccording to the present invention. For general reviews of the methodsof gene therapy, see Goldspiel et al., 1993, Clinical Pharmacy12:488-505; Wu and Wu, 1991, Biotherapy 3:87-95; Tolstoshev, 1993, Ann.Rev. Pharmacol. Toxicol. 32:573-596; Mulligan, Science 260:926-932(1993); and Morgan and Anderson, 1993, Ann. Rev. Biochem. 62:191-217;May, 1993, TIBTECH 11(5):155-215. Methods commonly known in the art ofrecombinant DNA technology which can be used are described in Ausubel etal. (eds.), Current Protocols in Molecular Biology, John Wiley &Sons, NY(1993); and Kriegler, Gene Transfer and Expression, A Laboratory Manual,Stockton Press, NY (1990). Detailed description of various methods ofgene therapy are disclosed in US20050042664 A1 which is incorporatedherein by reference.

Interleukin 12 plays a critical role in the pathology associated with avariety of diseases involving immune and inflammatory elements. Thesediseases include, but are not limited to, rheumatoid arthritis,osteoarthritis, juvenile chronic arthritis, septic arthritis, Lymearthritis, psoriatic arthritis, reactive arthritis, spondyloarthropathy,systemic lupus erythematosus, Crohn's disease, ulcerative colitis,inflammatory bowel disease, insulin dependent diabetes mellitus,thyroiditis, asthma, allergic diseases, psoriasis, dermatitisscleroderma, graft versus host disease, organ transplant rejection,acute or chronic immune disease associated with organ transplantation,sarcoidosis, atherosclerosis, disseminated intravascular coagulation,Kawasaki's disease, Grave's disease, nephrotic syndrome, chronic fatiguesyndrome, Wegener's granulomatosis, Henoch-Schoenlein purpurea,microscopic vasculitis of the kidneys, chronic active hepatitis,uveitis, septic shock, toxic shock syndrome, sepsis syndrome, cachexia,infectious diseases, parasitic diseases, acquired immunodeficiencysyndrome, acute transverse myelitis, Huntington's chorea, Parkinson'sdisease, Alzheimer's disease, stroke, primary biliary cirrhosis,hemolytic anemia, malignancies, heart failure, myocardial infarction,Addison's disease, sporadic, polyglandular deficiency type I andpolyglandular deficiency type II, Schmidt's syndrome, adult (acute)respiratory distress syndrome, alopecia, alopecia areata, seronegativearthopathy, arthropathy, Reiter's disease, psoriatic arthropathy,ulcerative colitic arthropathy, enteropathic synovitis, chlamydia,yersinia and salmonella associated arthropathy, spondyloarthopathy,atheromatous disease/arteriosclerosis, atopic allergy, autoimmunebullous disease, pemphigus vulgaris, pemphigus foliaceus, pemphigoid,linear IgA disease, autoimmune haemolytic anaemia, Coombs positivehaemolytic anaemia, acquired pernicious anaemia, juvenile perniciousanaemia, myalgic encephalitis/Royal Free Disease, chronic mucocutaneouscandidiasis, giant cell arteritis, primary sclerosing hepatitis,cryptogenic autoimmune hepatitis, Acquired Immunodeficiency DiseaseSyndrome, Acquired Immunodeficiency Related Diseases, Hepatitis B,Hepatitis C, common varied immunodeficiency (common variablehypogammaglobulinaemia), dilated cardiomyopathy, female infertility,ovarian failure, premature ovarian failure, fibrotic lung disease,cryptogenic fibrosing alveolitis, post-inflammatory interstitial lungdisease, interstitial pneumonitis, connective tissue disease associatedinterstitial lung disease, mixed connective tissue disease associatedlung disease, systemic sclerosis associated interstitial lung disease,rheumatoid arthritis associated interstitial lung disease, systemiclupus erythematosus associated lung disease,dermatomyositis/polymyositis associated lung disease, Sjögren's diseaseassociated lung disease, ankylosing spondylitis associated lung disease,vasculitic diffuse lung disease, haemosiderosis associated lung disease,drug-induced interstitial lung disease, fibrosis, radiation fibrosis,bronchiolitis obliterans, chronic eosinophilic pneumonia, lymphocyticinfiltrative lung disease, postinfectious interstitial lung disease,gouty arthritis, autoimmune hepatitis, type-1 autoimmune hepatitis(classical autoimmune or lupoid hepatitis), type-2 autoimmune hepatitis(anti-LKM antibody hepatitis), autoimmune mediated hypoglycaemia, type Binsulin resistance with acanthosis nigricans, hypoparathyroidism, acuteimmune disease associated with organ transplantation, chronic immunedisease associated with organ transplantation, osteoarthrosis, primarysclerosing cholangitis, psoriasis type 1, psoriasis type 2, idiopathicleucopaenia, autoimmune neutropaenia, renal disease NOS,glomerulonephritides, microscopic vasulitis of the kidneys, lymedisease, discoid lupus erythematosus, male infertility idiopathic orNOS, sperm autoimmunity, multiple sclerosis (all subtypes), sympatheticophthalmia, pulmonary hypertension secondary to connective tissuedisease, Goodpasture's syndrome, pulmonary manifestation ofpolyarteritis nodosa, acute rheumatic fever, rheumatoid spondylitis,Still's disease, systemic sclerosis, Sjörgren's syndrome, Takayasu'sdisease/arteritis, autoimmune thrombocytopaenia, idiopathicthrombocytopaenia, autoimmune thyroid disease, hyperthyroidism, goitrousautoimmune hypothyroidism (Hashimoto's disease), atrophic autoimmunehypothyroidism, primary myxoedema, phacogenic uveitis, primaryvasculitis, vitiligo acute liver disease, chronic liver diseases,alcoholic cirrhosis, alcohol-induced liver injury, choleosatatis,idiosyncratic liver disease, Drug-Induced hepatitis, Non-alcoholicSteatohepatitis, allergy and asthma, group B streptococci (GBS)infection, mental disorders (e.g., depression and schizophrenia), Th2Type and Th1 Type mediated diseases, acute and chronic pain (differentforms of pain), and cancers such as lung, breast, stomach, bladder,colon, pancreas, ovarian, prostate and rectal cancer and hematopoieticmalignancies (leukemia and lymphoma), Abetalipoprotemia, Acrocyanosis,acute and chronic parasitic or infectious processes, acute leukemia,acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), acuteor chronic bacterial infection, acute pancreatitis, acute renal failure,adenocarcinomas, aerial ectopic beats, AIDS dementia complex,alcohol-induced hepatitis, allergic conjunctivitis, allergic contactdermatitis, allergic rhinitis, allograft rejection, alpha-1-antitrypsindeficiency, amyotrophic lateral sclerosis, anemia, angina pectoris,anterior horn cell degeneration, anti cd3 therapy, antiphospholipidsyndrome, anti-receptor hypersensitivity reactions, aordic andperipheral aneuryisms, aortic dissection, arterial hypertension,arteriosclerosis, arteriovenous fistula, ataxia, atrial fibrillation(sustained or paroxysmal), atrial flutter, atrioventricular block, Bcell lymphoma, bone graft rejection, bone marrow transplant (BMT)rejection, bundle branch block, Burkitt's lymphoma, Burns, cardiacarrhythmias, cardiac stun syndrome, cardiac tumors, cardiomyopathy,cardiopulmonary bypass inflammation response, cartilage transplantrejection, cerebellar cortical degenerations, cerebellar disorders,chaotic or multifocal atrial tachycardia, chemotherapy associateddisorders, chromic myelocytic leukemia (CML), chronic alcoholism,chronic inflammatory pathologies, chronic lymphocytic leukemia (CLL),chronic obstructive pulmonary disease (COPD), chronic salicylateintoxication, colorectal carcinoma, congestive heart failure,conjunctivitis, contact dermatitis, cor pulmonale, coronary arterydisease, Creutzfeldt-Jakob disease, culture negative sepsis, cysticfibrosis, cytokine therapy associated disorders, Dementia pugilistica,demyelinating diseases, dengue hemorrhagic fever, dermatitis,dermatologic conditions, diabetes, diabetes mellitus, diabeticateriosclerotic disease, Diffuse Lewy body disease, dilated congestivecardiomyopathy, disorders of the basal ganglia, Down's Syndrome inmiddle age, drug-induced movement disorders induced by drugs which blockCNS dopamine receptors, drug sensitivity, eczema, encephalomyelitis,endocarditis, endocrinopathy, epiglottitis, epstein-barr virusinfection, erythromelalgia, extrapyramidal and cerebellar disorders,familial hematophagocytic lymphohistiocytosis, fetal thymus implantrejection, Friedreich's ataxia, functional peripheral arterialdisorders, fungal sepsis, gas gangrene, gastric ulcer, glomerularnephritis, graft rejection of any organ or tissue, gram negative sepsis,gram positive sepsis, granulomas due to intracellular organisms, hairycell leukemia, Hallerrorden-Spatz disease, hashimoto's thyroiditis, hayfever, heart transplant rejection, hemachromatosis, hemodialysis,hemolytic uremic syndrome/thrombolytic thrombocytopenic purpura,hemorrhage, hepatitis (A), His bundle arrythmias, HIV infection/HIVneuropathy, Hodgkin's disease, hyperkinetic movement disorders,hypersensitity reactions, hypersensitivity pneumonitis, hypertension,hypokinetic movement disorders, hypothalamic-pituitary-adrenal axisevaluation, idiopathic Addison's disease, idiopathic pulmonary fibrosis,antibody mediated cytotoxicity, Asthenia, infantile spinal muscularatrophy, inflammation of the aorta, influenza a, ionizing radiationexposure, iridocyclitis/uveitis/optic neuritis, ischemia-reperfusioninjury, ischemic stroke, juvenile rheumatoid arthritis, juvenile spinalmuscular atrophy, Kaposi's sarcoma, kidney transplant rejection,legionella, leishmaniasis, leprosy, lesions of the corticospinal system,lipedema, liver transplant rejection, lymphederma, malaria, malignantLymphoma, malignant histiocytosis, malignant melanoma, meningitis,meningococcemia, metabolic/idiopathic, migraine headache, mitochondrialmulti.system disorder, mixed connective tissue disease, monoclonalgammopathy, multiple myeloma, multiple systems degenerations (MencelDejerine-Thomas Shi-Drager and Machado-Joseph), myasthenia gravis,mycobacterium avium intracellulare, mycobacterium tuberculosis,myelodyplastic syndrome, myocardial infarction, myocardial ischemicdisorders, nasopharyngeal carcinoma, neonatal chronic lung disease,nephritis, nephrosis, neurodegenerative diseases, neurogenic I muscularatrophies, neutropenic fever, non-hodgkins lymphoma, occlusion of theabdominal aorta and its branches, occulsive arterial disorders, okt3therapy, orchitis/epidydimitis, orchitis/vasectomy reversal procedures,organomegaly, osteoporosis, pancreas transplant rejection, pancreaticcarcinoma, paraneoplastic syndrome/hypercalcemia of malignancy,parathyroid transplant rejection, pelvic inflammatory disease, perennialrhinitis, pericardial disease, peripheral atherlosclerotic disease,peripheral vascular disorders, peritonitis, pernicious anemia,pneumocystis carinii pneumonia, pneumonia, POEMS syndrome(polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy,and skin changes syndrome), post perfusion syndrome, post pump syndrome,post-MI cardiotomy syndrome, preeclampsia, Progressive supranucleoPalsy, primary pulmonary hypertension, radiation therapy, Raynaud'sphenomenon and disease, Raynoud's disease, Refsum's disease, regularnarrow QRS tachycardia, renovascular hypertension, reperfusion injury,restrictive cardiomyopathy, sarcomas, scleroderma, senile chorea, SenileDementia of Lewy body type, seronegative arthropathies, shock, sicklecell anemia, skin allograft rejection, skin changes syndrome, smallbowel transplant rejection, solid tumors, specific arrythmias, spinalataxia, spinocerebellar degenerations, streptococcal myositis,structural lesions of the cerebellum, Subacute sclerosingpanencephalitis, Syncope, syphilis of the cardiovascular system,systemic anaphalaxis, systemic inflammatory response syndrome, systemiconset juvenile rheumatoid arthritis, T-cell or FAB ALL, Telangiectasia,thromboangitis obliterans, thrombocytopenia, toxicity, transplants,trauma/hemorrhage, type III hypersensitivity reactions, type IVhypersensitivity, unstable angina, uremia, urosepsis, urticaria,valvular heart diseases, varicose veins, vasculitis, venous diseases,venous thrombosis, ventricular fibrillation, viral and fungalinfections, vital encephalitis/aseptic meningitis, vital-associatedhemaphagocytic syndrome, Wernicke-Korsakoff syndrome, Wilson's disease,xenograft rejection of any organ or tissue. (see Peritt et al. PCTpublication No. WO2002097048A2, Leonard et al., PCT publication No.WO9524918 A1, and Salfeld et al., PCT publication No. WO00/56772A1).

The antibodies, and antibody portions of the invention can be used totreat humans suffering from autoimmune diseases, in particular thoseassociated with inflammation, including, rheumatoid spondylitis,allergy, autoimmune diabetes, autoimmune uveitis. Preferably, theantibodies of the invention or antigen-binding portions thereof, areused to treat rheumatoid arthritis, Crohn's disease, multiple sclerosis,insulin dependent diabetes mellitus and psoriasis.

An antibody, or antibody portion, of the invention also can beadministered with one or more additional therapeutic agents useful inthe treatment of autoimmune and inflammatory diseases.

Antibodies of the invention, or antigen binding portions thereof can beused alone or in combination to treat such diseases. It should beunderstood that the antibodies of the invention or antigen bindingportion thereof can be used alone or in combination with an additionalagent, e.g., a therapeutic agent, said additional agent being selectedby the skilled artisan for its intended purpose. For example, theadditional agent can be a therapeutic agent art-recognized as beinguseful to treat the disease or condition being treated by the antibodyof the present invention. The additional agent also can be an agent thatimparts a beneficial attribute to the therapeutic composition e.g., anagent which effects the viscosity of the composition.

It should further be understood that the combinations which are to beincluded within this invention are those combinations useful for theirintended purpose. The agents set forth below are illustrative forpurposes and not intended to be limited. The combinations, which arepart of this invention, can be the antibodies of the present inventionand at least one additional agent selected from the lists below. Thecombination can also include more than one additional agent, e.g., twoor three additional agents if the combination is such that the formedcomposition can perform its intended function.

Binding proteins described herein may be used in combination withadditional therapeutic agents such as a Disease Modifying Anti-RheumaticDrug (DMARD) or a Nonsteroidal Antiinflammatory Drug (NSAID) or asteroid or any combination thereof. Preferred examples of a DMARD arehydroxychloroquine, leflunomide, methotrexate, parenteral gold, oralgold and sulfasalazine. Preferred examples of non-steroidalanti-inflammatory drug(s) also referred to as NSAIDS include drugs likeibuprofen. Other preferred combinations are corticosteroids includingprednisolone; the well known side effects of steroid use can be reducedor even eliminated by tapering the steroid dose required when treatingpatients in combination with the anti-IL-12 antibodies of thisinvention. Non-limiting examples of therapeutic agents for rheumatoidarthritis with which an antibody, or antibody portion, of the inventioncan be combined include the following: cytokine suppressiveanti-inflammatory drug(s) (CSAIDs); antibodies to or antagonists ofother human cytokines or growth factors, for example, TNF, LT, IL-1,IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-15, IL-16, IL-18, IL-21,IL-23, interferons, EMAP-II, GM-CSF, FGF, and PDGF. Antibodies of theinvention, or antigen binding portions thereof, can be combined withantibodies to cell surface molecules such as CD2, CD3, CD4, CD8, CD25,CD28, CD30, CD40, CD45, CD69, CD80 (B7.1), CD86 (B7.2), CD90, CTLA ortheir ligands including CD154 (gp39 or CD40L).

Preferred combinations of therapeutic agents may interfere at differentpoints in the autoimmune and subsequent inflammatory cascade; preferredexamples include TNF antagonists such as soluble p55 or p75 TNFreceptors, derivatives, thereof, (p75TNFR1gG (Enbrel™) or p55TNFR1gG(Lenercept), chimeric, humanized or human TNF antibodies, or a fragmentthereof, including infliximab (Remicade®, Johnson and Johnson; describedin U.S. Pat. No. 5,656,272, incorporated by reference herein), CDP571 (ahumanized monoclonal anti-TNF-alpha IgG4 antibody), CDP 870 (a humanizedmonoclonal anti-TNF-alpha antibody fragment), an anti-TNF dAb (Peptech),CNTO 148 (golimumab; Medarex and Centocor, see WO 02/12502), andadalimumab (Humira® Abbott Laboratories, a human anti-TNF mAb, describedin U.S. Pat. No. 6,090,382 as D2E7). Additional TNF antibodies which canbe used in the invention are described in U.S. Pat. Nos. 6,593,458;6,498,237; 6,451,983; and 6,448,380, each of which is incorporated byreference herein. Other combinations including TNFα converting enzyme(TACE) inhibitors; IL-1 inhibitors (Interleukin-1-converting enzymeinhibitors, IL-1RA etc.) may be effective for the same reason. Otherpreferred combinations include Interleukin 11. Yet another preferredcombination are other key players of the autoimmune response which mayact parallel to, dependent on or in concert with IL-12 function;especially preferred are IL-18 antagonists including IL-18 antibodies orsoluble IL-18 receptors, or IL-18 binding proteins. It has been shownthat IL-12 and IL-18 have overlapping but distinct functions and acombination of antagonists to both may be most effective. Yet anotherpreferred combination are non-depleting anti-CD4 inhibitors. Yet otherpreferred combinations include antagonists of the co-stimulatory pathwayCD80 (B7.1) or CD86 (B7.2) including antibodies, soluble receptors orantagonistic ligands.

The antibodies of the invention, or antigen binding portions thereof,may also be combined with agents, such as methotrexate, 6-MP,azathioprine sulphasalazine, mesalazine, olsalazinechloroquinine/hydroxychloroquine, pencillamine, aurothiomalate(intramuscular and oral), azathioprine, cochicine, corticosteroids(oral, inhaled and local injection), beta-2 adrenoreceptor agonists(salbutamol, terbutaline, salmeteral), xanthines (theophylline,aminophylline), cromoglycate, nedocromil, ketotifen, ipratropium andoxitropium, cyclosporin, FK506, rapamycin, mycophenolate mofetil,leflunomide, NSAIDs, for example, ibuprofen, corticosteroids such asprednisolone, phosphodiesterase inhibitors, adensosine agonists,antithrombotic agents, complement inhibitors, adrenergic agents, agentswhich interfere with signalling by proinflammatory cytokines such as TNF

or IL-1 (e.g. IRAK, NIK, IKK, p38 or MAP kinase inhibitors), IL-1βconverting enzyme inhibitors, TNF

converting enzyme (TACE) inhibitors, T-cell signalling inhibitors suchas kinase inhibitors, metalloproteinase inhibitors, sulfasalazine,azathioprine, 6-mercaptopurines, angiotensin converting enzymeinhibitors, soluble cytokine receptors and derivatives thereof (e.g.soluble p55 or p75 TNF receptors and the derivatives p75TNFRIgG (Enbrel™and p55TNFRIgG (Lenercept)), sIL-1RI, sIL-1RII, sIL-6R),antiinflammatory cytokines (e.g. IL-4, IL-10, IL-11, IL-13 and TGFβ),celecoxib, folic acid, hydroxychloroquine sulfate, rofecoxib,etanercept, infliximab, naproxen, valdecoxib, sulfasalazine,methylprednisolone, meloxicam, methylprednisolone acetate, gold sodiumthiomalate, aspirin, triamcinolone acetonide, propoxyphenenapsylate/apap, folate, nabumetone, diclofenac, piroxicam, etodolac,diclofenac sodium, oxaprozin, oxycodone hcl, hydrocodonebitartrate/apap, diclofenac sodium/misoprostol, fentanyl, anakinra,human recombinant, tramadol hcl, salsalate, sulindac,cyanocobalamin/fa/pyridoxine, acetaminophen, alendronate sodium,prednisolone, morphine sulfate, lidocaine hydrochloride, indomethacin,glucosamine sulf/chondroitin, amitriptyline hcl, sulfadiazine, oxycodonehcl/acetaminophen, olopatadine hcl, misoprostol, naproxen sodium,omeprazole, cyclophosphamide, rituximab, IL-1 TRAP, MRA, CTLA4-IG, IL-18BP, anti-IL-18, Anti-IL15, BIRB-796, SCIO-469, VX-702, AMG-548, VX-740,Roflumilast, IC-485, CDC-801, and Mesopram. Preferred combinationsinclude methotrexate or leflunomide and in moderate or severe rheumatoidarthritis cases, cyclosporine.

Nonlimiting additional agents which can also be used in combination withan IL-12 or IL-23 antibody, or antigen-binding portion thereof, to treatrheumatoid arthritis include, but are not limited to, the following:non-steroidal anti-inflammatory drug(s) (NSAIDs); cytokine suppressiveanti-inflammatory drug(s) (CSAIDs); CDP-571/BAY-10-3356 (humanizedanti-TNFα antibody; Celltech/Bayer); cA2/infliximab (chimeric anti-TNFαantibody; Centocor); 75 kdTNFR-IgG/etanercept (75 kD TNF receptor-IgGfusion protein; Immunex; see e.g., Arthritis & Rheumatism (1994) Vol.37, S295; J. Invest. Med. (1996) Vol. 44, 235A); 55 kdTNF-IgG (55 kD TNFreceptor-IgG fusion protein; Hoffmann-LaRoche); IDEC-CE9.1/SB 210396(non-depleting primatized anti-CD4 antibody; IDEC/SmithKline; see e.g.,Arthritis & Rheumatism (1995) Vol. 38, S185); DAB 486-IL-2 and/or DAB389-IL-2 (IL-2 fusion proteins; Seragen; see e.g., Arthritis &Rheumatism (1993) Vol. 36, 1223); Anti-Tac (humanized anti-IL-2Rα;Protein Design Labs/Roche); IL-4 (anti-inflammatory cytokine;DNAX/Schering); IL-10 (SCH 52000; recombinant IL-10, anti-inflammatorycytokine; DNAX/Schering); IL-4; IL-10 and/or IL-4 agonists (e.g.,agonist antibodies); IL-1RA (IL-1 receptor antagonist; Synergen/Amgen);anakinra (Kineret®/Amgen); TNF-bp/s-TNF (soluble TNF binding protein;see e.g., Arthritis & Rheumatism (1996) Vol. 39, No. 9 (supplement),S284; Amer. J. Physiol.—Heart and Circulatory Physiology (1995) Vol.268, pp. 3742); R973401 (phosphodiesterase Type IV inhibitor; see e.g.,Arthritis & Rheumatism (1996) Vol. 39, No. 9 (supplement), S282); MK-966(COX-2 Inhibitor; see e.g., Arthritis & Rheumatism (1996) Vol. 39, No. 9(supplement), S81); Iloprost (see e.g., Arthritis & Rheumatism (1996)Vol. 39, No. 9 (supplement), S82); methotrexate; thalidomide (see e.g.,Arthritis & Rheumatism (1996) Vol. 39, No. 9 (supplement), S282) andthalidomide-related drugs (e.g., Celgen); leflunomide (anti-inflammatoryand cytokine inhibitor; see e.g., Arthritis & Rheumatism (1996) Vol. 39,No. 9 (supplement), S131; Inflammation Research (1996) Vol. 45, pp.103-107); tranexamic acid (inhibitor of plasminogen activation; seee.g., Arthritis & Rheumatism (1996) Vol. 39, No. 9 (supplement), S284);T-614 (cytokine inhibitor; see e.g., Arthritis & Rheumatism (1996) Vol.39, No. 9 (supplement), S282); prostaglandin E1 (see e.g., Arthritis &Rheumatism (1996) Vol. 39, No. 9 (supplement), S282); Tenidap(non-steroidal anti-inflammatory drug; see e.g., Arthritis & Rheumatism(1996) Vol. 39, No. 9 (supplement), S280); Naproxen (non-steroidalanti-inflammatory drug; see e.g., Neuro Report (1996) Vol. 7, pp.1209-1213); Meloxicam (non-steroidal anti-inflammatory drug); Ibuprofen(non-steroidal anti-inflammatory drug); Piroxicam (non-steroidalanti-inflammatory drug); Diclofenac (non-steroidal anti-inflammatorydrug); Indomethacin (non-steroidal anti-inflammatory drug);Sulfasalazine (see e.g., Arthritis & Rheumatism (1996) Vol. 39, No. 9(supplement), S281); Azathioprine (see e.g., Arthritis & Rheumatism(1996) Vol. 39, No. 9 (supplement), S281); ICE inhibitor (inhibitor ofthe enzyme interleukin-1β converting enzyme); zap-70 and/or lckinhibitor (inhibitor of the tyrosine kinase zap-70 or lck); VEGFinhibitor and/or VEGF-R inhibitor (inhibitors of vascular endothelialcell growth factor or vascular endothelial cell growth factor receptor;inhibitors of angiogenesis); corticosteroid anti-inflammatory drugs(e.g., SB203580); TNF-convertase inhibitors; anti-IL-12 antibodies;anti-IL-18 antibodies; interleukin-11 (see e.g., Arthritis & Rheumatism(1996) Vol. 39, No. 9 (supplement), S296); interleukin-13 (see e.g.,Arthritis & Rheumatism (1996) Vol. 39, No. 9 (supplement), S308);interleukin-17 inhibitors (see e.g., Arthritis & Rheumatism (1996) Vol.39, No. 9 (supplement), S120); gold; penicillamine; chloroquine;chlorambucil; hydroxychloroquine; cyclosporine; cyclophosphamide; totallymphoid irradiation; anti-thymocyte globulin; anti-CD4 antibodies;CD5-toxins; orally-administered peptides and collagen; lobenzaritdisodium; Cytokine Regulating Agents (CRAs) HP228 and HP466 (HoughtenPharmaceuticals, Inc.); ICAM-1 antisense phosphorothioateoligo-deoxynucleotides (ISIS 2302; Isis Pharmaceuticals, Inc.); solublecomplement receptor 1 (TP10; T Cell Sciences, Inc.); prednisone;orgotein; glycosaminoglycan polysulphate; minocycline; anti-IL2Rantibodies; marine and botanical lipids (fish and plant seed fattyacids; see e.g., DeLuca et al. (1995) Rheum. Dis. Clin. North Am.21:759-777); auranofin; phenylbutazone; meclofenamic acid; flufenamicacid; intravenous immune globulin; zileuton; azaribine; mycophenolicacid (RS-61443); tacrolimus (FK-506); sirolimus (rapamycin); amiprilose(therafectin); cladribine (2-chlorodeoxyadenosine); methotrexate;antivirals; and immune modulating agents.

In one embodiment, the IL-12 antibody, or antigen-binding portionthereof, is administered in combination with one of the following agentsfor the treatment of rheumatoid arthritis: small molecule inhibitor ofKDR (ABT-123), small molecule inhibitor of Tie-2; methotrexate;prednisone; celecoxib; folic acid; hydroxychloroquine sulfate;rofecoxib; etanercept; infliximab; leflunomide; naproxen; valdecoxib;sulfasalazine; methylprednisolone; ibuprofen; meloxicam;methylprednisolone acetate; gold sodium thiomalate; aspirin;azathioprine; triamcinolone acetonide; propxyphene napsylate/apap;folate; nabumetone; diclofenac; piroxicam; etodolac; diclofenac sodium;oxaprozin; oxycodone hcl; hydrocodone bitartrate/apap; diclofenacsodium/misoprostol; fentanyl; anakinra, human recombinant; tramadol hcl;salsalate; sulindac; cyanocobalamin/fa/pyridoxine; acetaminophen;alendronate sodium; prednisolone; morphine sulfate; lidocainehydrochloride; indomethacin; glucosamine sulfate/chondroitin;cyclosporine; amitriptyline hcl; sulfadiazine; oxycodonehcl/acetaminophen; olopatadine hcl; misoprostol; naproxen sodium;omeprazole; mycophenolate mofetil; cyclophosphamide; rituximab; IL-1TRAP; MRA; CTLA4-IG; IL-18 BP; ABT-874; ABT-325 (anti-IL 18); anti-IL15; BIRB-796; SCIO-469; VX-702; AMG-548; VX-740; Roflumilast; IC-485;CDC-801; and mesopram. In another embodiment, an IL-12 or IL-23antibody, or antigen-binding portion thereof, is administered for thetreatment of an IL-12 or IL-23 related disorder in combination with oneof the above mentioned agents for the treatment of rheumatoid arthritis.

Non-limiting examples of therapeutic agents for inflammatory boweldisease with which an antibody, or antibody portion, of the inventioncan be combined include the following: budenoside; epidermal growthfactor; corticosteroids; cyclosporin, sulfasalazine; aminosalicylates;6-mercaptopurine; azathioprine; metronidazole; lipoxygenase inhibitors;mesalamine; olsalazine; balsalazide; antioxidants; thromboxaneinhibitors; IL-1 receptor antagonists; anti-IL-1β monoclonal antibodies;anti-IL-6 monoclonal antibodies; growth factors; elastase inhibitors;pyridinyl-imidazole compounds; antibodies to or antagonists of otherhuman cytokines or growth factors, for example, TNF, LT, IL-1, IL-2,IL-6, IL-7, IL-8, IL-15, IL-16, IL-17, IL-18, EMAP-II, GM-CSF, FGF, andPDGF. Antibodies of the invention, or antigen binding portions thereof,can be combined with antibodies to cell surface molecules such as CD2,CD3, CD4, CD8, CD25, CD28, CD30, CD40, CD45, CD69, CD90 or theirligands. The antibodies of the invention, or antigen binding portionsthereof, may also be combined with agents, such as methotrexate,cyclosporin, FK506, rapamycin, mycophenolate mofetil, leflunomide,NSAIDs, for example, ibuprofen, corticosteroids such as prednisolone,phosphodiesterase inhibitors, adenosine agonists, antithrombotic agents,complement inhibitors, adrenergic agents, agents which interfere withsignalling by proinflammatory cytokines such as TNFα or IL-1 (e.g. IRAK,NIK, IKK, p38 or MAP kinase inhibitors), IL-1β converting enzymeinhibitors, TNFα converting enzyme inhibitors, T-cell signallinginhibitors such as kinase inhibitors, metalloproteinase inhibitors,sulfasalazine, azathioprine, 6-mercaptopurines, angiotensin convertingenzyme inhibitors, soluble cytokine receptors and derivatives thereof(e.g. soluble p55 or p75 TNF receptors, sIL-1RI, sIL-1RII, sIL-6R) andantiinflammatory cytokines (e.g. IL-4, IL-10, IL-11, IL-13 and TGFβ).

Preferred examples of therapeutic agents for Crohn's disease in which anantibody or an antigen binding portion can be combined include thefollowing: TNF antagonists, for example, anti-TNF antibodies, D2E7 (PCTPublication No. WO 97/29131; HUMIRA), CA2 (REMICADE), CDP 571, TNFR-Igconstructs, (p75TNFRIgG (ENBREL) and p55TNFRIgG (LENERCEPT)) inhibitorsand PDE4 inhibitors. Antibodies of the invention, or antigen bindingportions thereof, can be combined with corticosteroids, for example,budenoside and dexamethasone. Antibodies of the invention or antigenbinding portions thereof, may also be combined with agents such assulfasalazine, 5-aminosalicylic acid and olsalazine, and agents whichinterfere with synthesis or action of proinflammatory cytokines such asIL-1, for example, IL-1β converting enzyme inhibitors and IL-1ra.Antibodies of the invention or antigen binding portion thereof may alsobe used with T cell signaling inhibitors, for example, tyrosine kinaseinhibitors 6-mercaptopurines. Antibodies of the invention, or antigenbinding portions thereof, can be combined with IL-11. Antibodies of theinvention, or antigen binding portions thereof, can be combined withmesalamine, prednisone, azathioprine, mercaptopurine, infliximab,methylprednisolone sodium succinate, diphenoxylate/atrop sulfate,loperamide hydrochloride, methotrexate, omeprazole, folate,ciprofloxacin/dextrose-water, hydrocodone bitartrate/apap, tetracyclinehydrochloride, fluocinonide, metronidazole, thimerosal/boric acid,cholestyramine/sucrose, ciprofloxacin hydrochloride, hyoscyaminesulfate, meperidine hydrochloride, midazolam hydrochloride, oxycodonehcl/acetaminophen, promethazine hydrochloride, sodium phosphate,sulfamethoxazole/trimethoprim, celecoxib, polycarbophil, propoxyphenenapsylate, hydrocortisone, multivitamins, balsalazide disodium, codeinephosphate/apap, colesevelam hcl, cyanocobalamin, folic acid,levofloxacin, methylprednisolone, natalizumab and interferon-gamma

Non-limiting examples of therapeutic agents for multiple sclerosis withwhich an antibody, or antibody portion, of the invention can be combinedinclude the following: corticosteroids; prednisolone;methylprednisolone; azathioprine; cyclophosphamide; cyclosporine;methotrexate; 4-aminopyridine; tizanidine; interferon-β1a (AVONEX;Biogen); interferon-β1b (BETASERON; Chiron/Berlex); interferon α-n3)(Interferon Sciences/Fujimoto), interferon-α (Alfa Wassermann/J&J),interferon β1A-IF (Serono/Inhale Therapeutics), Peginterferon α2b(Enzon/Schering-Plough), Copolymer 1 (Cop-1; COPAXONE; TevaPharmaceutical Industries, Inc.); hyperbaric oxygen; intravenousimmunoglobulin; clabribine; antibodies to or antagonists of other humancytokines or growth factors and their receptors, for example, TNF, LT,IL-1, IL-2, IL-6, IL-7, IL-8, IL-23, IL-15, IL-16, IL-18, EMAP-II,GM-CSF, FGF, and PDGF. Antibodies of the invention, or antigen bindingportions thereof, can be combined with antibodies to cell surfacemolecules such as CD2, CD3, CD4, CD8, CD19, CD20, CD25, CD28, CD30,CD40, CD45, CD69, CD80, CD86, CD90 or their ligands. The antibodies ofthe invention, or antigen binding portions thereof, may also be combinedwith agents, such as methotrexate, cyclosporine, FK506, rapamycin,mycophenolate mofetil, leflunomide, NSAIDs, for example, ibuprofen,corticosteroids such as prednisolone, phosphodiesterase inhibitors,adensosine agonists, antithrombotic agents, complement inhibitors,adrenergic agents, agents which interfere with signalling byproinflammatory cytokines such as TNFα or IL-1 (e.g. IRAK, NIK, IKK, p38or MAP kinase inhibitors), IL-1β converting enzyme inhibitors, TACEinhibitors, T-cell signaling inhibitors such as kinase inhibitors,metalloproteinase inhibitors, sulfasalazine, azathioprine,6-mercaptopurines, angiotensin converting enzyme inhibitors, solublecytokine receptors and derivatives thereof (e.g. soluble p55 or p75 TNFreceptors, sIL-1RI, sIL-1RII, sIL-6R) and antiinflammatory cytokines(e.g. IL-4, IL-10, IL-13 and TGFβ).

Preferred examples of therapeutic agents for multiple sclerosis in whichthe antibody or antigen binding portion thereof can be combined toinclude interferon-β, for example, IFNβ1a and IFNβ1b; copaxone,corticosteroids, caspase inhibitors, for example inhibitors ofcaspase-1, IL-1 inhibitors, TNF inhibitors, and antibodies to CD40ligand and CD80.

The antibodies of the invention, or antigen binding portions thereof,may also be combined with agents, such as alemtuzumab, dronabinol,Unimed, daclizumab, mitoxantrone, xaliproden hydrochloride, fampridine,glatiramer acetate, natalizumab, sinnabidol, a-immunokine NNSO3,ABR-215062, AnergiX.MS, chemokine receptor antagonists, BBR-2778,calagualine, CPI-1189, LEM (liposome encapsulated mitoxantrone), THC.CBD(cannabinoid agonist) MBP-8298, mesopram (PDE4 inhibitor), MNA-715,anti-IL-6 receptor antibody, neurovax, pirfenidone allotrap 1258(RDP-1258), sTNF-R1, talampanel, teriflunomide, TGF-beta2, tiplimotide,VLA-4 antagonists (for example, TR-14035, VLA4 Ultrahaler,Antegran-ELAN/Biogen), interferon gamma antagonists, IL-4 agonists.

Non-limiting examples of therapeutic agents for Angina with which anantibody, or antibody portion, of the invention can be combined includethe following: aspirin, nitroglycerin, isosorbide mononitrate,metoprolol succinate, atenolol, metoprolol tartrate, amlodipinebesylate, diltiazem hydrochloride, isosorbide dinitrate, clopidogrelbisulfate, nifedipine, atorvastatin calcium, potassium chloride,furosemide, simvastatin, verapamil hcl, digoxin, propranololhydrochloride, carvedilol, lisinopril, spironolactone,hydrochlorothiazide, enalapril maleate, nadolol, ramipril, enoxaparinsodium, heparin sodium, valsartan, sotalol hydrochloride, fenofibrate,ezetimibe, bumetanide, losartan potassium,lisinopril/hydrochlorothiazide, felodipine, captopril, bisoprololfumarate.

Non-limiting examples of therapeutic agents for Ankylosing Spondylitiswith which an antibody, or antibody portion, of the invention can becombined include the following: ibuprofen, diclofenac and misoprostol,naproxen, meloxicam, indomethacin, diclofenac, celecoxib, rofecoxib,Sulfasalazine, Methotrexate, azathioprine, minocyclin, prednisone,etanercept, infliximab.

Non-limiting examples of therapeutic agents for Asthma with which anantibody, or antibody portion, of the invention can be combined includethe following: albuterol, salmeterol/fluticasone, montelukast sodium,fluticasone propionate, budesonide, prednisone, salmeterol xinafoate,levalbuterol hcl, albuterol sulfate/ipratropium, prednisolone sodiumphosphate, triamcinolone acetonide, beclomethasone dipropionate,ipratropium bromide, azithromycin, pirbuterol acetate, prednisolone,theophylline anhydrous, methylprednisolone sodium succinate,clarithromycin, zafirlukast, formoterol fumarate, influenza virusvaccine, methylprednisolone, amoxicillin trihydrate, flunisolide,allergy injection, cromolyn sodium, fexofenadine hydrochloride,flunisolide/menthol, amoxicillin/clavulanate, levofloxacin, inhalerassist device, guaifenesin, dexamethasone sodium phosphate, moxifloxacinhcl, doxycycline hyclate, guaifenesin/d-methorphan,p-ephedrine/cod/chlorphenir, gatifloxacin, cetirizine hydrochloride,mometasone furoate, salmeterol xinafoate, benzonatate, cephalexin,pe/hydrocodone/chlorphenir, cetirizine hcl/pseudoephed,phenylephrine/cod/promethazine, codeine/promethazine, cefprozil,dexamethasone, guaifenesin/pseudoephedrine,chlorpheniramine/hydrocodone, nedocromil sodium, terbutaline sulfate,epinephrine, methylprednisolone, metaproterenol sulfate.

Non-limiting examples of therapeutic agents for COPD with which anantibody, or antibody portion, of the invention can be combined includethe following: albuterol sulfate/ipratropium, ipratropium bromide,salmeterol/fluticasone, albuterol, salmeterol xinafoate, fluticasonepropionate, prednisone, theophylline anhydrous, methylprednisolonesodium succinate, montelukast sodium, budesonide, formoterol fumarate,triamcinolone acetonide, levofloxacin, guaifenesin, azithromycin,beclomethasone dipropionate, levalbuterol hcl, flunisolide, ceftriaxonesodium, amoxicillin trihydrate, gatifloxacin, zafirlukast,amoxicillin/clavulanate, flunisolide/menthol,chlorpheniramine/hydrocodone, metaproterenol sulfate,methylprednisolone, mometasone furoate, p-ephedrine/cod/chlorphenir,pirbuterol acetate, p-ephedrine/loratadine, terbutaline sulfate,tiotropium bromide, (R,R)-formoterol, TgAAT, Cilomilast, Roflumilast.

Non-limiting examples of therapeutic agents for HCV with which anantibody, or antibody portion, of the invention can be combined includethe following: Interferon-alpha-2a, Interferon-alpha-2b,Interferon-alpha con1, Interferon-alpha-n1, Pegylatedinterferon-alpha-2a, Pegylated interferon-alpha-2b, ribavirin,Peginterferon alfa-2b+ribavirin, Ursodeoxycholic Acid, GlycyrrhizicAcid, Thymalfasin, Maxamine, VX-497 and any compounds that are used totreat HCV through intervention with the following targets:HCVpolymerase, HCV protease, HCV helicase, HCV IRES (internal ribosomeentry site).

Non-limiting examples of therapeutic agents for Idiopathic PulmonaryFibrosis with which an antibody, or antibody portion, of the inventioncan be combined include the following: prednisone, azathioprine,albuterol, colchicine, albuterol sulfate, digoxin, gamma interferon,methylprednisolone sod succ, lorazepam, furosemide, lisinopril,nitroglycerin, spironolactone, cyclophosphamide, ipratropium bromide,actinomycin d, alteplase, fluticasone propionate, levofloxacin,metaproterenol sulfate, morphine sulfate, oxycodone hcl, potassiumchloride, triamcinolone acetonide, tacrolimus anhydrous, calcium,interferon-alpha, methotrexate, mycophenolate mofetil,Interferon-gamma-1β.

Non-limiting examples of therapeutic agents for Myocardial Infarctionwith which an antibody, or antibody portion, of the invention can becombined include the following: aspirin, nitroglycerin, metoprololtartrate, enoxaparin sodium, heparin sodium, clopidogrel bisulfate,carvedilol, atenolol, morphine sulfate, metoprolol succinate, warfarinsodium, lisinopril, isosorbide mononitrate, digoxin, furosemide,simvastatin, ramipril, tenecteplase, enalapril maleate, torsemide,retavase, losartan potassium, quinapril hcl/mag carb, bumetanide,alteplase, enalaprilat, amiodarone hydrochloride, tirofiban hclm-hydrate, diltiazem hydrochloride, captopril, irbesartan, valsartan,propranolol hydrochloride, fosinopril sodium, lidocaine hydrochloride,eptifibatide, cefazolin sodium, atropine sulfate, aminocaproic acid,spironolactone, interferon, sotalol hydrochloride, potassium chloride,docusate sodium, dobutamine hcl, alprazolam, pravastatin sodium,atorvastatin calcium, midazolam hydrochloride, meperidine hydrochloride,isosorbide dinitrate, epinephrine, dopamine hydrochloride, bivalirudin,rosuvastatin, ezetimibe/simvastatin, avasimibe, cariporide.

Non-limiting examples of therapeutic agents for Psoriasis with which anantibody, or antibody portion, of the invention can be combined includethe following: small molecule inhibitor of KDR (ABT-123), small moleculeinhibitor of Tie-2, calcipotriene, clobetasol propionate, triamcinoloneacetonide, halobetasol propionate, tazarotene, methotrexate,fluocinonide, betamethasone diprop augmented, fluocinolone acetonide,acitretin, tar shampoo, betamethasone valerate, mometasone furoate,ketoconazole, pramoxine/fluocinolone, hydrocortisone valerate,flurandrenolide, urea, betamethasone, clobetasol propionate/emoll,fluticasone propionate, azithromycin, hydrocortisone, moisturizingformula, folic acid, desonide, pimecrolimus, coal tar, diflorasonediacetate, etanercept folate, lactic acid, methoxsalen, hc/bismuthsubgal/znox/resor, methylprednisolone acetate, prednisone, sunscreen,halcinonide, salicylic acid, anthralin, clocortolone pivalate, coalextract, coal tar/salicylic acid, coal tar/salicylic acid/sulfur,desoximetasone, diazepam, emollient, fluocinonide/emollient, mineraloil/castor oil/na lact, mineral oil/peanut oil, petroleum/isopropylmyristate, psoralen, salicylic acid, soap/tribromsalan, thimerosal/boricacid, celecoxib, infliximab, cyclosporine, alefacept, efalizumab,tacrolimus, pimecrolimus, PUVA, UVB, sulfasalazine.

Non-limiting examples of therapeutic agents for Psoriatic Arthritis withwhich an antibody, or antibody portion, of the invention can be combinedinclude the following: methotrexate, etanercept, rofecoxib, celecoxib,folic acid, sulfasalazine, naproxen, leflunomide, methylprednisoloneacetate, indomethacin, hydroxychloroquine sulfate, prednisone, sulindac,betamethasone diprop augmented, infliximab, methotrexate, folate,triamcinolone acetonide, diclofenac, dimethylsulfoxide, piroxicam,diclofenac sodium, ketoprofen, meloxicam, methylprednisolone,nabumetone, tolmetin sodium, calcipotriene, cyclosporine, diclofenacsodium/misoprostol, fluocinonide, glucosamine sulfate, gold sodiumthiomalate, hydrocodone bitartrate/apap, ibuprofen, risedronate sodium,sulfadiazine, thioguanine, valdecoxib, alefacept, efalizumab.

Non-limiting examples of therapeutic agents for Restenosis with which anantibody, or antibody portion, of the invention can be combined includethe following: sirolimus, paclitaxel, everolimus, tacrolimus, ABT-578,acetaminophen.

Non-limiting examples of therapeutic agents for Sciatica with which anantibody, or antibody portion, of the invention can be combined includethe following: hydrocodone bitartrate/apap, rofecoxib, cyclobenzaprinehcl, methylprednisolone, naproxen, ibuprofen, oxycodonehcl/acetaminophen, celecoxib, valdecoxib, methylprednisolone acetate,prednisone, codeine phosphate/apap, tramadol hcl/acetaminophen,metaxalone, meloxicam, methocarbamol, lidocaine hydrochloride,diclofenac sodium, gabapentin, dexamethasone, carisoprodol, ketorolactromethamine, indomethacin, acetaminophen, diazepam, nabumetone,oxycodone hcl, tizanidine hcl, diclofenac sodium/misoprostol,propoxyphene napsylate/apap, asa/oxycod/oxycodone ter,ibuprofen/hydrocodone bit, tramadol hcl, etodolac, propoxyphene hcl,amitriptyline hcl, carisoprodol/codeine phos/asa, morphine sulfate,multivitamins, naproxen sodium, orphenadrine citrate, temazepam.

Preferred examples of therapeutic agents for SLE (Lupus) in which anantibody or an antigen binding portion can be combined include thefollowing: NSAIDS, for example, diclofenac, naproxen, ibuprofen,piroxicam, indomethacin; COX2 inhibitors, for example, Celecoxib,rofecoxib, valdecoxib; anti-malarials, for example, hydroxychloroquine;Steroids, for example, prednisone, prednisolone, budenoside,dexamethasone; Cytotoxics, for example, azathioprine, cyclophosphamide,mycophenolate mofetil, methotrexate; inhibitors of PDE4 or purinesynthesis inhibitor, for example Cellcept. Antibodies of the inventionor antigen binding portions thereof, may also be combined with agentssuch as sulfasalazine, 5-aminosalicylic acid, olsalazine, Imuran andagents which interfere with synthesis, production or action ofproinflammatory cytokines such as IL-1, for example, caspase inhibitorslike IL-1β converting enzyme inhibitors and IL-1ra. Antibodies of theinvention or antigen binding portion thereof may also be used with Tcell signaling inhibitors, for example, tyrosine kinase inhibitors; ormolecules that target T cell activation molecules, for example,CTLA4-IgG or anti-B7 family antibodies, anti-PD-1 family antibodies.Antibodies of the invention, or antigen binding portions thereof, can becombined with IL-11 or anti-cytokine antibodies, for example,fonotolizumab (anti-IFNg antibody), or anti-receptor receptorantibodies, for example, anti-IL-6 receptor antibody and antibodies toB-cell surface molecules. Antibodies of the invention or antigen bindingportion thereof may also be used with LJP 394 (abetimus), agents thatdeplete or inactivate B-cells, for example, Rituximab (anti-CD20antibody), lymphostat-B (anti-BlyS antibody), TNF antagonists, forexample, anti-TNF antibodies, D2E7 (PCT Publication No. WO 97/29131;HUMIRA), CA2 (REMICADE), CDP 571, TNFR-Ig constructs, (p75TNFRIgG(ENBREL⁾ and p55TNFRIgG (LENERCEPT)).

The pharmaceutical compositions of the invention may include a“therapeutically effective amount” or a “prophylactically effectiveamount” of an antibody or antibody portion of the invention. A“therapeutically effective amount” refers to an amount effective, atdosages and for periods of time necessary, to achieve the desiredtherapeutic result. A therapeutically effective amount of the antibodyor antibody portion may be determined by a person skilled in the art andmay vary according to factors such as the disease state, age, sex, andweight of the individual, and the ability of the antibody or antibodyportion to elicit a desired response in the individual. Atherapeutically effective amount is also one in which any toxic ordetrimental effects of the antibody, or antibody portion, are outweighedby the therapeutically beneficial effects. A “prophylactically effectiveamount” refers to an amount effective, at dosages and for periods oftime necessary, to achieve the desired prophylactic result. Typically,since a prophylactic dose is used in subjects prior to or at an earlierstage of disease, the prophylactically effective amount will be lessthan the therapeutically effective amount.

Dosage regimens may be adjusted to provide the optimum desired response(e.g., a therapeutic or prophylactic response). For example, a singlebolus may be administered, several divided doses may be administeredover time or the dose may be proportionally reduced or increased asindicated by the exigencies of the therapeutic situation. It isespecially advantageous to formulate parenteral compositions in dosageunit form for ease of administration and uniformity of dosage. Dosageunit form as used herein refers to physically discrete units suited asunitary dosages for the mammalian subjects to be treated; each unitcontaining a predetermined quantity of active compound calculated toproduce the desired therapeutic effect in association with the requiredpharmaceutical carrier. The specification for the dosage unit forms ofthe invention are dictated by and directly dependent on (a) the uniquecharacteristics of the active compound and the particular therapeutic orprophylactic effect to be achieved, and (b) the limitations inherent inthe art of compounding such an active compound for the treatment ofsensitivity in individuals.

An exemplary, non-limiting range for a therapeutically orprophylactically effective amount of an antibody or antibody portion ofthe invention is 0.1-20 mg/kg, more preferably 1-10 mg/kg. It is to benoted that dosage values may vary with the type and severity of thecondition to be alleviated. It is to be further understood that for anyparticular subject, specific dosage regimens should be adjusted overtime according to the individual need and the professional judgment ofthe person administering or supervising the administration of thecompositions, and that dosage ranges set forth herein are exemplary onlyand are not intended to limit the scope or practice of the claimedcomposition.

It will be readily apparent to those skilled in the art that othersuitable modifications and adaptations of the methods of the inventiondescribed herein are obvious and may be made using suitable equivalentswithout departing from the scope of the invention or the embodimentsdisclosed herein. Having now described the present invention in detail,the same will be more clearly understood by reference to the followingexamples, which are included for purposes of illustration only and arenot intended to be limiting of the invention.

EXAMPLES Example 1 Generation and Isolation of Anti Human IL-12Monoclonal Antibodies Example 1.1 Assays to Identify Anti Human IL-12Antibodies

Throughout Example 1 the following assays were used to identify andcharacterize anti human IL-12 antibodies unless otherwise stated.

Example 1.1.A ELISA

Enzyme Linked Immunosorbent Assays to screen for antibodies that bindhuman IL-12 were performed as follows.

Example 1.1.A.1 ELISA to Detect Binding of Anti Human IL-12 Antibodiesto IL-12 p70

ELISA plates (Corning Costar, Acton, Mass.) were coated with 50 μL/wellof 5 μg/ml goat anti-mouse IgG Fc specific (Pierce #31170, Rockford,Ill.) in Phosphate Buffered Saline (PBS) overnight at 4 degrees Celsius.Plates were washed once with PBS containing 0.05% Tween-20. Plates wereblocked by addition of 200 μL/well blocking solution diluted to 2% inPBS (BioRad #170-6404, Hercules, Calif.) for 1 hour at room temperature.Plates were washed once after blocking with PBS containing 0.05%Tween-20.

Fifty microliters per well of mouse sera or hybridoma supernatantsdiluted in PBS containing 0.1% Bovine Serum Albumin (BSA) (Sigma, St.Louis, Mo.) was added to the ELISA plate prepared as described above andincubated for 1 hour at room temperature. Wells were washed three timeswith PBS containing 0.05% Tween-20. Fifty microliters of biotinylatedrecombinant purified human IL-12 p70 diluted to 100 ng/mL in PBScontaining 0.1% BSA was added to each well and incubated for 1 hour atroom temperature. Plates were washed 3 times with PBS containing 0.05%Tween-20. Streptavidin HRP (Pierce #21126, Rockland, Ill.) was diluted1:20000 in PBS containing 0.1% BSA; 50 μL/well was added and the platesincubated for 1 hour at room temperature. Plates were washed 3 timeswith PBS containing 0.05% Tween-20. Fifty microliters of TMB solution(Sigma #T0440, St. Louis, Mo.) was added to each well and incubated for10 minutes at room temperature. The reaction was stopped by addition of1N sulphuric acid. Plates were read spectrophotmetrically at awavelength of 450 nm.

Example 1.1.A.2 ELISA to Assess Ability of IL-12 p70 or IL-12 p40 toCompete with Binding of Anti Human IL-12 Antibodies to IL-12 p70

ELISA plates (Corning Costar, Acton, Mass.) were coated with 50 μL/wellof 5 μg/ml goat anti-mouse IgG Fc specific (Pierce #31170, Rockford,Ill.) in PBS overnight at 4 degrees Celsius. Plates were washed oncewith PBS+0.05% Tween-20. Plates were blocked by addition of PBS+10%powdered milk for 1 hour at room temperature. Plates were washed threetimes after blocking with PBS+0.05% Tween-20.

Example 1.1.A 2(a) IL-12 p70 Competition ELISA Protocol

Mouse sera or hybridoma supernatants were diluted in PBS containing 0.1%BSA (Sigma, St. Louis, Mo.) depending on anticipated antibody titer.Biotinylated recombinant purified human IL-12 p70 was prepared as athree times concentrated (3×) stock at 0.1 μg/ml in PBS containing 0.1%BSA. Recombinant purified human IL-12 p70 was prepared at variousconcentrations ranging from 0.1 to 10 μg/ml in PBS containing 0.1% BSA.Equal volumes (75 μL) of each of the following solutions were mixed:diluted mouse sera or hybridoma supernatant, biotinylated recombinantpurified human IL-12 p70, and recombinant purified human IL-12 p70.Fifty microliters of this mixture was added to the coated ELISA platesdescribed above and were incubated for 1 hour at room temperature. Wellswere washed three times with PBS containing 0.05% Tween-20. StreptavidinHRP (Pierce #21126, Rockland, Ill.) was diluted 1:20000 in PBScontaining 0.1% BSA; 50 μL/well was added and the plates incubated for 1hour at room temperature. Plates were washed 3 times with PBS containing0.05% Tween-20. Fifty microliters of TMB solution (Sigma #T0440, St.Louis, Mo.) was added to each well and incubated for 10 minutes at roomtemperature. The reaction was stopped by addition of 1N sulphuric acid.Plates were read spectrophotmetrically at a wavelength of 450 nm.

Example 1.1.A 2(b) IL-12 p40 Competition ELISA Protocol

Mouse sera or hybridoma supernatants were diluted in PBS containing 0.1%BSA (Sigma, St. Louis, Mo.) depending on anticipated antibody titer.Biotinylated recombinant purified human IL-12 p70 was prepared as athree times concentrated (3×) stock at 0.1 μg/ml in PBS containing 0.1%BSA. Recombinant purified human IL-12 p40 was prepared at variousconcentrations ranging from 0.1 to 10 μg/ml in PBS containing 0.1% BSA.Equal volumes (75 μL) of each of the following solutions were mixed:diluted mouse sera or hybridoma supernatant, biotinylated recombinantpurified human IL-12 p70, and recombinant purified human IL-12 p40.Fifty microliters of this mixture was added to the coated ELISA platesand incubated for 1 hour at room temperature. Wells were washed threetimes with PBS containing 0.05% Tween-20. Streptavidin HRP (Pierce#21126, Rockland, Ill.) was diluted 1:20000 in PBS containing 0.1% BSA;50 μL/well was added and the plates incubated for 1 hour at roomtemperature. Plates were washed 3 times with PBS containing 0.05%Tween-20. Fifty microliters of TMB solution (Sigma #T0440, St. Louis,Mo.) was added to each well and incubated for 10 minutes at roomtemperature. The reaction was stopped by addition of 1N sulphuric acid.Plates were read spectrophotmetrically at a wavelength of 450 nm.

Example 1.1.B Affinity Determinations Using BIACORE Technology

The BIACORE assay (Biacore, Inc, Piscataway, N.J.) determines theaffinity of antibodies with kinetic measurements of on-, off-rateconstants. Binding of antibodies to recombinant purified human IL-12 p70or recombinant purified human IL-12 p40 were determined by surfaceplasmon resonance-based measurements with a Biacore® 3000 instrument(Biacore® AB, Uppsala, Sweden) using running HBS-EP (10 mM HEPES [pH7.4], 150 mM NaCl, 3 mM EDTA, and 0.005% surfactant P20) at 25° C. Allchemicals were obtained from Biacore® AB (Uppsala, Sweden) or otherwisefrom a different source as described in the text. Approximately 5000 RUof goat anti-mouse IgG, (Fcγ), fragment specific polyclonal antibody(Pierce Biotechnology Inc, Rockford, Ill.) diluted in 10 mM sodiumacetate (pH 4.5) was directly immobilized across a CM5 research gradebiosensor chip using a standard amine coupling kit according tomanufacturer's instructions and procedures at 25 μg/ml. Unreactedmoieties on the biosensor surface were blocked with ethanolamine.Modified carboxymethyl dextran surface in flowcell 2 and 4 was used as areaction surface. Unmodified carboxymethyl dextran without goatanti-mouse IgG in flow cell 1 and 3 was used as the reference surface.For kinetic analysis, rate equations derived from the 1:1 Langmuirbinding model were fitted simultaneously to association and dissociationphases of all eight injections (using global fit analysis) with the useof Biaevaluation 4.0.1 software. Purified antibodies were diluted inHEPES-buffered saline for capture across goat anti-mouse IgG specificreaction surfaces. Mouse antibodies to be captured as a ligand (25μg/ml) were injected over reaction matrices at a flow rate of 5 μl/min.The association and dissociation rate constants, k_(on) (unit M⁻¹s⁻¹)and k_(off) (unit s⁻¹) were determined under a continuous flow rate of25 μl/min. Rate constants were derived by making kinetic bindingmeasurements at ten different antigen concentrations ranging from 10-200nM. The equilibrium dissociation constant (unit M) of the reactionbetween mouse antibodies and recombinant purified human IL-12 p70 orrecombinant purified human IL-12 p40 was then calculated from thekinetic rate constants by the following formula: K_(D)=k_(off)/k_(on).Binding is recorded as a function of time and kinetic rate constants arecalculated. In this assay, on-rates as fast as 10⁶ M⁻¹s⁻¹ and off-ratesas slow as 10⁻⁶ s⁻¹ can be measured.

Example 1.1.C Functional Activity of Anti Human IL-12 Antibodies

To examine the functional activity of the anti-human IL-12 antibodies ofthe invention, the antibodies were used in the following assays thatmeasure the ability of an antibody to inhibit IL-12 activity.

Example 1.1.C1 Preparation of Human PHA-Activated Lymphoblasts

Human peripheral blood mononuclear cells (PBMCs) were isolated from aleukopac collected from a healthy donor by Ficoll-Hypaque gradientcentrifugation for 45 minutes at 1500 rpm as described in CurrentProtocols in Immunology, Unit 7.1. PBMC at the interface of the aqueousblood solution and the lymphocyte separation medium were collected andwashed three times with phosphate-buffered saline (PBS) bycentrifugation for 15 minutes at 1500 rpm to remove Ficoll-Paqueparticles.

The PBMC were then activated to form lymphoblasts as described inCurrent Protocols in Immunology, Unit 6.16. The washed PBMC wereresuspended at 0.5-1×I0⁶ cells/mL in RPMI complete medium (RPMI 1640medium, 10% fetal bovine serum (FBS), 100 U/ml penicillin, 100 tg/mlstreptomycin), supplemented with 0.01 mg/mL PHA-P (Sigma #L8754, St.Louis, Mo.) and cultured for 4 days at 37° C. in a 5% CO₂ atmosphere.After four days, cell cultures were then re-seeded at 1×10⁶ cells/mL inculture media with 0.01 mg/mL PHA-P and 50 U/mL recombinant human IL-2(R&D Systems #202-IL, Minneapolis, Minn.). Cells were incubated at 37°C. for 24 hours, washed with RPMI complete medium, then frozen in 95%FBS, 5% DMSO at 1×10⁷ cells/ml.

Example 1.1.C2 PHA Blast IFN-γ Induction Assay: Inhibition of HumanIL-12 Activity

The ability of anti-human IL-12 antibodies to inhibit the human IL-12induced production of IFN-γ by PHA blasts was analyzed as follows.Various concentrations of immunized mouse serum, murine hybridomasupernatant or purified anti-human IL-12 antibodies were preincubatedfor one hour at 37 degrees C. with 400 pg/ml recombinant purified humanIL-12 p70 in 100 μL RPMI complete medium in a microtiter plate(U-bottom, 96-well, Costar). PHA blasts isolated as described above,were washed once and resuspended in RPMI complete medium to a celldensity of 1×10⁷ cells/ml. PHA blasts (100 μL of 1×10⁶ cells/ml) wereadded to the antibody plus recombinant purified human IL-12 p70 mixture(final IL-12 p70 concentration was 200 pg/ml) and incubated for 18 hoursat 37 deg C. After incubation, 150 μL of cell-free supernatant waswithdrawn from each well and the level of human IFN-γ produced wasmeasured using a human IFN-γ ELISA (R&D Systems Cat#DIF50).

Example 1.1.C3 PHA Blast IFN-γ Induction Assay: Inhibition of CynomolgusMonkey (Cyno) IL-12 Activity

The ability of anti-human IL-12 antibodies to inhibit the cynomolgusmonkey IL-12 induced production of IFN-γ by PHA blasts was analyzed asfollows. Various concentrations of immunized mouse serum, murinehybridoma supernatant or purified anti-human IL-12 antibodies werepreincubated for one hour at 37 degrees C. with 150 pg/mL recombinantpurified cyno IL-12 p70 in 100 μL RPMI complete medium in a microtiterplate (U-bottom, 96-well, Costar). PHA blasts isolated as describedabove, were washed once and resuspended in RPMI complete medium to acell density of 1×10⁷ cells/ml. PHA blasts (100 μL of 1×10⁷ cells/mL)were added to the antibody plus recombinant purified cyno IL-12 p70mixture (final cyno IL-12 p70 concentration was 75 μg/ml) and incubatedfor 18 hours at 37 deg C. After incubation, 150 μL of cell-freesupernatant was withdrawn from each well and the level of human IFN-γproduced was measured using a human IFN-γ ELISA (R&D Systems Cat#DIF50).

Example 1.2 Generation of Anti Human IL-12 Monoclonal Antibodies

Anti human IL-12 mouse monoclonal antibodies were obtained as follows:

Example 1.2.A Immunization of Mice with Human IL-12 Antigen

Twenty micrograms of recombinant purified human IL-12 p70 mixed withcomplete Freund's adjuvant (Rockland Immunochemicals, Gilbertsville,Pa.) was injected subcutaneously into five 6-8 week-old Balb/C and 5 AJmice on Day 1. On days 24, 38, and 49, twenty micrograms of recombinantpurified human IL-12 p70 mixed with Immunoeasy adjuvant (Qiagen,Valencia, Calif.) was injected subcutaneously into the same 5 Balb/C and5 AJ mice. On day 84 or day 112 or day 144, mice were injectedintravenously with 10 ug recombinant purified human IL-12 p70 or 2 ugrecombinant purified human IL-12 p40 (R & D Systems, Minneapolis,Minn.).

Example 1.2.B Generation of Hybridoma

Splenocytes obtained from the immunized mice described in Example 1.2.Awere fused with SP2/O-Ag-14 cells at a ratio of 5:1 according to theestablished method described in Kohler, G. and Milstein 1975, Nature,256:495 to generate hybridomas. Fusion products were plated in selectionmedia containing azaserine and hypoxanthine in 96-well plates at adensity of 2.5×10⁶ spleen cells per well. Seven to ten days post fusion,macroscopic hybridoma colonies were observed. Supernatant from each wellcontaining hybridoma colonies was tested by ELISA for the presence ofantibody to IL-12 p70 (as described in Example 1.1.A.1). Supernatantstesting positive for binding to IL-12 p70 were then tested to determinewhether they were p40-specific by the IL-12 p70 or IL-12 p40 competitionELISA (as described in Example 1.1.A.2). Supernatants displaying IL-12p40-specific activity were then tested for the ability to neutralizeIL-12 in the PHA blast assay for IFN-γ (as described in Example 1.1.C).

TABLE 8 Fusion and screening data following immunizations of mice withhuman IL-12 Number Number of Mouse Number Number of Number of of clonesp40 Number strain used of wells wells with anti-IL-12 p40- neutralizingof clones in fusion plated growth clones specific clones subcloned A/J-2750 450 50 14 6 4 A/J-5 650 300 20 Balb/C-3 480 457 50 13 6 5 Balb/C-4768 649 25 17 13 4 Total 2648  1856  145  44 25 13

Example 1.2.C Identification and Characterization of Anti Human IL-12p40Monoclonal Antibodies

Hybridomas producing antibodies that bound IL-12, generated according toExamples 1.2.B and 1.2.C, and capable of binding IL-12 p40 specificallyand particularly those with IC₅₀ values in the PHA blast assay of 12 nMor less than 12 nM were scaled up and cloned by limiting dilution.

Hybridoma cells were expanded into media containing 10% low IgG fetalbovine serum (Hyclone #SH30151, Logan, Utah.). On average, 250 mL ofeach hybridoma supernatant (derived from a clonal population) washarvested, concentrated and purified by protein A affinitychromatography, as described in Harlow, E. and Lane, D. 1988“Antibodies: A Laboratory Manual”. The ability of purified mAbs toinhibit IL-12 activity was determined using the PHA blast assay asdescribed in Examples 1.1.C 2 and 1.1.C3. Table 9 shows IC₅₀ values fromthe PHA blast assays for ten monoclonal antibodies.

TABLE 9 Neutralization of IL-12 by anti IL-12p40 Murine MonoclonalAntibodies Murine Monoclonal Average IC₅₀ (uM) Average IC₅₀ (uM)Antibody Human IL-12 Cyno IL-12 1D4 0.031 0.078 1A6 0.052 0.044 1D8 0.311.4 3G7 0.15 0.35 5E8 12 N/D 8E1 0.19 0.18 1H6 0.69 1.6 3A11 3.4 N/D 4B40.039 0.028 7G3 0.047 >20

The binding affinities of the monoclonal antibodies to recombinantpurified human IL-12 p70 were determined using surface plasmon resonance(Biacore®) measurement as described in Example 1.B. Table 10 shows theaffinity of the ten monoclonal antibodies described above for humanIL-12 p70.

TABLE 10 Affinity of anti IL-12p40 Murine Monoclonal Antibodies forIL-12 p70 Name k_(on) (1/M · s) k_(off) (1/s) K_(D) (nM) 1D4 2.5 × 10⁵2.9 × 10⁻⁵ 0.12 1A6 1.5 × 10⁵ 3.5 × 10⁻⁵ 0.23 1D8 5.1 × 10⁵ 2.3 × 10⁻⁵0.044 3G7 8.2 × 10⁵ 3.8 × 10⁻⁵ 0.047 5E8 5.7 × 10⁵ 2.3 × 10⁻³ 4 8E1 6.9× 10⁵ 5.1 × 10⁻⁵ 0.074 1H6 4.3 × 10⁵ 9.9 × 10⁻⁵ 0.25 3A11 1.5 × 10⁵ 1.9× 10⁻⁴ 1.2 4B4 1.3 × 10⁵ 1.4 × 10⁻⁵ 0.1 7G3 1.1 × 10⁶ 2.8 × 10⁻⁴ 0.27

Example 1.2.C.1 Species Specificity of Murine Monoclonal Anti-HumanIL-12p40 Antibodies

To determine whether the ten monoclonal antibodies described aboverecognize murine IL-12, two ELISAs were set up. First, a direct ELISAwas set up by directly coating ELISA plates with 5 ug/ml of recombinantpurified mouse IL-12 (Peprotech). Murine-anti-human IL-12 p40 mAbs wereprepared at various concentrations ranging from 3 to 200 ng/ml in PBScontaining 0.1% BSA (Sigma, St. Louis, Mo.). 50 μl of each antibodydilution was added to the coated ELISA plate and incubated for 1 hour atroom temperature. Wells were washed 3 times with PBS containing 0.05%Tween-20. Anti-mouse IgG-HRP antibody (R&D #HAF007, Minneapolis, Minn.)was diluted 1:2000 in PBS containing 0.1% BSA; 50 ul/well was added andthe plates incubated for 1 hour at room temperature. Fifty microlitersof TMB solution (Sigma #T0440, St. Louis, Mo.) was added to each welland incubated for 10 minutes at room temperature. The reaction wasstopped by addition of 2N sulphuric acid. Plates were readspectrophotmetrically at a wavelength of 450 nm.

Second, an indirect ELISA was set up by coating ELISA plates with 5ug/ml of goat anti-mouse IgG, Fc fragment specific antibody (Pierce#31170, Rockland, Ill.). Murine anti-human IL-12 p40 mAbs were preparedat various concentrations ranging from 0.1 to 100 ng/ml in PBScontaining 0.1% BSA; 50 ul of each antibody dilution was added to thecoated ELISA plate and incubated for 1 hour at room temperature. Wellswere washed 3 times with PBS containing 0.05% Tween-20. Recombinantpurified mouse IL-12 (Preprotech) was diluted at 0.2 ug/ml in PBScontaining 0.1% BSA; 50 ul/well was added and the plates incubated for 1hour at room temperature. Wells were washed 3 times with PBS containing0.05% Tween-20. Biotinylated anti-mouse IL-12 antibody (R&D #BAF419) wasdiluted at 0.2 ug/ml in PBS containing 0.1% BSA; 50 ul/well was addedand the plates incubated for 1 hour at room temperature. Wells werewashed 3 times with PBS containing 0.05% Tween-20. Streptavidin HRP(Pierce #21126, Rockland, Ill.) was diluted 1:20000 in PBS containing0.1% BSA; 50 μL/well was added and the plates incubated for 1 hour atroom temperature. Plates were washed 3 times with PBScontaining 0.05%Tween-20. Fifty microliters of TMB solution was added to each well andincubated for 10 minutes at room temperature. The reaction was stoppedby addition of 2N sulphuric acid. Plates were read spectrophotmetricallyat a wavelength of 450 nm. Results from the direct and indirect ELISAsperformed with the ten monoclonal antibodies are shown in Table 11.

TABLE 11 Binding of anti IL-12 Murine Monoclonal Antibodies to mouseIL-12 p40 Direct ELISA Indirect ELISA Name Binding of mAb to mu IL-12Binding of mAb to mu IL-12 1D4 No N/D 1A6 No N/D 1D8 No No 3G7 No No 5E8No No 8E1 No No 1H6 No No 3A11 No No 4B4 No N/D 7G3 No N/D

Example 1.2.D Determination of the Amino Acid Sequence of the VariableRegion for Each Murine Anti-Human IL-12 p40 mAb

For each amino acid sequence determination, approximately 10×10⁶hybridoma cells were isolated by centrifugation and processed to isolatetotal RNA with Trizol (Gibco BRL/Invitrogen, Carlsbad, Calif.) followingmanufacturer's instructions. Total RNA was subjected to first strand DNAsynthesis using the SuperScript First-Strand Synthesis System(Invitrogen, Carlsbad, Calif.) per the manufacturers instructions.Oligo(dT) was used to prime first-strand synthesis to select forpoly(A)⁺ RNA. The first-strand cDNA product was then amplified by PCRwith primers designed for amplification of murine immunoglobulinvariable regions (Ig-Primer Sets, Novagen, Madison, Wis.). PCR productswere resolved on an agarose gel, excised, purified, and then subclonedwith the TOPO Cloning kit into pCR2.1-TOPO vector (Invitrogen, Carlsbad,Calif.) and transformed into TOP10 chemically competent E. coli(Invitrogen, Carlsbad, Calif.). Colony PCR was performed on thetransformants to identify clones containing insert. Plasmid DNA wasisolated from clones containing insert using a QIAprep Miniprep kit(Qiagen, Valencia, Calif.). Inserts in the plasmids were sequenced onboth strands to determine the variable heavy or variable light chain DNAsequences using M13 forward and M13 reverse primers (Fermentas LifeSciences, Hanover Md.). Variable heavy and variable light chainsequences of the ten monoclonal antibodies described in Example 1.2.Care described in Table 1.

Example 2 Recombinant Anti Human IL-12p40 Antibodies Example 2.1Construction and Expression of Recombinant Chimeric Anti Human IL-12p40Antibodies

The DNA encoding the heavy chain constant region of murine anti-humanIL-12p40 monoclonal antibodies 3G7, 8E1, 1A6, and 1D4 was replaced by acDNA fragment encoding the human IgG1 constant region containing 2hinge-region amino acid mutations by homologous recombination inbacteria. These mutations are a leucine to alanine change at position234 (EU numbering) and a leucine to alanine change at position 235 (Lundet al., 1991, J. Immunol., 147:2657). The light chain constant region ofeach of these antibodies was replaced by a human kappa constant region.Full-length chimeric antibodies were transiently expressed in COS cellsby co-transfection of chimeric heavy and light chain cDNAs ligated intothe pBOS expression plasmid (Mizushima and Nagata, Nucleic AcidsResearch 1990, Vol 18, pg 5322) comprising a heavy chain signal sequenceMEFGLSWLFLVAILKGVQC (SEQ ID NO. 110), and a light chain signal sequenceMDMRVPAQLLGLLLLWFPGSRC ((SEQ ID NO. 111).

Cell supernatants containing recombinant chimeric antibody were purifiedby Protein A Sepharose chromatography and bound antibody was eluted byaddition of acid buffer. Antibodies were neutralized and dialyzed intoPBS.

The heavy chain cDNA encoding chimeric 3G7 (described above) wasco-transfected with the 1D4 chimeric light chain cDNA (both ligated inthe pBOS vector) into COS cells. Cell supernatant containing recombinantchimeric antibody was purified by Protein A Sepharose chromatography andbound antibody was eluted by addition of acid buffer. Antibodies wereneutralized and dialyzed into PBS.

The purified chimeric anti-human IL-12 monoclonal antibodies were thentested for their ability to inhibit the IL-12 induced production ofIFN-γ by PHA blasts as described in Examples 1.1.C 2 and 1.1.C3. Table12 shows IC₅₀ values from the PHA blast assays for five chimericantibodies.

TABLE 12 Neutralization of IL-12 by anti IL-12 Chimeric Antibodies NameOf Average IC₅₀ (nM) Average IC₅₀ (nM) Chimeric Human IL-12 Cyno IL-121D4-Chim 0.021 0.07 1A6-Chim 0.021 0.02 3G7-Chim 0.12 0.32 8E1-Chim 0.170.15 3G7/1D4-Chim 0.11 0.29

Example 2.2 Construction and Expression of CDR Grafted Anti HumanIL-12p40 Antibodies

CDR-grafted anti-human IL-12 antibodies were generated as follows.

Example 2.2.1 Selection of Human Antibody Frameworks

Each murine variable heavy and variable light chain gene sequence (asdescribed in Table 3) was separately aligned against 44 humanimmunoglobulin germline variable heavy chain or 46 germline variablelight chain sequences (derived from NCBI Ig Blast website athttp://www.ncbi.nlm.nih.gov/igblast/retrieveig.html.) using Vector NTIsoftware. Human variable domain sequences having the highest overallhomology to the original murine sequences (as well as the highesthomology at positions known to be important for antigen binding)(Welschof, M. and Krauss, J. Methods In Molecular Biology, Vol 207) wereselected for each heavy chain and light chain sequence to provide theframework (FW) 1, 2 and 3 sequences for CDR-grafting purposes.Identification of a suitable human variable heavy and light chain FW4region (also known as the “joining” region) was accomplished byseparately aligning each murine heavy chain and light chain FW4 regionwith 6 human immunoglobulin germline joining heavy chain and 5 germlinejoining light chain sequences in the NCBI database. In silicoconstruction of complete CDR grafted antibodies was accomplished bysubstitution of human variable domain CDR sequences (derived from theNCBI website) with murine CDR sequences (derived from the hybridomas)with addition of a FW4 region (derived from the NCBI website) to each 3′end.

Example 2.2.2 Construction of CDR-Grafted Antibodies

In silico constructed CDR grafted antibodies described above wereconstructed de novo using oligonucleotides. For each variable regioncDNA, 6 oligonucleotides of 60-80 nucleotides each were designed tooverlap each other by 20 nucleotides at the 5′ and/or 3′ end of eacholigonucleotide. In an annealing reaction, all 6 oligos were combined,boiled, and annealed in the presence of dNTPs. Then DNA polymerase I,Large (Klenow) fragment (New England Biolabs #M0210, Beverley, Mass.)was added to fill-in the approximately 40 bp gaps between theoverlapping oligonucleotides. PCR was then performed to amplify theentire variable region gene using two outermost primers containingoverhanging sequences complementary to the multiple cloning site in amodified pBOS vector (Mizushima, S, and Nagata, S., (1990) Nucleic acidsResearch Vol 18, No. 17)).

The PCR products derived from each cDNA assembly were separated on anagarose gel and the band corresponding to the predicted variable regioncDNA size was excised and purified. The variable heavy region wasinserted in-frame onto a cDNA fragment encoding the human IgG1 constantregion containing 2 hinge-region amino acid mutations (SEQ ID NO. 3) byhomologous recombination in bacteria. These mutations are a leucine toalanine change at position 234 (EU numbering) and a leucine to alaninechange at position 235 (Lund et al., 1991, J. Immunol., 147:2657). Thevariable light chain region was inserted in-frame with the human kappaconstant region (SEQ ID NO. 4) by homologous recombination. Bacterialcolonies were isolated and plasmid DNA extracted; cDNA inserts weresequenced in their entirety. Correct CDR-grafted heavy and light chainscorresponding to each antibody were co-transfected into COS cells totransiently produce full-length CDR-grafted anti-human IL-12 antibodies.For 1A6, pBOS vectors containing the 1A6 heavy chain grafted cDNA andthe 1D4 light chain grafted cDNA were co-transfected into COS cells (the1A6 light chain sequence, when grafted, was identical to the 1D4 lightchain sequence). Cell supernatants containing recombinant chimericantibody were purified by Protein A Sepharose chromatography and boundantibody was eluted by addition of acid buffer. Antibodies wereneutralized and dialyzed into PBS. Nine CDR grafted antibodies aredescribed in Table 5.

The ability of purified CDR grafted antibodies to inhibit IL-12 activitywas determined using the PHA blast assay as described in Examples 1.1.C2 and 1.1.C3. The binding affinities of the purified CDR graftedantibodies to recombinant purified human IL-12p70 were determined usingsurface plasmon resonance (Biacore®) measurement as described in Example1.1.B. Table 13 shows IC₅₀ values from the PHA blast assays and theaffinity of the nine CDR grafted antibodies described in Table 7 forhuman IL-12p70 and cynomolgous IL-12p70.

TABLE 13 Neutralization of IL-12 by anti IL-12p40 CDR grafted Antibodiesand Affinity of anti IL-12p40 CDR grafted Antibodies for human andcynomolgous IL-12p70 and Anti IL-12p40 CDR grafted Antibody 1D4.1 1D4.21D4.3 1A6.1 1A6.2 On-rate 2.6 × 10⁵  1.6 × 10⁵ 2.1 × 10⁵  1.1 × 10⁵   1× 10⁵ (1/M · s) Off-rate 2.9 × 10⁻⁵ 2.610⁻⁴ 5.3 × 10⁻⁵ 2.9 × 10⁻⁵ 5.4 ×10⁻⁵ (1/s) K_(D) (nM) 0.12 1.7 0.25 0.27 0.54 Av. IC₅₀ (nM) 0.47 3 0.830.48 1.1 Hu IL-12 Av. IC₅₀ (nM) 1.5 3 1.6 0.57 0.84 Cyno IL-12 AntiIL-12p40 CDR grafted Antibody 8E1.1 8E1.2 3G7.1 3G7.2 1A6.5 1A6.6On-rate 5.2 × 10⁵  0 4.2 × 10⁵  6.1 × 10⁵  1.3 × 10⁵  1.3 × 10⁵  (1/M ·s) Off-rate 8.7 × 10⁻⁴ 0 9.1 × 10⁻⁵ 1.4 × 10⁻⁴ 5.6 × 10⁻⁵ 1.0 × 10⁻⁴(1/s) K_(D) (nM) 1.7 0 0.22 0.23 0.43 0.078 Av. IC₅₀ (nM) 2.8 0 0.560.24 1.9 0.59 Hu IL-12 Av. IC₅₀ (nM) 4.6 0 1.2 0.7 1.1 0.14 Cyno IL-12

Example 2.3 Construction of Humanized Anti Human IL-12 Antibodies

Humanization of the anti human IL-12 antibodies was carried out asfollows.

Example 2.3.1 Homology Modeling with CDR-Grafted Antibodies

Homology modeling was used was to identify residues unique to the murineantibody sequences that are predicted to be critical to the structure ofthe antibody combining site (the CDRs).

Homology modeling is a computational method whereby approximate threedimensional coordinates are generated for a protein. The source ofinitial coordinates and guidance for their further refinement is asecond protein, the reference protein, for which the three dimensionalcoordinates are known and the sequence of which is related to thesequence of the first protein. The relationship among the sequences ofthe two proteins is used to generate a correspondence between thereference protein and the protein for which coordinates are desired, thetarget protein. The primary sequences of the reference and targetproteins are aligned with coordinates of identical portions of the twoproteins transferred directly from the reference protein to the targetprotein. Coordinates for mismatched portions of the two proteins, e.g.from residue mutations, insertions, or deletions, are constructed fromgeneric structural templates and energy refined to insure consistencywith the already transferred model coordinates. This computationalprotein structure may be further refined or employed directly inmodeling studies. It should be clear from this description that thequality of the model structure is determined by the accuracy of thecontention that the reference and target proteins are related and theprecision with which the sequence alignment is constructed.

For the murine sequences 1A6, 8E1 and 1D4, a combination of BLASTsearching and visual inspection was used to identify suitable referencestructures. The reference structures chosen for 1A6 and 1D4 was the PDBentry 1JRH. For 8E1, the heavy chain reference structure was PDB entry1FL3 and the light chain reference was 1MEX. Sequence identity of 25%between the reference and target amino acid sequences is considered theminimum necessary to attempt a homology modeling exercise. Sequencealignments were constructed manually and model coordinates weregenerated with the program Jackal (see Petrey, D., Xiang, Z., Tang, C.L., Xie, L., Gimpelev, M., Mitros, T., Soto, C. S., Goldsmith-Fischman,S., Kernytsky, A., Schlessinger, A., et al. 2003. Using multiplestructure alignments, fast model building, and energetic analysis infold recognition and homology modeling. Proteins 53 (Suppl. 6):430-435).

The primary sequences of the murine and human framework regions of theselected antibodies share significant identity. Residue positions thatdiffer are candidates for inclusion of the murine residue in thehumanized sequence in order to retain the observed binding potency ofthe murine antibody. A list of framework residues that differ betweenthe human and murine sequences was constructed manually.

The likelihood that a given framework residue would impact the bindingproperties of the antibody depends on its proximity to the CDR residues.Therefore, using the model structures, the residues that differ betweenthe murine and human sequences were ranked according to their distancefrom any atom in the CDRs. Those residues that fell within 4.5 Å of anyCDR atom were identified as most important and were recommended to becandidates for retention of the murine residue in the humanized antibody(i.e. back mutation).

Examination of the computer model suggested that in antibody 1A6.1,residues L1, L2, L36, and L67 of the light chain (1D4.1 VKB3) are insignificant contact with the CDRs and therefore suggests that murineresidues should be retained at these positions. In the case of 1D4.1,residues H1 and H98 of the heavy chain (1D4.1 VH2-70), as well as L2 andL67 of the light chain (1D4.1 VKB3) were identified as positions forback mutation.

Example 2.3.2 Generation of Hybrid Antibodies

To determine which CDR-grafted chain (VH, VL or both) may benefit fromframework back-mutations, “hybrid” antibodies were constructed bypairing a CDR-grafted H or L chain with an appropriate chimeric murine Hor L chain followed by co-transfection into COS cells. Table 14 showsthe VH and VL amino acid sequences of the hybrid antibodies 1A6.3,1A6.4, 1A6.7, 1A6.8, 1D4.4, and 1D4.5.

TABLE 14 Amino acid sequences of hybrid antibodies SEQ ID No. Proteinregion 123456789012345678901234567890 69 VH 1A6.3EVTLKESGPVLVKPTETLTLTCTVSGFSLS (10) (VH2-26/JH6TSGMGVSWIRQPPGKALEWLAHIW- FR1) WDGDNY  (7) (VH2-70/JH6YNPSLKSRLTISKDTSKSQVVLTMTNMDPV FR2) DTATYYCARRTRVNYAMDYWGQGT- (11)(VH2-26/JH6 TVTVSS FR3)  (9) (VH2-70/JH6 FR4) 38 VL 1A6.3SVVMTQTPKFLLVSAGDRVTITCKASQSVS NDVAWFQQKPGQSPKLLIYYASNRYTGVPDRFTGSGYGTDFTFTISTVQAEDLAVYFCQQ DYNSPWTFGGGTKLEIKR 37 VH 1A6.4QVTLKESGPGILKPSQTLSLTCSFSGFSLS TSGMGVSWIRQPSGKGLEWLAHIW- WDGDNYYNPSLKSQLTISKDTSRNQVFLRIATVDTA DTATYYCARRTRVNYAMDYWGQGTS- VTVSS 70 VL1A6.4 EIVMTQSPATLSVSPGERATLSCKASQSVS (27) (L2/JK4 FR1)NDVAWYQQKPGQAPRLLIYYASNRYTGIPA (28) (L2/JK4 FR2)RFSGSGSGTEFTLTISSLQSEDFAVYYCQQ (29) (L2/JK4 FR3) DYNSPWTFGGGTKVEIKR (26)(B3/JK4 FR4) 37 VH 1A6.7 QVTLKESGPGILKPSQTLSLTCSFSGFSLSTSGMGVSWIRQPSGKGLEWLAHIW- WDGDNY YNPSLKSQLTISKDTSRNQVFLRTATVDTADTATYYCARRTRVNYAMDYWGQGTS- VTVSS 68 VL 1A6.7DIVMTQSPDSLAVSLGERATINCKASQSVS (23) (B3/JK4 FR1)NDVAWYQQKPGQPPKLLIYYASNRYT- GVPD (24) (B3/JK4 FR2)RFSGSGSGTDFTLTISSLQAEDVAVYYCQQ (25) (B3/JK4 FR3) DYNSPWTFGGGTKVEIKR (26)(B3/JK4 FR4) 67 VH 1A6.8 EVTLRESGPALVKPTQTLTLTCTFSGFSLS  (6) (VH2-70/JH6TSGMGVSWIRQPPGKALEWLAHIW- FR1) WDGDNY  (7) (VH2-70/JH6YNPSLKSRLTISKDTSKNQVVLTMTNMDPV FR2) DTATYYCARRTRVNYAMDYWGQGT-  (8)(VH2-70/JH6 TVTVSS FR3)  (9) (VH2-70/JH6 FR4) 38 VL 1A6.8SVVMTQTPKFLLVSAGDRVTITCKASQSVS NDVAWFQQKPGQSPKLLIYYASNRYTGVPDRFTGSGYGTDFTFTISTVQAEDLAVYFCQQ DYNSPWTFGGGTKLEIKR 65 VH 1D4.4EVTLRESGPALVKPTQTLTLTCTFSGFSLS  (6) (VH2-70/JH6KSVMGVSWIRQPPGKALEWLAHIYWD- FR1) DDKY  (7) (VH2-70/JH6YNPSLKSRLTISKDTSKNQVVLTMTNMDPV FR2) DTATYYCARRGIRSAMDYWGQGTTVTVSS  (8)(VH2-70/JH6 FR3)  (9) (VH2-70/JH6 FR4) 36 VL 1D4.4SVVMTQTPKFLLVSAGDRVTITCKASQSVS NDVAWYQQKPGQSPKLLIYYASNRYT- GVPDRFTGSGYGTDFTFIISTVRAEDLAVYFCQQ DYNSPWTFGGGTKLEIKR 35 VH 1D4.5QVTLKESGPGILQPSQTLSLTCSFSGFSLR KSVMGVSWIRQPSGKGLEWLAHIYWD- DDKYYNPSLKSRLTISKDPSRNQVFLKITSVDTA DAATYYCTRRGIRSAMDYWGQGTSVTVSS 62 VL 1D4.5DIVMTQSPDSLAVSLGERATINCKASQSVS (23) (B3/JK4 FR1)NDVAWYQQKPGQPPKLLIYYASNRYT- (24) (B3/JK4 FR2) GVPD (25) (B3/JK4 FR3)RFSGSGSGTDFTLTISSLQAEDVAVYYCQQ (26) (B3/JK4 FR4) DYNSPWTFGGGTKVEIKR

Hybrid antibodies were purified by protein A affinity chromatography(Example 1.2.C) and tested for potency in the PHA blast assay as inExamples 1.1.C2 and 1.1.C3. Kinetic measurements were determined usingBIAcore as in Example 1.1.B. Table 15 shows the K_(D) and IC₅₀ values ofthe hybrid antibodies. The potency and affinity data derived with thehybrid mAbs was compared to data generated with the appropriateCDR-grafted mAbs (Example 2.3.1) to identify changes in potency andaffinity attributed to a particular VH or VL chain. Whether or not, ahumanized VH or VL chain was the optimum chain, was assessed using themethods described in Example 2.3.1. In some cases residues that did notfall within 4.5 A⁰ of any CDR atom were additionally targeted for backmutations.

TABLE 15 Neutralization of IL-12 by anti-IL-12p40 hybrid antibodies andaffinity of anti-IL-12p40 hybrid antibodies Antibody 1D4.4 1D4.5 1A6.31A6.4 1A6.7 1A6.8 On-rate 2.8 × 10⁵   3 × 10⁵ 1.9 × 10⁵  1.1 × 10⁵  NDND (1/M · s) Off-rate 2.1 × 10⁻⁵ 3.1 × 10⁻⁵ 2.6 × 10⁻⁵ 1.1 × 10⁻⁴ ND ND(1/s) KD (nM) 0.074 0.11 0.14 1.0 ND ND Av. IC₅₀(nM) 0.64 0.053 0.0682.1 0.29 0.08 huIL-12 Av. IC₅₀(nM) 1.1 0.11 0.049 1.2 0.35 0.06 cynoIL-12

Example 2.3.3 Construction of Framework Back Mutations in CDR-GraftedAntibodies

To generate humanized antibodies framework back mutations wereintroduced into the CDR-grafted antibodies using mutagenic primers andthe QuikChange Multi Site-Directed Mutagenesis kit (Stratagene #200513,La Jolla, Calif.) following manufacturers instructions. Differentcombinations of back mutations were constructed for each of theCDR-grafts to identify the relative importance of each residue. 1A6.1light chain VKB3 variant 1 (L1-D→S, L2-I→V, L36-Y→F, L67-S→Y), 1D4.1VKB3 variant 2 (L1-D→S, L36-Y→F, L67-S→Y), 1D4.1 VKB3 variant 3 (L1-D→S,L67-S→Y), 1D4.1 VKB3 variant 4 (L2-I→V, L67-S→Y), and 1D4.1 VKB3 variant5 (L67-S→Y). 1D4.1 heavy chain VH2-70 variant 1 (H1-E→Q, H93-A→T), and1D4.1 VH2-70 variant 2 (H93-A→T). Mutated single stranded DNA was thentransformed into XL10-Gold ultracompetent cells. Colony sequencing wasperformed on the transformants to identify clones bearing the desiredmutations. Plasmid DNA was isolated from positive clones using a QiagenMaxiprep kit (Qiagen, Valencia, Calif.) and the variable and constantregions were sequenced in their entirety.

As described above several additional combinations of back mutationswere constructed for each of the CDR grafted antibodies.Characterization of the humanized antibodies generated, as disclosedabove, was carried out as disclosed below in Example 2.3.4.

Example 2.3.4 Expression and Characterization of Humanized Antibodies

PBOS expression vectors (see Example 2.1 and 2.2.2) harboring heavy andlight chains containing framework back mutations were co-transfectedinto COS cells to transiently produce full-length humanized antibodies.The amino acid sequences of the VH and VL regions of the humanizedantibodies are disclosed in Table 16.

TABLE 16 Sequences of Humanized Antibodies SEQ ID Sequence No. Proteinregion 123456789012345678901234567890 67 VH 1A6.9EVTLRESGPALVKPTQTLTLTCTFSGFSLS  (6) (VH2-70/JH6TSGMGVSWIRQPPGKALEWLAHIW- FR1) WDGDNY  (7) (VH2-70/JH6YNPSLKSRLTISKDTSKNQVVLTMTNMDPV FR2) DTATYYCARRTRVNYAMDYWGQGTTVTVSS  (8)(VH2-70/JH6 FR3)  (9) (VH2-70/JH6 FR4) 79 VL 1A6.9SVVMTQSPDSLAVSLGERATINCKASQSVS NDVAWFQQKPGQPPKLLIYYASNRYTGVPDRFSGSGYGTDFTLTISSLQAEDVAVYYCQQ DYNSPWTFGGGTKVEIKR 80 VH 1D4.6EVTLRESGPALVKPTQTLTLTCTFSGFSLS KSVMGVSWIRQPPGKALEWLAHIYWD- DDKYYNPSLKSRLTISKDTSKNQVVLTMTNMDPV DTATYYCTRRGIRSAMDYWGQGTTVTVSS 81 VL 1D4.6DVVMTQSPDSLAVSLGERATINCKASQSVS NDVAWYQQKPGQPPKLLIYYASNRYTGVPDRFSGSGYGTDFTLTISSLQAEDVAVYYCQQ DYNSPWTFGGGTKVEIKR 82 VH 1D4.7EVTLRESGPALVKPTQTLTLTCTFSGFSLR KSVMGVSWIRQPPGKALEWLAHIYWD- DDKYYNPSLKSRLTISKDTSKNQVVLTMTNMDPV DTATYYCTRRGIRSAMDYWGQGTTVTVSS 83 VL 1D4.7DVVMTQSPDSLAVSLGERATINCKASQSVS NDVAWYQQKPGQPPKLLIYYASNRYTGVPDRFSGSGYGTDFTLTISSLQAEDVAVYYCQQ DYNSPWTFGGGTKVEIKR 84 VH 1D4.8EVTLRESGPALVKPTQTLTLTCTFSGFSLR KSVMGVSWIRQPPGKALEWLAHIYWD- DDKYYNPSLKSRLTISKDTSKNQVVLTMTNMDPV DTATYYCTRRGIRSAMDYWGQGTTVTVSS 85 VL 1D4.8DIVMTQSPDSLAVSLGERATINCKASQSVS NDVAWYQQKPGQPPKLLIYYASNRYTGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQ DYNSPWTFGGGTKVEIKR 86 VH 1D4.9EVTLRESGPALVKPTQTLTLTCTFSGFSLR KSVMGVSWIRQPPGKALEWLAHIYWD- DDKYYNPSLKSRLTISKDTSKNQVVLTMTNMDPV DTATYYCTRRGIRSAMDYWGQQTTVTVSS 87 VL 1D4.9DIVMTQSPDSLAVSLGERATINCKASQSVS NDVAWYQQKPGQPPKLLIYYASNRYTGVPDRFSGSGYGTDFTLTISSLQAEDVAVYYCQQ DYNSPWTFGGGTKVEIKR 88 VH 8E1.3EVKLVESGGGLVQPGGSLRLSCAASGFTFS DYGMVWVRQAPGKGLEWVASISSGSSNIYYADTVKGRFTISRDDSKNTLYLQMNSLKTED TAVYYCARNPYWGQGTTVTVSS 89 VL 8E1.3DIVMTQSPSSLSASVGDRVTITCKASQNVG TNVAWYQQKPEKAPKSLIYSASHRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQ YNSYPLTFGGGTKVEIKR 90 VH 3G7.3EVQLVQSGAEVKKPGASVKVSCKATGYTFN DYWIEWVRQAPGQGLEWMGGFSHGSG- STNYNEKPKGRVTMTADSSTNTAYMELRSLRSDD TAVYYCARRRFRGMDYWGQGTTVTVSS 91 VL 3G7.3EIVMTQSPATLSVSPGERATLSCKASQSVS NDVAWYQQKPGQAPRLLIYYASNRYTGVPDRFSGSGSGTEFTLTISSLQSEDFAVYYCQQ DYSSPWSFGGGTKVEIKR

The amino acid positions back mutated in the VH and VL of theCDR-grafted antibodies are listed in Table 17.

TABLE 17 Back mutated amino acids present in humanized antibodiesAntibody Name Mutations in VH Mutations in VK 1A6.9 None L1 D −> S L2 I−> V L36 Y −> F L67 S −> Y 1D4.6 H93 A −>T L2 I −>V L67 S −>Y 1D4.7 H30S −> R L2 I −>V H93 A −>T L67 S −>Y 1D4.8 H30 S −> R None H93 A −>T1D4.9 H30 S −> R L67 S −>Y H93 A −>T 8E1.3 H3 Q −>K L3 Q −> V H49 G −> AH77 S −> T 3G7.3 H25 S −> T L58 I −> V H30 T −> N L60 A −> D H71 T −> AH73 T −> S H76 S −> N

Cell supernatants containing humanized antibodies were purified asdescribed in Example 1.2.C. The ability of the purified humanizedantibodies to neutralize IL-12 in vitro was determined using the PHAblast assay as described in Examples 1.1.C2 and 1.1.C3. The bindingaffinities of the purified antibodies to recombinant purified humanIL-12p70 were determined using BIAcore as described in Example 1.1.B.Table 18 shows the IC₅₀ values from the PHA blast assay and the K_(D)sfrom BIAcore.

TABLE 18 Neutralization of IL-12 by anti-IL-12p40 humanized antibodiesand affinity of anti-IL-12p40 humanized antibodies Antibody 1D4.6 1D4.71D4.8 1D4.9 1A6.9 8E1.3 3G7.3 On-rate 4.8 × 10⁵ >1 × 10⁵  1.2 × 10⁵ 5.3× 10⁵ 3.5 × 10⁵ 1.3 × 10⁶  7.8 × 10⁵  (1/M · s) Off-rate   <1 × 10⁻⁵ <1× 10⁻⁵   <1 × 10⁻⁵    1 × 10⁻⁶   <1 × 10⁻⁵ 1.0 × 10⁻³ 1.5 × 10⁻⁴ (1/s)KD (nM) <0.01 <0.01 <0.01 <0.01 <0.01 0.76 0.2 Av. IC₅₀ (nM) 0.15 0.0140.095 0.035 0.15 10 0.42 huIL-12 Av. IC₅₀ (nM) ND 0.031 ND ND ND ND NDcyno IL-12

Example 2.4 Generation of Additional Humanized Anti Human IL-12Antibodies

Humanization of the variable regions of the murine monoclonal antibodies8E1 and 1A6 were carried out essentially according to the procedure ofQueen, C., et al., Proc. Natl. Acad. Sci. USA 86: 10029-10033 (1989).First, human V segments with high homology to the murine monoclonalantibody VH or VL amino acid sequences were identified. Next, thecomplementarity-determining region (CDR) sequences together withframework amino acids important for maintaining the structures of theCDRs were grafted into the selected human framework sequences. Inaddition, human framework amino acids that were found to be rare in thecorresponding V region subgroup were substituted with consensus aminoacids to reduce potential immunogenicity. The resulting humanizedmonoclonal antibodies were expressed in cells, purified andcharacterized as described below.

Humanized monoclonal antibodies 8E1.4, 8E1.5, 8E1.6, 1A6.10, 1A6.11, and1A6.12 were generated as follows.

Example 2.4.1 Generation of Humanized Monoclonal Antibodies 8E1.4,8E1.5, 8E1.6

For humanization of the 8E1 variable regions, human V region frameworksused as acceptors for the CDRs of 8E1 were chosen based on sequencehomology. First, a molecular model of the 8E1 variable regions wasconstructed with the aid of the computer programs ABMOD and ENCAD(Levitt, M., J. Mol. Biol. 168: 595-620 (1983)). Next, based on ahomology search against human V and J segment sequences, the VH segmentHA3D1 (Olee, T., et al., J. Exp. Med. 175: 831-842 (1992)) and the Jsegment JH4 (Ravetch, J. V., et al., Cell 27: 583-591 (1981)) wereselected to provide the frameworks for the 8E1.4, 8E1.5, and 8E1.6 heavychain variable regions. For the 8E1.4, 8E1.5 and 8E1.6 light chainvariable regions, the VL segment HK137 (Bentley, D. L., and Rabbitts, T.H., Cell 32: 181-189 (1983)) and the J segment JK2 (Hieter, P. A., etal., J. Biol. Chem. 257: 1516-1522 (1982)) were used. The identity ofthe framework amino acids between 8E1 VH and the acceptor human HA3D1and JH4 segments was 84%, while the identity between 8E1 VL and theacceptor human HK137 and JK4 segments was 67%. Human antibody heavychain and light chain acceptor sequences used to generate additionalhumanized anti-human IL-12 antibodies are listed in Table 19 and 20.

TABLE 19 Heavy Chain Acceptor Sequences used for Additional HumanizedAntibodies SEQ ID Protein Sequence No. region123456789012345678901234567890 92 M60/JH4 QVTLRESGPALVKPTQTLTLTCTLYGFSLSFR1 7 M60/JH4 WIRQPPGKALEWLA FR2 8 M60/JH4RLTISKDTSKNQVVLTMTNMDPVDTATYYCAR FR3 93 M60/JH4 WGQGTLVTVSS FR4 94HA3D1/ EVQLVESGGGLVQPGGSLRLSCAASGFTFS JH4 FR1 16 HA3D1/ WVRQAPGKGLEWVSJH4 FR2 17 HA3D1/ RFTISRDNAKNSLYLQMNSLRAEDTAVYYCAR JH4 FR3 95 HA3D1/WGQGTLVTVSS JH4 FR4

TABLE 20 Light Chain Acceptor used for Additional Humanized AntibodiesSEQ ID Sequence No. Protein region 123456789012345678901234567890 30III-3R/JK4 FR1 DIQMTQSPSSLSASVGDRVTITC 34 III-3R/JK4 FR2 WYQQKPGKAPKLLIY96 III-3R/JK4 FR3 GVPSRISGSGSGTDFTFTISSLQPEDIATYYC 26 III-3R/JK4 FR4FGGGTKVEIKR 30 HK137/JK4 DIQMTQSPSSLSASVGDRVTITC FR1 97 HK137/JK4WFQQKPGKAPKSLIY FR2 32 HK137/JK4 GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC FR3 26HK137/JK4 FGGGTKVEIKR FR4

Example 2.4.2 Construction of 8E1.4, 8E1.5 and 8E1.6 Antibodies

The heavy and light chain variable region genes were constructed andamplified using approximately 30 overlapping synthetic oligonucleotidesranging in length from approximately 20 to 40 bases following apublished method (Rouillard, J.-M., et al., Nucleic Acids Res. 32:W176-W180 (2004)). The oligonucleotides were annealed and assembled withthe Expand High Fidelity PCR System (Roche Diagnostics Corporation,Indianapolis, Ind.), yielding a full-length product. The resultingproduct was amplified by the polymerase chain reaction (PCR) using theExpand High Fidelity PCR System. The PCR-amplified fragments weregel-purified, digested with MluI and XbaI, gel-purified, and subcloned,respectively, into a modified form of pVg1.D.Tt (Cole, M. S., et al., J.Immunol. 159: 3613-3621 (1997); and see below) and pVk (Co, M. S., etal., J. Immunol. 148: 1149-1154 (1992)).

At framework positions in which the computer model suggested significantcontact with the CDRs, the amino acids from the mouse V regions weresubstituted for the original human framework amino acids. This was doneat residue 49 for 8E1.4 and 8E1.5 heavy chains, and additionally atresidue 74 for the heavy chain of 8E1.6. For the light chains of 8E1.5and 8E1.6, replacements were made at residue 46, and additionally atresidue 60 for 8E1.5. Framework residues that occurred only rarely attheir respective positions in the corresponding human V region subgroupswere replaced with human consensus amino acids at those positions. Thiswas done at residue 78 for both 8E1.5 and 8E1.6 heavy chains, and atresidue 36 for the 8E1.5 and 8E1.6 light chains.

Site-directed mutagenesis of the synthetic V-genes was done using theQuikChange II Site-Directed Mutagenesis Kit (Stratagene, La Jolla,Calif.), following the manufacturer's recommendations. Specificmutations in the 8E1.6 VH gene were created using mutagenesis oligos andPCR methods well known in the art. The PCR step was done using PfuUltraHF DNA Polymerase (Stratagene), following the manufacturer'srecommendations, by incubating at 95° C. for 30 sec, followed by 18cycles of 95° C. for 30 sec, 55° C. for 1 min and 68° C. for 1 min,followed by incubating at 68° C. for 7 min. Following digestion withDpnI, E. coli strain TOP10 Chemically Competent Cells (InvitrogenCorporation, Carlsbad, Calif.) were transformed with a small portion ofthe PCR product. Sequence verified miniprep DNA was digested with MluIand XbaI, and the resulting restriction fragment containing the mutated8E1.6 VH gene was subcloned into the modified pVg1.D.Tt expressionvector described below.

Similarly, specific mutations in the 8E1.5 VL gene were created usingmutagenesis oligos and PCR methods well known in the art. The PCR stepwas done as described above, and following digestion with MluI and XbaI,the resulting restriction fragment was subcloned into the pVk expressionvector. Mutations were verified by nucleotide sequencing.

Genes encoding humanized VH or VL were designed as mini-exons includingsignal peptides, splice donor signals, and appropriate restrictionenzyme sites for subsequent cloning into a mammalian expression vector.The splice donor signals in the VH and VL mini-exons were derived fromthe corresponding human germline JH and JK sequences, respectively. Thesignal peptide sequences in the humanized VH mini exon wasMEFGLSWLFLVAILKGVQC (SEQ ID NO. 110), and in the humanized VL mini-exonswas MDMRVPAQLLGLLLLWFPGSRC(SEQ ID NO. 111). The 8E1.4, 8E1.5 and 8E1.6VH and VL genes were constructed by assembly of overlapping syntheticoligonucleotides and PCR methods well known in the art.

Example 2.4.3 Generation of Humanized Monoclonal Antibodies 1A6.10,1A6.11 and 1A6.12

For humanization of the 1A6.10, 1A6.11 and 1A6.12 variable regions, thegeneral approach provided in the present invention was followed. First,a molecular model of the 1A6 variable regions was constructed with theaid of the computer programs ABMOD and ENCAD (Levitt, M., J. Mol. Biol.168: 595-620 (1983)). Next, based on a homology search against human Vand J segment sequences, the VH segment M60 (Schroeder, Jr., H. W. andWang, J. Y., Proc. Natl. Acad. Sci. USA 87: 6146-6150 (1990)) and the Jsegment JH4 (Ravetch, J. V., et al., Cell 27: 583-591 (1981)) wereselected to provide the frameworks for the 1A6.10 and 1A6.12 heavy chainvariable regions. For the 1A6.10, 1A6.11 and 1A6.12 light chain variableregions, the VL segment III-3R (Manheimer-Lory, A., et al., J. Exp. Med.174: 1639-1652 (1991)) and the J segment JK4 (Hieter, P. A., et al., J.Biol. Chem. 257: 1516-1522 (1982)) were used. The identity of theframework amino acids between 1A6 VH and the acceptor human M60 and JH4segments was 74%, while the identity between 1A6 VL and the acceptorhuman III-3R and JK4 segments was 71%. The antibody sequences weregenerated as disclosed in Example 2.3.3.

At framework positions in which the computer model suggested significantcontact with the CDRs, the amino acids from the mouse V regions weresubstituted for the original human framework amino acids. This was doneat residue 68 for the 1A6.10, 1A6.11 and 1A6.12 heavy chains. For thelight chains, replacements were made at residues 36 and 67 for 1A6.11and 1A6.12, and additionally at residue 60 for 1A6.12. Frameworkresidues that occurred only rarely at their respective positions in thecorresponding human V region subgroups were replaced with humanconsensus amino acids at those positions. This was done at residues 10,46, 83, 84, 86 and 87 of the heavy chain, and at residue 62 of the lightchains of 1A6.10, 1A6.11 and 1A6.12. Site directed mutagenesis wasperformed using mutagenic oligos and PCR method as described above.

The amino acid sequences of the resulting VH and VL regions of theadditional humanized anti-IL-12 antibodies generated are listed in Table21.

TABLE 21 Sequences of Additional Humanized Antibodies SEQ ID SequenceNo. Protein region 123456789012345678901234567890 98 VH 1A6.10EVTLRESGPGLVKPTQTLTLTCTLYGFSLS TSGMGVSWIRQPPGKGLEWLAHIW- WDGDNYYNPSLKSQLTISKDTSKNQVVLKLTSVDPV DTATYYCARRTRVNYAMDYWGQGTLVTVSS 99 VL1A6.10 DIQMTQSPSSLSASVGDRVTITCKASQSVS NDVAWYQQKPGKAPKLLIYYASNRYTGVPDRFSGSGYGTDFTFTISSLQPEDIATYYCQQ DYNSPWTFGGGTKVEIKR 100 VH 1A6.11EVTLRESGPGLVKPTQTLTLTCTLYCFSLS TSGMGVSWIRQPPGKGLEWLAHIW- WDGDNYYNPSLKSQLTISKDTSKNQVVLKLTSVDPV DTATYYCARRTRVNYAMDYWGQGTLVTVSS 101 VL1A6.11 DIQMTQSPSSLSASVGDRVTITCKASQSVS NDVAWYQQKPGKAPKLLIYYASNRYTGVPSRFSGSGYGTDFTFTISSLQPEDIATYYCQQ DYNSPWTFGGGTKVEIKR 102 VH 1A6.12EVTLRESGPGLVKPTQTLTLTCTLYGFSLS TSGMGVSWIRQPPGKGLEWLAHIW- WDGDNYYNPSLKSQLTISKDTSKNQVVLKLTSVDPV DTATYYCARRTRVNYAMDYWGQGTLVTVSS 103 VL1A6.12 DIQMTQSPSSLSASVGDRVTITCKASQSVS NDVAWFQQKPGKAPKLLIYYASNRYTGVPDRFSGSGYGTDFTFTISSLQPEDIATYYCQQ DYNSPWTFGGGTKVEIKR 104 VH 8E1.4EVQLVESGGGLVQPGGSLRLSCAASGFTFS DYGMVWVRQAPGKGLEWVASISSGSSNIYYADTVKGRFTISRDNAKNTLYLQMNSLRAED TAVYYCARNPYWGQGTLVTVSS 105 VL 8E1.4DIQMTQSPSSLSASVGDRVTITCKASQNVG TNVAWYQQKPGKAPKGLIYSASHRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQ YNSYPLTFGGGTKVEIKR 106 VH 8E1.5EVQLVESGGGLVQPGGSLRLSCAASGFTFS DYGMVWVRQAPGKGLEWVASISSGSSNIYYADTVKGRFTISRDNAKNTLYLQMNSLRAED TAVYYCARNPYWGQGTLVTVSS 107 VL 8E1.5DIQMTQSPSSLSASVGDRVTITCKASQNVG TNVAWYQQKPGKAPKGLIYSASHRYSGVPDRFSGSGSGTDFTLTISSLQPEDFATYYCQQ YNSYPLTFGGGTKVEIKR 108 VH 8E1.6EVQLVESCGGLVQPGGSLRLSCAASGFTFS DYGMVWVRQAPGKGLEWVASISSGSSNIYYADTVKGRFTISRDDAKNTLYLQNNSLRAED TAVYYCARNPYWGQGTLVTVSS 109 VL 8E1.6DIQMTQSPSSLSASVGDRVTITCKASQNVG TNVAWYQQKPGKAPKGLIYSASHRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQ YNSYPLTFGGGTKVEIKR

The amino acid positions in the framework that were mutated are listedin Table 22.

TABLE 22 Positions of Framework Mutations in Additional HumanizedAntibodies Antibody Name Mutations in VH Mutations in VK 1A6.10 H10 A −>G L62 I −> F H46 A −> G L67 S −> Y H68 R −> Q H83 T −> K H84 M −> L H86N −> S H87 M −> V 1A6.11 H10 A −> G L36 Y −> F H46 A −> G L62 I −> F H68R −> Q L67 S −> Y H83 T −> K H84 M −> L H86 N −> S H87 M −> V 1A6.12 H10A −> G L36 Y −> F H46 A −> G L60 S −> D H68 R −> Q L62 I −> F H83 T −> KL67 S −> Y H84 M −> L H86 N −> S H87 M −> V 8E1.4 H49 S −> A L36 F −> YH78 S −> T L46 S −> G 8E1.5 H49 S −> A L36 F −> Y H78 S −> T L46 S −> GL60 S −> D 8E1.6 H49 S −> A L36 F −> Y H74 N −> D L46 S −> G H78 S −> T

Example 2.4.4 Expression of Additional Humanized Antibodies

The allotype of the human gamma-1 constant region gene in the expressionplasmid pVg1.D.Tt was modified from G1m (z,a) to the z, non-a allotype.The overlap-extension PCR method (Higuchi, R., in “PCR Technology:Principles and Applications for DNA Amplification”, Stockton Press, NewYork (1989), pp. 61-70) was used to generate the amino acidsubstitutions D356E and L358M (numbered according to the EU index ofKabat, E. A., et al., “Sequences of Proteins of Immunological Interest”,5th ed., National Institutes of Health, Bethesda, Md. (1991)), usingmutagenesis primers. The PCR step was done using the QuikChange IISite-Directed Mutagenesis Kit (Stratagene). Following digestion or PCRgenerated product with SfiI and EagI, the resulting restriction fragmentwas subcloned into a modified form of the pVg1.D.Tt expression vectorcontaining an NheI restriction site in the intron between the hinge andCH2 exons.

Mutations to the lower hinge region of the gamma-1 constant region genewere also generated by site-directed mutagenesis. Specifically aminoacid substitutions L234A and L235A (numbered according to the EU indexof Kabat, E. A., et al.) were generated using mutagenesis oligos. ThePCR step was done using the QuikChange II Site-Directed Mutagenesis Kit(Stratagene) as described above. Following digestion of PCR generatedproduct with NheI and EagI, the resulting restriction fragment wassubcloned into the modified pVg1.D.Tt expression vector described abovecontaining the D356E and L358M mutations and an NheI site in the intronbetween the hinge and CH2 exons. Mutations were verified by nucleotidesequencing.

The amino acid sequences of the humanized VH and VL mini-exons are shownin Table 21. The resulting V gene fragments were cloned, respectively,into a modified form of pVg1.D.Tt and pVk.

Human kidney cell line 293T/17 (American Type Culture Collection,Manassus, Va.) was maintained in DMEM (BioWhittaker, Walkersville, Md.)containing 10% Fetal Bovine Serum (FBS) (HyClone, Logan, Utah), 0.1 mMMEM non-essential amino acids (Invitrogen Corporation) and 2 mML-glutamine (Invitrogen Corporation), hereinafter referred to as 293medium, at 37° C. in a 7.5% CO₂ incubator. For expression andpurification of monoclonal antibodies after transient transfection,293T/17 cells were incubated in DMEM containing 10% low-IgG FBS(HyClone), 0.1 mM MEM non-essential amino acids and 2 mM L-glutamine,hereinafter referred to as low-IgG 293 medium.

Transient transfection of 293T/17 cells was carried out usingLipofectamine 2000 (Invitrogen Corporation) following the manufacturer'srecommendations. Approximately 2×10⁷ cells per transfection were platedin a T-175 flask in 50 ml of 293 medium and grown overnight toconfluence. The next day, 35 μg of light chain plasmid and 35 μg ofheavy chain plasmid were combined with 3.75 ml of Hybridoma-SFM (HSFM)(Life Technologies, Rockville, Md.). In a separate tube, 175 μl ofLipofectamine 2000 reagent and 3.75 ml of HSFM were combined andincubated for 5 min at room temperature. The 3.75 ml Lipofectamine2000-HSFM mixture was mixed gently with the 3.75 ml DNA-HSFM mixture andincubated at room temperature for 20 min. The medium covering the293T/17 cells was aspirated and replaced with low-IgG 293 medium, thenthe lipofectamine-DNA complexes were added dropwise to the cells, mixedgently by swirling, and the cells were incubated for 7 days at 37° C. ina 7.5% CO₂ incubator before harvesting the supernatants.

Transient transfectants producing 8E1.4, 8E1.5 and 8E1.6 were generatedas described above.

Expression of humanized 8E1.4, 8E1.5 and 8E1.6 antibodies was measuredby sandwich ELISA. MaxiSorp ELISA plates (Nunc Nalge International,Rochester, N.Y.) were coated overnight at 4° C. with 100 μl/well of a1:1000 dilution of AffiniPure goat anti-human IgG Fcγ-chain specificpolyclonal antibodies (Jackson ImmunoResearch Laboratories, Inc., WestGrove, Pa.) in 0.2 M sodium carbonate-bicarbonate buffer, pH 9.4, washedwith Wash Buffer (PBS containing 0.1% Tween 20), and blocked for 1 hr atroom temperature with 300 μl/well of SuperBlock Blocking Buffer in TBS(Pierce Chemical Company, Rockford, Ill.). After washing with WashBuffer, samples containing 8E1.4, 8E1.5 or 8E1.6 were appropriatelydiluted in ELISA Buffer (PBS containing 1% BSA and 0.1% Tween 20) and100 μl/well was applied to the ELISA plates. As a standard, humanizedIgG1/κ antibody daclizumab (PDL BioPharma, Inc.) was used. Afterincubating the plates for 1 hr at room temperature, and washing withWash Buffer, bound antibodies were detected using 100 μl/well of a1:1000 dilution of HRP-conjugated goat anti-human kappa light chainspecific polyclonal antibodies (Southern Biotechnology Associates, Inc.,Birmingham, Ala.). After incubating for 1 hr at room temperature, andwashing with Wash Buffer, color development was performed by adding 100μl/well of ABTS Peroxidase Substrate/Peroxidase Solution B (KPL, Inc.,Gaithersburg, Md.). After incubating for 7 min at room temperature,color development was stopped by adding 50 μl/well of 2% oxalic acid.Absorbance was read at 415 nm using a VersaMax microplate reader(Molecular Devices Corporation, Sunnyvale, Calif.). Culture supernatantsobtained from transiently transfected 293T/17 cells were analyzed byELISA for production of 8E1.4, 8E1.5 and 8E1.6. Expression levels ofapproximately 30-50 μg/ml were typically observed. Samples that werepositive were subjected purification as described below.

Example 2.4.5 Purification of Additional Humanized Antibodies

8E1.4, 8E1.5 and 8E1.6 IgG1/κ monoclonal antibodies were purified fromexhausted culture supernatant with a protein A Sepharose column asfollows. Culture supernatants from transient transfections wereharvested by centrifugation, and sterile filtered. The pH of thefiltered supernatants was adjusted by addition of 1/50 volume of 1 Msodium citrate, pH 7.0. Supernatants were run over a 1 ml HiTrap ProteinA HP column (GE Healthcare Bio-Sciences Corporation, Piscataway, N.J.)that was pre-equilibrated with 20 mM sodium citrate, 150 mM NaCl, pH7.0. The column was washed with the same buffer, and bound antibody waseluted with 20 mM sodium citrate, pH 3.5. After neutralization byaddition of 1/50 volume of 1.5 M sodium citrate, pH 6.5, the pooledantibody fractions were concentrated to ˜0.5-1.0 mg/mil using a 15 mlAmicon Ultra-15 centrifugal filter device (30,000 dalton MWCO)(Millipore Corporation, Bedford, Mass.). Samples were then filtersterilized using a 0.2 μm Acrodisc syringe filter with HT Tuffrynmembrane (Pall Corporation, East Hills, N.Y.). The concentrations of thepurified antibodies were determined by UV spectroscopy by measuring theabsorbance at 280 nm (1 mg/ml=1.4 A₂₈₀).

SDS-PAGE analysis under non-reducing conditions indicated that theantibodies had a molecular weight of about 150-160 kD. Analysis underreducing conditions indicated that the antibodies were comprised of aheavy chain with a molecular weight of about 50 kD and a light chainwith a molecular weight of about 25 kD. The purity of the antibodiesappeared to be more than 95%.

Example 2.4.6 Characterization of Additional Humanized Antibodies UsingCompetition ELISA

MaxiSorp ELISA plates (Nalge Nunc International) were coated overnightat 4° C. with 100 μl/well of 1.0 μg/ml human IL-12 in 0.2 M sodiumcarbonate-bicarbonate buffer, pH 9.4, washed with Wash Buffer (PBScontaining 0.1% Tween 20), and blocked for 1 hr at room temperature with300 μl/well of SuperBlock Blocking Buffer in TBS (Pierce ChemicalCompany). After washing with Wash Buffer, a mixture of biotinylated 8E1(0.8 μg/ml final concentration) and competitor antibody (8E1 or 8E1.4 or8E1.5 or 8E1.6) starting at 100 μg/ml final concentration and seriallydiluted 3-fold) in 100 μl/well of ELISA buffer was added in duplicate.As isotype controls, 100 μl/well of 100 μg/ml mouse IgG1/κ (MuFd79) orhumanized IgG1/κ (HuFd79) monoclonal antibodies in ELISA buffer wasused. As a no-competitor control, 100 μl/well of ELISA Buffer was used.After incubating the plates for 1 hr at room temperature, and washingwith Wash Buffer, bound antibodies were detected using 100 μl/well of 1μg/ml HRP-conjugated streptavidin (Pierce Chemical Company) in ELISAbuffer. After incubating for 1 hr at room temperature, and washing withWash Buffer, color development was performed by adding 100 μl/well ofABTS Peroxidase Substrate/Peroxidase Solution B (KPL, Inc.). Afterincubating for 5 min at room temperature, color development was stoppedby adding 50 μl/well of 2% oxalic acid. Absorbance was read at 415 nm.

The affinity of 8E1.4, 8E1.5 and 8E1.6 to human IL-12 was analyzed bycompetition ELISA as described above. Both 8E1 and the three humanizedversions competed with biotinylated 8E1 in a concentration-dependentmanner. Table 23 shows the IC₅₀ values of 8E1, 8E1.4, 8E1.5 and 8E1.6obtained using the computer software GraphPad Prism (GraphPad SoftwareInc., San Diego, Calif.).

TABLE 23 Binding properties of 8E1.4, 8E1.5 and 8E1.6 antibodiesAntibody Expt. 1 Expt. 2 Expt. 3 Average S.D. 8E1 2.63 2.78 2.28 2.560.26 8E1.4 N.D. N.D. 8.33 N/A N/A 8E1.5 N.D. N.D. 13.4 N/A N/A 8E1.62.25 2.43 1.61 2.10 0.43 The values represent IC50 (μg/ml) required tocompete 0.8 (μg/ml) biotinylated 8E1 antibody.

Antibodies 1A6.10, 1A6.11, 1A6.12, 8E1.4 and 8E1.5 were also generatedusing methods described in Example 2.3. Antibodies were expressed in COScells and purified by Protein A affinity chromatography as described inexamples 2.2.2 and 1.2.C, respectively. These purified mAbs werecharacterized for IC₅₀ and K_(D) according to example 1.1.B and 1.1.C2.Table 24 shows the binding properties of 1A6.10, 1A6.11, 1A6.12, 8E1.4and 8E1.5.

TABLE 24 Kinetic and potency parameters of additional humanizedantibodies Antibody 1A6.10 1A6.11 1A6.12 8E1.4 8E1.5 8E1.6 On-rate 3.2 ×10⁵  ND 7.4 × 10⁵ 8 × 10⁵  1.6 × 10⁶ 1.7 × 10⁶ (1/M · s) Off-rate 7.6 ×10⁻⁶ ND    3 × 10⁻⁴ 1 × 10⁻³ 1.24 × 10⁻³    8 × 10⁻⁵ (1/s) KD (nM) 0.024ND 0.4 1.3 0.75 0.046 Av. IC₅₀(nM) 0.15 ND 0.088 12 8 ND huIL-12 Av.IC₅₀(nM) ND ND ND ND ND ND cyno IL-12

The present invention incorporates by reference in their entiretytechniques well known in the field of molecular biology. Thesetechniques include, but are not limited to, techniques described in thefollowing publications:

-   Ausubel, F. M. et al. eds., Short Protocols In Molecular Biology    (4th Ed. 1999) John Wiley & Sons, NY. (ISBN 0-471-32938-X).-   Lu and Weiner eds., Cloning and Expression Vectors for Gene Function    Analysis (2001) BioTechniques Press. Westborough, Mass. 298 pp.    (ISBN 1-881299-21-X).-   Kontermann and Dubel eds., Antibody Engineering (2001)    Springer-Verlag. New York. 790 pp. (ISBN 3-540-41354-5).-   Old, R. W. & S. B. Primrose, Principles of Gene Manipulation: An    Introduction To Genetic Engineering (3d Ed. 1985) Blackwell    Scientific Publications, Boston. Studies in Microbiology; V. 2:409    pp. (ISBN 0-632-01318-4).-   Sambrook, J. et al. eds., Molecular Cloning: A Laboratory Manual (2d    Ed. 1989) Cold Spring Harbor Laboratory Press, NY. Vols. 1-3. (ISBN    0-87969-309-6).-   Winnacker, E. L. From Genes To Clones: Introduction To Gene    Technology (1987) VCH Publishers, NY (translated by Horst    Ibelgaufts). 634 pp. (ISBN 0-89573-614-4).

REFERENCES U.S. Patents

-   U.S. Pat. No. 4,816,397,-   U.S. Pat. No. 4,816,567,-   U.S. Pat. No. 4,880,078;-   U.S. Pat. No. 5,985,309,-   U.S. Pat. No. 5,223,409;-   U.S. Pat. No. 5,225,539;-   U.S. Pat. No. 5,258,498;-   U.S. Pat. No. 5,290,540,-   U.S. Pat. No. 5,290,540,-   U.S. Pat. No. 5,403,484;-   U.S. Pat. No. 5,427,908;-   U.S. Pat. No. 5,516,637;-   U.S. Pat. No. 5,530,101;-   U.S. Pat. No. 5,571,698;-   U.S. Pat. No. 5,580,717;-   U.S. Pat. No. 5,585,089,-   U.S. Pat. No. 5,658,727;-   U.S. Pat. No. 5,693,762,-   U.S. Pat. No. 5,714,352,-   U.S. Pat. No. 5,723,323,-   U.S. Pat. No. 5,733,743-   U.S. Pat. No. 5,750,753;-   U.S. Pat. No. 5,766,886,-   U.S. Pat. No. 5,780,225;-   U.S. Pat. No. 5,817,483,-   U.S. Pat. No. 5,821,047;-   U.S. Pat. No. 5,824,514,-   U.S. Pat. No. 5,855,913,-   U.S. Pat. No. 5,874,064,-   U.S. Pat. No. 5,934,272,-   U.S. Pat. No. 5,939,598,-   U.S. Pat. No. 5,969,108;-   U.S. Pat. No. 5,976,862,-   U.S. Pat. No. 5,985,320,-   U.S. Pat. No. 5,985,309,-   U.S. Pat. No. 5,985,615,-   U.S. Pat. No. 5,998,209,-   U.S. Pat. No. 5,723,323,-   U.S. Pat. No. 5,763,192,-   U.S. Pat. No. 5,814,476,-   U.S. Pat. No. 6,075,181,-   U.S. Pat. No. 6,091,001,-   U.S. Pat. No. 6,180,370,-   U.S. Pat. No. 6,204,023,-   U.S. Pat. No. 6,350,861,-   U.S. Pat. No. 5,585,089,-   U.S. Pat. No. 4,526,938,-   U.S. Pat. No. 4,980,286,-   U.S. Pat. No. 5,912,015;-   U.S. Pat. No. 4,946,778,-   U.S. Pat. No. 5,916,597;-   U.S. Pat. No. 5,128,326;-   U.S. Pat. No. 5,565,352).-   U.S. Pat. No. 5,679,377;-   U.S. Pat. No. 5,989,463;-   U.S. Pat. No. 5,225,539;-   U.S. Pat. No. 5,565,332,-   U.S. Pat. No. 5,698,426;-   U.S. Pat. No. 5,714,350,-   U.S. Pat. No. 5,807,715,-   U.S. Pat. No. 6,019,968,-   U.S. Pat. No. 6,019,968,-   U.S. Pat. No. 5,627,052,-   U.S. Pat. No. 5,916,771,-   U.S. Pat. No. 5,648,260,-   U.S. Pat. No. 6,699,658,

U.S. Application

-   Ser. No. 09/428,082

U.S Patent Publication

-   20020137134,-   20040018590,-   20030186374,-   20050042664 A1-   US2006104968

Foreign Patents

-   WO 97/15327,-   WO 00/56772 A1-   WO 91/17271,-   WO 92/09690,-   WO9937682 A2,-   WO 92/15679,-   WO 92/01047,-   WO2002097048A2,-   WO9524918 A1,-   PCT/GB91/01134,-   WO 99/25044,-   WO 97/29131,-   WO 98/31700-   WO 99/15154;-   WO 99/20253,-   WO 92/19244,-   WO 92/19244,-   WO 00/37504,-   WO 00/56772.-   WO 91/05548,-   WO 91/09967,-   WO 91/09967;-   WO 92/02551-   WO92/22324-   WO96/20698,-   WO 97/29131-   WO01/83525.-   WO2003016466A2,-   WO2005100584 A2).-   WO 03/035835;-   WO 90/02809,-   PCT/US91/05939,-   PCT/US91/09630,-   PCT/US94/01234,-   PCT/US96/18978,-   PCT/US98/16280,-   WO 92/20791,-   WO 90/05144 A1-   WO 00 09560,-   WO 00/037504%-   WO 02072636,-   WO 91/10737,-   WO 91/10741-   WO 92/01047,-   WO 92/18619,-   WO 93/11236,-   WO 94/02602,-   WO 95/15982,-   WO 95/20401,-   WO 96/33735-   WO 96/34096-   WO 97/32572,-   WO 97/32572,-   WO 97/44013,-   WO 97/44013,-   WO 98/16654-   WO 98/24893,-   WO 98/31346,-   WO 98/31346,-   WO 98/50433,-   WO 99/45031,-   WO 99/53049,-   WO 99/543428,-   WO 99/66903-   WO 99/66903,-   WO90/14424,-   WO90/14430,-   WO2004078140,

European Patent No

-   EP 229246,-   EP 239,400,-   EP 239,400;-   EP 519,596,-   EP 519,596;-   EP 592,106;-   EP 592,106;-   EP 1,176,195;-   GB89/01334,-   GB91/01134,-   GB92/01755;

Other References

-   Ames et al., J. Immunol. Methods 184:177-186 (1995),-   Babcock, J. S. et al. (1996) Proc. Natl. Acad. Sci. USA    93:7843-7848,-   Barbas et al. (1991) PNAS 88:7978-7982,-   Bentley, D. L., and Rabbitts, T. H., Cell 32: 181-189 (1983),-   Berrebi et al. (1998) Am. J Path 152:667-672,-   Better et al., Science 240:1041-1043 (1988),-   Bird et al. (1988) Science 242:423-426,-   Breitling et al. PCT Publication No. WO 93/01288,-   Brinkman et al., J. Immunol. Methods 182:41-50 (1995),-   Broberg, et al. (2002) J. Interferon Cytokine Res. 22:641-651,-   Brown et al. (1991) Proc. Natl. Acad. Sci. 88:2663-2667,-   Bucht et al., (1996) Clin. Exp. Immunol. 103:347-367,-   Buchwald et al., 1980, Surgery 88:507;-   Burton et al., Advances in Immunology 57:191-280 (1994),-   Carter et al., Proc. Natl. Acad. Sci. U.S.A. 89:4285 (1992);-   Chothia &Lesk, J. Mol. Biol. 196:901-917 (1987),-   Chothia et al., J. Mol. Biol. 227:799 (1992),-   Chothia et al., Nature 342:877-883 (1989),-   Clackson et al. (1991) Nature 352:624-628,-   Cleek et al., 1997, “Biodegradable Polymeric Carriers for a bFGF    Antibody for Cardiovascular Application,” Pro. Int'l. Symp. Control.    Rel. Bioact. Mater. 24:853-854,-   Co, M. S., et al., J. Immunol. 148: 1149-1154 (1992)-   Co, M. S., et al., Mol. Immunol. (1993) 30:1361-1367,-   Cole, M. S., et al., J. Immunol. 159: 3613-3621 (1997),-   Cooper, et al. (2002) J. Immunol. 168:1322-1327,-   Cua et al. (2003) Nature 421:744-748,-   Duchmarm et al., J Immunol. 26:934-938 (1996),-   During et al., 1989, Ann. Neurol. 25:351;-   Durocher et al., Nucleic Acids Research 2002, Vol 30, No. 2,-   Elkins, et al. (2002) Infection Immunity 70:1936-1948,-   Fais et al. (1994) J Interferon Res. 14:235-238;-   Foote and Winter (1992), J. Mol. Biol. 224:487-499,-   Fuchs et al. (1991) Bio/Technology 9: 1370-1372,-   Fuss, et al., (1996) J Immunol. 157:1261-1270,-   Garrad et al. (1991) Bio/Technology 9:1373-1377,-   Giege, R. and Ducruix, A. Barrett, Crystallization of Nucleic Acids    and Proteins, a Practical Approach, 2nd ea., pp. 20 1-16, Oxford    University Press, New York, N.Y., (1999),-   Gillies et al., (1989) J. Immunol. Methods 125:191-202,-   Goldspiel et al., 1993, Clinical Pharmacy 12:488-505;-   Goodson, in Medical Applications of Controlled Release, supra, vol.    2, pp. 115-138 (1984),-   Gram et al. (1992) PNAS 89:3576-3580,-   Green and Jakobovits J. Exp. Med. 188:483-495 (1998),-   Green et al. Nature Genetics 7:13-21 (1994)-   Griffiths et al. (1993) EMBO J 12:725-734,-   Hammerling, et al., Monoclonal Antibodies and T-Cell Hybridomas    563-681 (Elsevier, N.Y., 1981),-   Harlow et al., Antibodies: A Laboratory Manual, (Cold Spring Harbor    Laboratory Press, 2nd ed. 1988),-   Hawkins et al. (1992) J Mol Biol 226:889-896-   Hay et al. (1992) Hum Antibod Hybridomas 3:81-85,-   Hieter, P. A., et al., J. Biol. Chem. 257: 1516-1522 (1982),-   Higuchi, R., in “PCR Technology: Principles and Applications for DNA    Amplification”, Stockton Press, New York (1989), pp. 61-70),-   Holliger, P., et al. (1993) Proc. Natl. Acad. Sci. USA 90:6444-6448,-   Hoogenboom et al. (1991) Nuc Acid Res 19:4133-4137,-   Hoogenboom H. R., (1997) TIB Tech. 15:62-70;-   Azzazy H., and Highsmith W. E., (2002) Clin. Biochem. 35:425-445;-   Gavilondo J. V., and Larrick J. W. (2002) BioTechniques 29:128-145;-   Hoogenboom H., and Chames P. (2000) Immunology Today 21:371-378,-   Howard et al., 1989, J. Neurosurg. 7 1:105);-   Huse et al. (1989) Science 246:1275-1281,-   Huston et al. (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883,-   Huston et al., Methods in Enzymology 203:46-88 (1991);-   Johnnson, B., et al. (1991) Anal. Biochem. 198:268-277.-   Johnsson, B., et al. (1995) J. Mol. Recognit. 8:125-131,-   Joliot et al., 1991, Proc. Natl. Acad. Sci. USA 88:1864-1868,-   Jones et al., Nature 321:522 (1986);-   Jönsson, U., et al. (1993) Ann. Biol. Clin. 51:19-26; Jönsson,-   Junghans, et al. (1990) Cancer Res. 50:1495-1502,-   Kabat et al. (1971) Ann. NY Acad, Sci. 190:382-391,-   Kabat, E. A., et al. (1991) Sequences of Proteins of Immunological    Interest, Fifth Edition, U.S. Department of Health and Human    Services, NIH Publication No. 91-3242,-   Kang et al. PCT Publication No. WO 92/18619,-   Kellermann S-A., and Green L. L. (2002) Current Opinion in    Biotechnology 13:593-597,-   Kettleborough et al. (1991) Prot. Engineer. 4:773-783,-   Kettleborough et al., Eur. J. Immunol. 24:952-958 (1994),-   Kipriyanov, S. M., et al. (1994) Mol. Immunol. 31:1047-1058,-   Kipriyanov, S. M., et al. (1995) Human Antibodies and Hybridomas    6:93-101,-   Kobayashi, et al. (1989) J Exp Med 170:827-845;-   Kohler, G. and Milstein 1975, Nature, 256:495,-   Kontermann and Dubel eds., Antibody Engineering (2001)    Springer-Verlag. New York. 790 pp. (ISBN 3-540-41354-5),-   Ladner et al. U.S. Pat. No. 5,223,409,-   Lam et al., 1997, “Microencapsulation of Recombinant Humanized    Monoclonal Antibody for Local Delivery,” Proc. Int'l. Symp. Control    Rel. Bioact. Mater. 24:759-760,-   Langer (1990), Science 249:1527-1533,-   Langrish et. al. (2004) Immunological Reviews 202: 96-105,-   Levitt, M., J. Mol. Biol. 168: 595-620 (1983),-   Levy et al., 1985, Science 228:190;-   Ling, et al. (1995) J Exp Med 154:116-127;-   Little M. et al (2000) Immunology Today 21:364-370,-   Lund et al., 1991, J. Immunol., 147:2657,-   MacCallum (J Mol Biol 262(5):732-45 (1996),-   Manheimer-Lory, A., et al., J. Exp. Med. 174: 1639-1652 (1991),-   Marchalonis et al., Adv Exp Med Biol. 484:13-30 (2001),-   McCafferty et al., Nature (1990) 348:552-554,-   Medical Applications of Controlled Release, Langer and Wise (eds.),    CRC Pres., Boca Raton, Fla. (1974); Controlled Drug Bioavailability,    Drug Product Design and Performance,-   Mendez et al., Nature Genetics 15:146-156 (1997),-   Mizushima and Nagata, Nucleic Acids Research 1990, Vol 18, pg 5322,-   Mizushima, S. and Nagata, S., (1990) Nucleic acids Research Vol 18,    No. 17,-   Monteleone et al., (1997) Gastroent. 112:1169-1178,-   Morgan and Anderson, 1993, Ann. Rev. Biochem. 62:191-217; May, 1993,    TIBTECH 11(5):155-215,-   Morita et al., (1998) Arth. and Rheumat. 41:306-314,-   Morrison et al., 1984, Proc. Natl. Acad. Sci. 81:851-855,-   Morrison, Science 229:1202 (1985),-   Mulligan, Science 260:926-932 (1993);-   Mullinax et al., BioTechniques 12(6):864-869 (1992),-   Murphy et al. J Exp Med 198:1951-1957;-   Neuberger et al., 1984, Nature 312:604-608,-   Neurath et al., J Exp. Med 182:1281-1290 (1995),-   Ning et al., 1996, “Intratumoral Radioimmunotheraphy of a Human    Colon Cancer Xenograft Using a Sustained-Release Gel,” Radiotherapy    &Oncology 39:179-189,-   Oi et al., BioTechniques 4:214 (1986);-   Olee, T., et al., J. Exp. Med. 175: 831-842 (1992),-   Oppmann et al. (2000) Immunity 13:715-725,-   Padlan (FASEB J. 9:133-139 (1995),-   Padlan, Molecular Immunology 28(4/5):489-498 (1991),-   Parham, et al. (2002) J. Immunol. 168:5699-5708,-   Parronchi et al (1997) Am. J. Path. 150:823-832,-   Persic et al., Gene 187 9-18 (1997),-   Petrey, D., Xiang, Z., Tang, C. L., Xie, L., Gimpelev, M., Mitros,    T., Soto, C. S., Goldsmith-Fischman, S., Kernytsky, A.,    Schlessinger, A., et al. 2003. Using multiple structure alignments,    fast model building, and energetic analysis in fold recognition and    homology modeling. Proteins 53 (Suppl. 6): 430-435),-   Pirhonen, et al. (2002) J. Immunol. 169:5673-5678,-   Podlaski, et al. (1992) Arch. Biochem. Biophys. 294:230-237,-   Poljak, R. J., et al. (1994) Structure 2:1121-1123,-   Presta et al., J. Immunol. 151:2623 (1993),-   Queen, C., et al., Proc. Natl. Acad. Sci. USA 86: 10029-10033    (1989),-   R. Jefferis, Biotechnol. Prog. 21 (2005), pp. 11-16,-   R. J. Kaufman and P. A. Sharp (1982) Mol. Biol. 159:601-621),-   Ranger and Peppas, 1983, J., Macromol. Sci. Rev. Macromol. Chem.    23:61;-   Ravetch, J. V., et al., Cell 27: 583-591 (1981),-   Remington's Pharmaceutical Sciences and Introduction to    Pharmaceutical Dosage Forms, 19th ed., Mack Pub. Co., Easton, Pa.    (1995),-   Riechmann et al., Nature 332:323 (1988),-   Roberts, R. W. and Szostak, J. W. (1997) Proc. Natl. Acad. Sci. USA    94:12297-12302,-   Roguska. et al., PNAS 91:969-973 (1994);-   Rouillard, J.-M., et al., Nucleic Acids Res. 32: W176-W180 (2004),-   Saudek et al., 1989, N. Engl. J. Med. 321:574),-   Sawai et al., AJRI 34:26-34 (1995),-   Schroeder, Jr., H. W. and Wang, J. Y., Proc. Natl. Acad. Sci. USA    87: 6146-6150 (1990),-   Seder, et al. (1993) Proc. Natl. Acad. Sci. 90:10188-10192,-   Sefton, 1987, CRC Crit. Ref. Biomed. Eng. 14:20;-   Shapiro et al., Crit. Rev. Immunol. 22(3): 183-200 (2002),-   Shields, R. L. et al. (2002) J. Biol. Chem. 277:26733-26740,-   Shu et al., PNAS 90:7995-7999 (1993);-   Sims et al., J. Immunol. 151: 2296 (1993);-   Skerra et al., Science 240:1038-1040 (1988).-   Smolen and Ball (eds.), Wiley, New York (1984);-   Song et al., 1995, “Antibody Mediated Lung Targeting of    Long-Circulating Emulsions,” PDA Journal of Pharmaceutical Science    &Technology 50:372-397,-   Studnicka et al., Protein Engineering 7(6):805-814 (1994);-   Sustained and Controlled Release Drug Delivery Systems, J. R.    Robinson, ed., Marcel Dekker, Inc., New York, 1978.-   Takeda et al., 1985, Nature 314:452-454-   Taylor, L. D., et al. (1992) Nucl. Acids Res. 20:6287-6295,-   Tolstoshev, 1993, Ann. Rev. Pharmacol. Toxicol. 32:573-596;-   Trinchieri et al., (2003) Immunity 19:641-644,-   Trinchieri, G. (2003) Nat. Rev. Immun. 3:133-146,-   U., et al. (1991) Biotechniques 11:620-627,-   Umana et al. (1999) Nat. Biotech. 17:176-1,-   Urlaub and Chasin, (1980) Proc. Natl. Acad. Sci. USA 77:4216-4220,-   Verhoeyen et al., Science 239:1534 (1988)),-   Wallick, S. C., et al., Exp. Med. (1988) 168:1099-1109,-   Ward et al., (1989) Nature 341:544-546,-   Welschof, M. and Krauss, J. Methods In Molecular Biology, Vol 207,-   Windhagen et al., (1995) J Exp. Med. 182:1985-1996,-   Winnaker, From Genes to Clones (Verlagsgesellschaft, Weinheim,    Germany 1987),-   Wright, A., et al., EMBO J. (1991) 10:2717 2723),-   Wu and Wu, 1991, Biotherapy 3:87-95;-   Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987),

Although a number of embodiments and features have been described above,it will be understood by those skilled in the art that modifications andvariations of the described embodiments and features may be made withoutdeparting from the present disclosure or the invention as defined in theappended claims. Each of the publications mentioned herein isincorporated by reference.

1. An isolated binding protein comprising an antigen binding domain,said binding protein capable of binding a p40 subunit of IL-12, saidantigen binding domain comprising six CDRs: CDR-H1, CDR-H2, CDR-H3,CDR-L1, CDR-L2, and CDR-L3, as defined below: CDR-H1.X₁-X₂-X₃-X₄-X₅-X₆-X₇ (SEQ ID NO: 55), wherein; X₁ is D, K, T, or S; X₂is Y, S, or T; X₃ is Y, V, G, W, S, or F; X₄ is I, or M; X is H, G, E,or V; X₆ is V, or is not present; and X₇ is S, or is not present;CDR-H2.X₁-X₂-X₃-X₄-X₅-X₆-X₇-X₈-X₉-X₁₀-X₁₁-X₁₂-X₁₃-X₁₄-X₁₅-X₁₆-X₁₇-X₁₈-X₁₉-X₂₀(SEQ ID NO: 56), wherein; X₁ is H, D, G, W, S, Y or R; X₂ is I, or F; X₃is Y, W, L, S, N, D or G; X₄ is W, P, H, T, or S; X₅ is D, G, E, A, orI; X₆ is D, G, S, T, or N; X₇ is D, G, S, or P; X₈ is K, N, S, E, T, orH; X₉ is Y, T, P, I, or N; X₁₀ is Y, N, T, H, K, S, or G; X₁₁ is N, orY; X₁₂ is P, N, A, D, or S; X₁₃ is S, E, D, or P; X₁₄ is L, K, D, T, orY; X₁₅ is K, F, V, M, R, or A; X₁₆ is S, K, Q, P, or is not present; X₁₇is D, G, R, or is not present; X₁₈ is F, or is not present; X₁₉ is Q, oris not present; and X₂₀ is D, or is not present; CDR-H3.X₁-X₂-X₃-X₄-X₅-X₆-X₇-X₈-X₉-X₁₀-X₁₁-X₁₂-X₁₃ (SEQ ID NO: 57), wherein; X₁is R, N, or W; X₂ is G, T, R, P, or H; X₃ is I, R, F, Y, or Q; X₄ is R,V, Y, F, or A; X₅ is S, N, G, A, or R; X₆ is A, Y, L, F, or M; X₇ is M,A, D, L, or F; X₈ is D, M, Y, or W; X₉ is Y, D, or N; X₁₀ is Y, A, or isnot present; X₁₁ is M, or is not present; X₁₂ is D, or is not present;and X₁₃ is Y, or is not present; CDR-L1.X₁-X₂-X₃-X₄-X₅-X₆-X₇-X₈-X₉-X₁₀-X₁₁-X₁₂-X₁₃-X₁₄-X₁₅ (SEQ ID NO: 58)_(r)wherein; X₁ is K, or R; X₂ is A; X₃ is S; X₄ is Q, or E; X₅ is S, or N;X₆ is V, or I; X₇ is S, G, or D; X₈ is N, T, or K; X₉ is D, N, or Y; X₁₀is V, G, or L; X₁₁ is A, I, or H; X₁₂ is S, or is not present; X₁₃ is F,or is not present; X₁₄ is M, or is not present; and X₁₅ is N, or is notpresent; CDR-L2. X₁-X₂-X₃-X₄-X₅-X₆-X₇-X₈ (SEQ ID NO: 59), wherein; X₁ isY, or S; X₂ is A, or T; X₃ is S, or A; X₄ is N, H, S, or Q; X₅ is R, N,or S; X₆ is Y, Q, or I; X₇ is T, S, or G; and X₈ is S, or is notpresent; and CDR-L3. X₁-X₂-X₃-X₄-X₅-X₆-X₇-X₈-X₉ (SEQ ID NO: 60),wherein; X₁ is Q; X₂ is Q; X₃ is D, Y, or S; X₄ is Y, N, K, or I; X₅ isN, T, S, or E; X₆ is S, Y, V, or W; X₇ is P; X₈ is W, F, Y, L, or P; andX₉ is T, or S.
 2. An isolated binding protein comprising an antigenbinding domain, said binding protein capable of binding a p40 subunit ofIL-12 and said antigen binding domain comprising aCDR-H1CDR-H2CDR-H3CDR-L1 CDR-L2 and CDR-L3 amino acid sequenceindependently selected from the group consisting of: residues 31-37 ofSEQ ID NO.:35 (CDR-H1); residues 52-67 of SEQ ID NO.:35 (CDR-H2);residues 100-108 of SEQ ID NO.:35 (CDR-H3); residues 24-34 of SEQ IDNO.:36 (CDR-L1); residues 50-56 of SEQ ID NO.:36 (CDR-L2); residues89-97 of SEQ ID NO.:36 (CDR-L3); residues 31-37 of SEQ ID NO.:37(CDR-H1); residues 52-67 of SEQ ID NO.:37 (CDR-H2); residues.100-109 ofSEQ ID NO.:37 (CDR-H3); residues 24-34 of SEQ ID NO.:38 (CDR-L1);residues 50-56 of SEQ ID NO.:38 (CDR-L2); residues 89-97 of SEQ IDNO.:38 (CDR-L3); residues 31-35 of SEQ ID NO.:39 (CDR-H1); residues50-66 of SEQ ID NO.:39 (CDR-H2); residues 99-106 of SEQ ID NO.:39(CDR-H3); residues 24-34 of SEQ ID NO.:40 (CDR-L1); residues 50-56 ofSEQ ID NO.:40 (CDR-L2); residues 89-97 of SEQ ID NO.:40 (CDR-L3);residues 31-35 of SEQ ID NO.:41 (CDR-H1); residues 50-66 of SEQ IDNO.:41 (CDR-H2) residues 99-106 of SEQ ID NO.:41 (CDR-H3); residues24-34 of SEQ ID NO.:42 (CDR-L1); residues 50-56 of SEQ ID NO.:42(CDR-L2); residues 89-97 of SEQ ID NO.:42 (CDR-L3); residues 31-35 ofSEQ ID NO.:43 (CDR-H1); residues 50-66 of SEQ ID NO.:43 (CDR-H2);residues 99-106 of SEQ ID NO.:43 (CDR-H3); residues 24-34 of SEQ IDNO.:44 (CDR-L1); residues 50-56 of SEQ ID NO.:44 (CDR-L2); residues89-97 of SEQ ID NO.:44 (CDR-L3); residues 31-35 of SEQ ID NO.:45(CDR-H1); residues 50-66 of SEQ ID NO.:45 (CDR-H2); residues 99-101 ofSEQ ID NO.:45 (CDR-H3); residues 24-34 of SEQ ID NO.:46 (CDR-L1);residues 50-56 of SEQ ID NO.:46 (CDR-L2); residues 89-97 of SEQ IDNO.:46 (CDR-L3); residues 31-35 of SEQ ID NO.:47 (CDR-H1); residues50-66 of SEQ ID NO.:47 (CDR-H2); residues 99-106 of SEQ ID NO.:47(CDR-H3); residues 24-34 of SEQ ID NO.:48 (CDR-L1); residues 50-56 ofSEQ ID NO.:48 (CDR-L2); residues 89-97 of SEQ ID NO.:48 (CDR-L3);residues 31-35 of SEQ ID NO.:49 (CDR-H1); residues 50-66 of SEQ IDNO.:49 (CDR-H2); residues 99-111 of SEQ ID NO.:49 (CDR-H3); residues24-38 of SEQ ID NO.:50 (CDR-L1); residues 53-60 of SEQ ID NO.:50(CDR-L2); residues 93-101 of SEQ ID NO.:50 (CDR-L3); residues 31-37 ofSEQ ID NO.:51 (CDR-H1); residues 52-67 of SEQ ID NO.:51 (CDR-H2);residues 100-109 of SEQ ID NO.:51 (CDR-H3); residues 24-34 of SEQ IDNO.:52 (CDR-L1); residues 50-56 of SEQ ID NO.:52 (CDR-L2); residues89-97 of SEQ ID NO.:52 (CDR-L3); residues 31-35 of SEQ ID NO.:53(CDR-H1); residues 47-66 of SEQ ID NO.:53 (CDR-H2); residues 99-107 ofSEQ ID NO.:53 (CDR-H3); residues 24-34 of SEQ ID NO.:54 (CDR-L1);residues 50-56 of SEQ ID NO.:54 (CDR-L2); and residues 89-97 of SEQ IDNO.:54 (CDR-L3).


3. An isolated binding protein comprising an antigen binding domain,said binding protein capable of binding a p40 subunit of IL-12 and saidantigen binding domain comprising a variable heavy chain (VH) set of 3CDRs and a variable light chain (VL) set of 3 CDRs wherein said VH setof 3 CDRs is selected from any one of the VH sets in the group below andsaid VL set of 3 CDRs is selected from any one of the VL sets in thegroup of below: VH 1D4 CDR Set VH 1D4 CDR-H1 Residues 31-37 of SEQ IDNO.:35 VH 1D4 CDR-H2 Residues 52-67 of SEQ ID NO.:35 VH 1D4 CDR-H3Residues 100-108 of SEQ ID NO.:35 VL 1D4 CDR Set VL 1D4 CDR-L1 Residues24-34 of SEQ ID NO.:36 VL 1D4 CDR-L2 Residues 50-56 of SEQ ID NO.:36 VL1D4 CDR-L3 Residues 89-97 of SEQ ID NO.:36 VH 1A6 CDR Set VH 1A6 CDR-H1Residues 31-37 of SEQ ID NO.:37 VH 1A6 CDR-H2 Residues 52-67 of SEQ IDNO.:37 VH 1A6 CDR-H3 Residues 100-109 of SEQ ID NO.:37 VL 1A6 CDR Set VL1A6 CDR-L1 Residues 24-34 of SEQ ID NO.:38 VL 1A6 CDR-L2 Residues 50-56of SEQ ID NO.:38 VL 1A6 CDR-L3 Residues 89-97 of SEQ ID NO.:38 VH 1D8CDR Set VH 1D8 CDR-H1 Residues 31-35 of SEQ ID NO.:39 VH 1D8 CDR-H2Residues 50-66 of SEQ ID NO.:39 VH 1D8 CDR-H3 Residues 99-106 of SEQ IDNO.:39 VL 1D8 CDR Set VL 1D8 CDR-L1 Residues 24-34 of SEQ ID NO.:40 VL1D8 CDR-L2 Residues 50-56 of SEQ ID NO.:40 VL 1D8 CDR-L3 Residues 89-97of SEQ ID NO.:40 VH 3G7 CDR Set VH 3G7 CDR-H1 Residues 31-35 of SEQ IDNO.:41 VH 3G7 CDR-H2 Residues 50-66 of SEQ ID NO.:41 VH 3G7 CDR-H3Residues 99-106 of SEQ ID NO.:41 VL 3G7 CDR Set VL 3G7 CDR-L1 Residues24-34 of SEQ ID NO.:42 VL 3G7 CDR-L2 Residues 50-56 of SEQ ID NO.:42 VL3G7 CDR-L3 Residues 89-97 of SEQ ID NO.:42 VH 5E8 CDR Set VH 5E8 CDR-H1Residues 31-35 of SEQ ID NO.:43 VH 5E8 CDR-H2 Residues 50-66 of SEQ IDNO.:43 VH 5E8 CDR-H3 Residues 99-106 of SEQ ID NO.:43 VL 5E8 CDR Set VL5E8 CDR-L1 Residues 24-34 of SEQ ID NO.:44 VL 5E8 CDR-L2 Residues 50-56of SEQ ID NO.:44 VL 5E8 CDR-L3 Residues 89-97 of SEQ ID NO.:44 VH 8E1CDR Set VH 8E1 CDR-H1 Residues 31-35 of SEQ ID NO.:45 VH 8E1 CDR-H2Residues 50-66 of SEQ ID NO.:45 VH 8E1 CDR-H3 Residues 99-101 of SEQ IDNO.:45 VL 8E1 CDR Set VL 8E1 CDR-L1 Residues 24-34 of SEQ ID NO.:46 VL8E1 CDR-L2 Residues 50-56 of SEQ ID NO.:46 VL 8E1 CDR-L3 Residues 89-97of SEQ ID NO.:46 VH 1H6 CDR Set VH 1H6 CDR-H1 Residues 31-35 of SEQ IDNO.:47 VH 1H6 CDR-H2 Residues 50-66 of SEQ ID NO.:47 VH 1H6 CDR-H3Residues 99-106 of SEQ ID NO.:47 VL 1H6 CDR Set VL 1H6 CDR-L1 Residues24-34 of SEQ ID NO.:48 VL 1H6 CDR-L2 Residues 50-56 of SEQ ID NO.:48 VL1H6 CDR-L3 Residues 89-97 of SEQ ID NO.:48 VH 3A11 CDR Set VH 3A11CDR-H1 Residues 31-35 of SEQ ID NO.:49 VH 3A11 CDR-H2 Residues 50-66 ofSEQ ID NO.:49 VH 3A11 CDR-H3 Residues 99-111 of SEQ ID NO.:49 VL 3A11CDR Set VL 3A11 CDR-L1 Residues 24-38 of SEQ ID NO.:50 VL 3A11 CDR-L2Residues 53-60 of SEQ ID NO.:50 VL 3A11 CDR-L3 Residues 93-101 of SEQ IDNO.:50 VH 4B4 CDR Set VH 4B4 CDR-H1 Residues 31-37 of SEQ ID NO.:51 VH4B4 CDR-H2 Residues 52-67 of SEQ ID NO.:51 VH 4B4 CDR-H3 Residues100-109 of SEQ ID NO.:51 VL 4B4 CDR Set VL 4B4 CDR-L1 Residues 24-34 ofSEQ ID NO.:52 VL 4B4 CDR-L2 Residues 50-56 of SEQ ID NO.:52 VL 4B4CDR-L3 Residues 89-97 of SEQ ID NO.:52 VH 7G3 CDR Set VH 7G3 CDR-H1Residues 31-35 of SEQ ID NO.:53 VH 7G3 CDR-H2 Residues 47-66 of SEQ IDNO.:53 VH 7G3 CDR-H3 Residues 99-107 of SEQ ID NO.:53 And VL 7G3 CDR SetVL 7G3 CDR-L1 Residues 24-34 of SEQ ID NO.:54 VL 7G3 CDR-L2 Residues50-56 of SEQ ID NO.:54 VL 7G3 CDR-L3 Residues 89-97 of SEQ ID NO.:54.


4. The binding protein according to claim 3, wherein said VH set of 3CDRs and VL set of 3 CDRs are selected from a group consisting of: VH1D4 CDR Set & VL 1D4 CDR Set; VH 1A6 CDR Set & VL 1A6 CDR Set; VH 1D8CDR Set & VL 1D8 CDR Set; VH 3G7 CDR Set & VL 3G7 CDR Set; VH 5E8 CDRSet & VL 5E8 CDR Set; VH 8E1 CDR Set & VL 8E1 CDR Set; VH 1H6 CDR Set &VL 1H6 CDR Set; VH 3A11 CDR Set & VL 3A11 CDR Set; VH 4B4 CDR Set & VL4B4 CDR Set; and VH 7G3 CDR Set & VL 7G3 CDR Set.
 5. The binding proteinaccording to claim 1, further comprising a human acceptor framework. 6.The binding protein according to claim 2, further comprising a humanacceptor framework.
 7. The binding protein according to claim 4, furthercomprising a human acceptor framework.
 8. The binding protein accordingto claim 4, further comprising a human acceptor framework.
 9. Thebinding protein according to claim 5, wherein said human acceptorframework comprises an amino acid sequence selected from the groupconsisting of: SEQ ID NO.:6 SEQ ID NO.:7 SEQ ID NO.:8 SEQ ID NO.:9 SEQID NO.:10 SEQ ID NO.:11 SEQ ID NO.:12 SEQ ID NO.:13 SEQ ID NO.:14 SEQ IDNO.:15 SEQ ID NO.:16 SEQ ID NO.:17 SEQ ID NO.:18 SEQ ID NO.:19 SEQ IDNO.:20 SEQ ID NO.:21 SEQ ID NO.:22 SEQ ID NO.:23 SEQ ID NO.:24 SEQ IDNO.:25 SEQ ID NO.:26 SEQ ID NO.:27 SEQ ID NO.:28 SEQ ID NO.:29 SEQ IDNO.:30 SEQ ID NO.:31 SEQ ID NO.:32 SEQ ID NO.:33 SEQ ID NO.:34 SEQ IDNO.:92 SEQ ID NO.:93 SEQ ID NO.:94 SEQ ID NO.:95 SEQ ID NO.:96 AND SEQID NO.:97.


10. The binding protein according to claim 6, wherein said humanacceptor framework comprises an amino acid sequence selected from thegroup consisting of: SEQ ID NO.:6 SEQ ID NO.:7 SEQ ID NO.:8 SEQ ID NO.:9SEQ ID NO.:10 SEQ ID NO.:11 SEQ ID NO.:12 SEQ ID NO.:13 SEQ ID NO.:14SEQ ID NO.:15 SEQ ID NO.:16 SEQ ID NO.:17 SEQ ID NO.:18 SEQ ID NO.:19SEQ ID NO.:20 SEQ ID NO.:21 SEQ ID NO.:22 SEQ ID NO.:23 SEQ ID NO.:24SEQ ID NO.:25 SEQ ID NO.:26 SEQ ID NO.:27 SEQ ID NO.:28 SEQ ID NO.:29SEQ ID NO.:30 SEQ ID NO.:31 SEQ ID NO.:32 SEQ ID NO.:33 SEQ ID NO.:34SEQ ID NO.:92 SEQ ID NO.:93 SEQ ID NO.:94 SEQ ID NO.:95 SEQ ID NO.:96AND SEQ ID NO.:97.


11. The binding protein according to claim 7, wherein said humanacceptor framework comprises an amino acid sequence selected from thegroup consisting of: SEQ ID NO.:6 SEQ ID NO.:7 SEQ ID NO.:8 SEQ ID NO.:9SEQ ID NO.:10 SEQ ID NO.:11 SEQ ID NO.:12 SEQ ID NO.:13 SEQ ID NO.:14SEQ ID NO.:15 SEQ ID NO.:16 SEQ ID NO.:17 SEQ ID NO.:18 SEQ ID NO.:19SEQ ID NO.:20 SEQ ID NO.:21 SEQ ID NO.:22 SEQ ID NO.:23 SEQ ID NO.:24SEQ ID NO.:25 SEQ ID NO.:26 SEQ ID NO.:27 SEQ ID NO.:28 SEQ ID NO.:29SEQ ID NO.:30 SEQ ID NO.:31 SEQ ID NO.:32 SEQ ID NO.:33 SEQ ID NO.:34SEQ ID NO.:92 SEQ ID NO.:93 SEQ ID NO.:94 SEQ ID NO.:95 SEQ ID NO.:96AND SEQ ID NO.:97.


12. The binding protein according to claim 8, wherein said humanacceptor framework comprises an amino acid sequence selected from thegroup consisting of: SEQ ID NO.:6 SEQ ID NO.:7 SEQ ID NO.:8 SEQ ID NO.:9SEQ ID NO.:10 SEQ ID NO.:11 SEQ ID NO.:12 SEQ ID NO.:13 SEQ ID NO.:14SEQ ID NO.:15 SEQ ID NO.:16 SEQ ID NO.:17 SEQ ID NO.:18 SEQ ID NO.:19SEQ ID NO.:20 SEQ ID NO.:21 SEQ ID NO.:22 SEQ ID NO.:23 SEQ ID NO.:24SEQ ID NO.:25 SEQ ID NO.:26 SEQ ID NO.:27 SEQ ID NO.:28 SEQ ID NO.:29SEQ ID NO.:30 SEQ ID NO.:31 SEQ ID NO.:32 SEQ ID NO.:33 SEQ ID NO.:34SEQ ID NO.:92 SEQ ID NO.:93 SEQ ID NO.:94 SEQ ID NO.:95 SEQ ID NO.:96AND SEQ ID NO.:97.


13. The binding protein according to claim 1, wherein said bindingprotein comprises at least one variable domain having an amino acidsequence selected from the group consisting of: SEQ ID NO.:61 SEQ IDNO.:62 SEQ ID NO.:63 SEQ ID NO.:64 SEQ ID NO.:65 SEQ ID NO.:66 SEQ IDNO.:67 SEQ ID NO.:68 SEQ ID NO.:69 and SEQ ID NO.:70.


14. The binding protein according to claim 13 wherein said bindingprotein comprises two variable domains, wherein said two variabledomains have amino acid sequences selected from the group consisting of:SEQ ID NO.:61 & SEQ ID NO.:62, SEQ ID NO.:63 & SEQ ID NO.:64, SEQ IDNO.:65 & SEQ ID NO.:66, SEQ ID NO.:67 & SEQ ID NO.:68, SEQ ID NO.:69 &SEQ ID NO.:70 SEQ ID NO.:67 & SEQ ID NO.:70, AND SEQ ID NO.:69 & SEQ IDNO.:68.
 15. The binding protein according to claim 5, wherein said humanacceptor framework comprises at least one Framework Region amino acidsubstitution at a key residue, said key residue selected from the groupconsisting of: a residue adjacent to a CDR; a glycosylation siteresidue; a rare residue; a residue capable of interacting with a p40subunit of human IL-12; a residue capable of interacting with a CDR; acanonical residue; a contact residue between heavy chain variable regionand light chain variable region; a residue within a Vernier zone; and aresidue in a region that overlaps between a Chothia-defined variableheavy chain CDR1 and a Kabat-defined first heavy chain framework. 16.The binding protein according to claim 6, wherein said human acceptorframework comprises at least one Framework Region amino acidsubstitution at a key residue, said key residue selected from the groupconsisting of: a residue adjacent to a CDR; a glycosylation siteresidue; a rare residue; a residue capable of interacting with a p40subunit of human IL-12; a residue capable of interacting with a CDR; acanonical residue; a contact residue between heavy chain variable regionand light chain variable region; a residue within a Vernier zone; and aresidue in a region that overlaps between a Chothia-defined variableheavy chain CDR1 and a Kabat-defined first heavy chain framework. 17.The binding protein according to claim 7, wherein said human acceptorframework comprises at least one Framework Region amino acidsubstitution at a key residue, said key residue selected from the groupconsisting of: a residue adjacent to a CDR; a glycosylation siteresidue; a rare residue; a residue capable of interacting with a p40subunit of human IL-12; a residue capable of interacting with a CDR; acanonical residue; a contact residue between heavy chain variable regionand light chain variable region; a residue within a Vernier zone; and aresidue in a region that overlaps between a Chothia-defined variableheavy chain CDR1 and a Kabat-defined first heavy chain framework. 18.The binding protein according to claim 15, wherein key residue selectedfrom the group consisting of 3H, 5H, 10H, 11H, 12H, 13H, 15H, 16H, 18H,19H, 23H, 24H, 25H, 30H, 41H, 44H, 46H, 49H, 66H, 68H, 71H, 73H, 74H,75H, 76H, 77H, 78H, 79H, 81H, 82H, 82AH, 82BH, 82CH, 83H, 84H, 85H, 86H,87H, 89H, 93H, 98H, 108H, 109H, 1L, 2L, 3L, 7L, 8L, 9L, 10L, 11L, 12L,13L, 15L, 17L, 19L, 20L, 21L, 22L, 36L, 41L, 42L, 43L, 45L, 46L, 58L,60L, 62L, 63L, 67L, 70L, 73L, 74L, 77L, 78L, 79L, 80L, 83L, 85L, 87L,104L, and 106L.
 19. The binding protein according to claim 16, whereinkey residue selected from the group consisting of 3H, 5H, 10H, 11H, 12H,13H, 15H, 16H, 18H, 19H, 23H, 24H, 25H, 30H, 41H, 44H, 46H, 49H, 66H,68H, 71H, 73H, 74H, 75H, 76H, 77H, 78H, 79H, 81H, 82H, 82AH, 82BH, 82CH,83H, 84H, 85H, 86H, 87H, 89H, 93H, 98H, 108H, 109H, 1L, 2L, 3L, 7L, 8L,9L, 10L, 11L, 12L, 13L, 15L, 17L, 19L, 20L, 21L, 22L, 36L, 41L, 42L,43L, 45L, 46L, 58L, 60L, 62L, 63L, 67L, 70L, 73L, 74L, 77L, 78L, 79L,80L, 83L, 85L, 87L, 104L, and 106L.
 20. The binding protein according toclaim 17, wherein key residue selected from the group consisting of 3H,5H, 10H, H, 12H, 13H, 15H, 16H, 18H, 19H, 23H, 24H, 25H, 30H, 41H, 44H,46H, 49H, 66H, 68H, 71H, 73H, 74H, 75H, 76H, 77H, 78H, 79H, 81H, 82H,82AH, 82BH, 82CH, 83H, 84H, 85H, 86H, 87H, 89H, 93H, 98H, 108H, 109H,1L, 2L, 3L, 7L, 8L, 9L, 10L, 11L, 12L, 13L, 15L, 17L, 19L, 20L, 21L,22L, 36L, 41L, 42L, 43L, 45L, 46L, 58L, 60L, 62L, 63L, 67L, 70L, 73L,74L, 77L, 78L, 79L, 80L, 83L, 85L, 87L, 104L, and 106L.
 21. The bindingprotein according to claim 15, wherein the binding protein is aconsensus human variable domain.
 22. The binding protein according toclaim 16, wherein the binding protein is a consensus human variabledomain.
 23. The binding protein according to claim 17, wherein thebinding protein is a consensus human variable domain.
 24. The bindingprotein according to claim 5, wherein said human acceptor frameworkcomprises at least one Framework Region amino acid substitution, whereinthe amino acid sequence of the framework is at least 65% identical tothe sequence of said human acceptor framework and comprises at least 70amino acid residues identical to said human acceptor framework.
 25. Thebinding protein according to claim 6, wherein said human acceptorframework comprises at least one Framework Region amino acidsubstitution, wherein the amino acid sequence of the framework is atleast 65% identical to the sequence of said human acceptor framework andcomprises at least 70 amino acid residues identical to said humanacceptor framework.
 26. The binding protein according to claim 7,wherein said human acceptor framework comprises at least one FrameworkRegion amino acid substitution, wherein the amino acid sequence of theframework is at least 65% identical to the sequence of said humanacceptor framework and comprises at least 70 amino acid residuesidentical to said human acceptor framework.
 27. The binding proteinaccording to claim 1, wherein said binding protein comprises at leastone variable domain having an amino acid sequence selected from thegroup consisting of: SEQ ID NO.:67 SEQ ID NO.:79 SEQ ID NO.:80 SEQ IDNO.:81 SEQ ID NO.:82 SEQ ID NO.:83 SEQ ID NO.:84 SEQ ID NO.:85 SEQ IDNO.:86 SEQ ID NO.:87 SEQ ID NO.:98 SEQ ID NO.:99 SEQ ID NO.:100 SEQ IDNO.:101 SEQ ID NO.:102 SEQ ID NO.:103.


28. The binding protein according to claim 27 wherein said bindingprotein comprises two variable domains, wherein said two variabledomains have amino acid sequences selected from the group consisting of:SEQ ID NO.:67 & SEQ ID NO.:79, SEQ ID NO.:80 & SEQ ID NO.:81, SEQ IDNO.:82 & SEQ ID NO.:83, SEQ ID NO.:84 & SEQ ID NO.:85, SEQ ID NO.:86 &SEQ ID NO.:87, SEQ ID NO.:98 & SEQ ID NO.:99, SEQ ID NO.:100 & SEQ IDNO.:101, and SEQ ID NO.:102 & SEQ ID NO.:103.
 29. The binding proteinaccording to claim 18, wherein said binding protein comprises at leastone variable domain having an amino acid sequence selected from thegroup consisting of; SEQ ID NO.:79 SEQ ID NO.:80 SEQ ID NO.:81 SEQ IDNO.:82 SEQ ID NO.:83 SEQ ID NO.:84 SEQ ID NO.:85 SEQ ID NO.:86 SEQ IDNO.:87 SEQ ID NO.:98 SEQ ID NO.:99 SEQ ID NO.:100 SEQ ID NO.:101 SEQ IDNO.:102, and SEQ ID NO.:103.


30. The binding protein according to claim 19, wherein said bindingprotein comprises at least one variable domain having an amino acidsequence selected from the group consisting of: SEQ ID NO.:67 SEQ IDNO.:79 SEQ ID NO.:80 SEQ ID NO.:81 SEQ ID NO.:82 SEQ ID NO.:83 SEQ IDNO.:84 SEQ ID NO.:85 SEQ ID NO.:86 SEQ ID NO.:87 SEQ ID NO.:88 SEQ IDNO.:89 SEQ ID NO.:90 SEQ ID NO.:91 SEQ ID NO.:98 SEQ ID NO.:99 SEQ IDNO.:100 SEQ ID NO.:101 SEQ ID NO.:102 SEQ ID NO.:103 SEQ ID NO.:104 SEQID NO.:105 SEQ ID NO.:106 SEQ ID NO.:107 SEQ ID NO.:108, AND SEQ IDNO.:109.


31. The binding protein according to claim 20, wherein said bindingprotein comprises at least one variable domain having an amino acidsequence selected from the group consisting of: SEQ ID NO.:67 SEQ IDNO.:79 SEQ ID NO.:80 SEQ ID NO.:81 SEQ ID NO.:82 SEQ ID NO.:83 SEQ IDNO.:84 SEQ ID NO.:85 SEQ ID NO.:86 SEQ ID NO.:87 SEQ ID NO.:88 SEQ IDNO.:89 SEQ ID NO.:90 SEQ ID NO.:91 SEQ ID NO.:98 SEQ ID NO.:99 SEQ IDNO.:100 SEQ ID NO.:101 SEQ ID NO.:102 SEQ ID NO.:103 SEQ ID NO.:104 SEQID NO.:105 SEQ ID NO.:106 SEQ ID NO.:107 SEQ ID NO.:108, AND SEQ IDNO.:109.


32. The binding protein according to claim 1, wherein the bindingprotein is capable of binding a target selected from the groupconsisting of IL-12 and IL-23.
 33. The binding protein according toclaim 3, wherein the binding protein is capable of binding a targetselected from the group consisting of IL-12 and IL-23.
 34. The bindingprotein according to claim 4, wherein the binding protein is capable ofbinding a target selected from the group consisting of IL-12 and IL-23.35. The binding protein according to claim 5, wherein the bindingprotein is capable of binding a target selected from the groupconsisting of IL-12 and IL-23.
 36. The binding protein according toclaim 9, wherein the binding protein is capable of binding a targetselected from the group consisting of IL-12 and IL-23.
 37. The bindingprotein according to claim 13, wherein the binding protein is capable ofbinding a target selected from the group consisting of IL-12 and IL-23.38. The binding protein according to claim 15, wherein the bindingprotein is capable of binding a target selected from the groupconsisting of IL-12 and IL-23.
 39. The binding protein according toclaim 18, wherein the binding protein is capable of binding a targetselected from the group consisting of IL-12 and IL-23.
 40. The bindingprotein according to claim 24, wherein the binding protein is capable ofbinding a target selected from the group consisting of IL-12 and IL-23.41. The binding protein according to claim 27, wherein the bindingprotein is capable of binding a target selected from the groupconsisting of IL-12 and IL-23.
 42. The binding protein according toclaim 32, wherein the binding protein is capable of modulating abiological function of a target selected from the group consisting ofIL-12 and IL-23.
 43. The binding protein according to claim 37, whereinthe binding protein is capable of modulating a biological function of atarget selected from the group consisting of IL-12 and IL-23.
 44. Thebinding protein according to claim 41, wherein the binding protein iscapable of modulating a biological function of a target selected fromthe group consisting of IL-12 and IL-23.
 45. The binding proteinaccording to claim 32, wherein the binding protein is capable ofneutralizing a target selected from the group consisting of IL-12 andIL-23.
 46. The binding protein according to claim 37, wherein thebinding protein is capable of neutralizing a target selected from thegroup consisting of IL-12 and IL-23.
 47. The binding protein accordingto claim 41, wherein the binding protein is capable of neutralizing atarget selected from the group consisting of IL-12 and IL-23.
 48. Thebinding protein according to claim 32, wherein said binding protein hasan on rate constant (Kon) to said target selected from the groupconsisting of: at least about 10²M⁻¹s⁻¹; at least about 10³M⁻¹s⁻¹; atleast about 10⁴M⁻¹s⁻¹; at least about 10⁵M⁻¹s⁻¹; and at least about10⁶M⁻¹s⁻¹, as measured by surface plasmon resonance.
 49. The bindingprotein according to claim 37, wherein said binding protein has an onrate constant (Kon) to said target selected from the group consistingof: at least about 10²M⁻¹s⁻¹; at least about 10³M⁻¹s⁻¹; at least about10⁴M⁻¹s⁻¹; at least about 10⁵M⁻¹s⁻¹; and at least about 10⁶M⁻¹s⁻¹, asmeasured by surface plasmon resonance.
 50. The binding protein accordingto claim 40, wherein said binding protein has an on rate constant (Kon)to said target selected from the group consisting of: at least about10²M⁻¹s⁻¹; at least about 10³M⁻¹s⁻¹; at least about 10⁴M⁻¹s⁻¹; at leastabout 10⁵M⁻¹s⁻¹; and at least about 10⁶M⁻¹s⁻¹, as measured by surfaceplasmon resonance.
 51. The binding protein according to claim 41,wherein said binding protein has an on rate constant (Kon) to saidtarget selected from the group consisting of: at least about 10²M⁻¹s⁻¹;at least about 10³M⁻¹s⁻¹; at least about 10⁴M⁻¹s⁻¹; at least about10⁵M⁻¹s⁻¹; and at least about 10⁶M⁻¹s⁻¹, as measured by surface plasmonresonance.
 52. The binding protein according to claim 32, wherein saidbinding protein has an off rate constant (Koff) to said target selectedfrom the group consisting of: at most about 10⁻³s⁻¹; at most about10⁻⁴s⁻¹; at most about 10⁻⁵s⁻¹; and at most about 10⁻⁶s⁻¹, as measuredby surface plasmon resonance.
 53. The binding protein according to claim37, wherein said binding protein has an off rate constant (Koff) to saidtarget selected from the group consisting of: at most about 10⁻³s⁻¹; atmost about 10⁻⁴s⁻¹; at most about 10⁻⁵s⁻¹; and at most about 10⁻⁶s⁻¹, asmeasured by surface plasmon resonance.
 54. The binding protein accordingto claim 40, wherein said binding protein has an off rate constant(Koff) to said target selected from the group consisting of: at mostabout 10⁻³s⁻¹; at most about 10⁻⁴s⁻¹; at most about 10⁻⁵s⁻¹; and at mostabout 10⁻⁶s⁻¹, as measured by surface plasmon resonance.
 55. The bindingprotein according to claim 41, wherein said binding protein has an offrate constant (Koff) to said target selected from the group consistingof: at most about 10⁻³s⁻¹; at most about 10⁻⁴s⁻¹; at most about 10⁻⁵s⁻¹;and at most about 10⁻⁶s⁻¹, as measured by surface plasmon resonance. 56.The binding protein according to claim 32, wherein said binding proteinhas a dissociation constant (K_(D)) to said target selected from thegroup consisting of: at most about 10⁻⁷ M; at most about 10⁻⁸ M; at mostabout 10⁻⁹ M; at most about 10⁻¹⁰ M; at most about 10⁻¹¹ M; at mostabout 10⁻¹² M; and at most 10⁻¹³M.
 57. The binding protein according toclaim 37, wherein said binding protein has a dissociation constant(K_(D)) to said target selected from the group consisting of: at mostabout 10⁻⁷ M; at most about 10⁻⁸ M; at most about 10⁻⁹ M; at most about10⁻¹⁰ M; at most about 10⁻¹¹ M; at most about 10⁻¹² M; and at most10⁻¹³M.
 58. The binding protein according to claim 40, wherein saidbinding protein has a dissociation constant (K_(D)) to said targetselected from the group consisting of: at most about 10⁻⁷ M; at mostabout 10⁻⁸ M; at most about 10⁻⁹ M; at most about 10⁻¹⁰ M; at most about10⁻¹¹ M; at most about 10⁻¹² M; and at most 10⁻¹³ M.
 59. The bindingprotein according to claim 41, wherein said binding protein has adissociation constant (K_(D)) to said target selected from the groupconsisting of: at most about 10⁻⁷ M; at most about 10⁻⁸ M; at most about10⁻⁹ M; at most about 10⁻¹⁰ M; at most about 10⁻¹¹ M; at most about10⁻¹² M; and at most 10⁻¹³ M.
 60. An antibody construct comprising abinding protein as described in claim 1, 2, or 3, said antibodyconstruct further comprising a linker polypeptide or an immunoglobulinconstant domain.
 61. The antibody construct according to claim 60,wherein said binding protein is selected from the group consisting of:an immunoglobulin molecule, a monoclonal antibody, a chimeric antibody,a CDR-grafted antibody, a humanized antibody, a Fab, a Fab′, a F(ab′)2,a Fv, a disulfide linked Fv, a scFv, a diabody, a multispecificantibody, a dual specific antibody, and a bispecific antibody.


62. The antibody construct according to claim 60, wherein said bindingprotein comprises a heavy chain immunoglobulin constant domain selectedfrom the group consisting of: a human IgM constant domain, a human IgG1constant domain, a human IgG2 constant domain, a human IgG3 constantdomain, a human IgG4 constant domain, a human IgE constant domain, and ahuman IgA constant domain.


63. The antibody construct according to claim 60, comprising animmunoglobulin constant domain having an amino acid sequence selectedfrom the group consisting of: SEQ ID NO:2 SEQ ID NO:3 SEQ ID NO:4 andSEQ ID NO:5.
 64. An antibody conjugate comprising an antibody constructaccording to claim 60, said antibody conjugate further comprising anagent selected from the group consisting of: an immunoadhensionmolecule, an imaging agent, a therapeutic agent, and a cytotoxic agent.65. The antibody conjugate according to claim 64, wherein said agent isan imaging agent selected from the group consisting of a radiolabel, anenzyme, a fluorescent label, a luminescent label, a bioluminescentlabel, a magnetic label, and biotin.
 66. The antibody conjugateaccording to claim 64, wherein said imaging agent is a radiolabelselected from the group consisting of: ³H, ¹⁴C, ³⁵S, ⁹⁰Y, ⁹⁹Tc, ¹¹¹In,¹²⁵I, ¹³¹I, ¹⁷⁷Lu, ¹⁶⁶Ho, and ¹⁵³Sm.
 67. The antibody conjugateaccording to claim 64, wherein said agent is a therapeutic or cytotoxicagent selected from the group consisting of: an anti-metabolite, analkylating agent, an antibiotic, a growth factor, a cytokine, ananti-angiogenic agent, an anti-mitotic agent, an anthracycline, toxin,and an apoptotic agent.
 68. The antibody construct according to claim62, wherein said binding protein possesses a human glycosylationpattern.
 69. The antibody conjugate according to claim 64, wherein saidbinding protein possesses a human glycosylation pattern.
 70. The bindingprotein according to claim 1, wherein said binding protein exists as acrystal.
 71. The antibody construct according to claim 60, wherein saidantibody construct exists as a crystal.
 72. The antibody conjugateaccording to claim 64, wherein said antibody conjugate exists as acrystal.
 73. The binding protein according to claim 70, wherein saidcrystal is a carrier-free pharmaceutical controlled release crystal. 74.The antibody construct according to claim 71, wherein said crystal is acarrier-free pharmaceutical controlled release crystal.
 75. The antibodyconjugate according to claim 72, wherein said crystal is a carrier-freepharmaceutical controlled release crystal.
 76. The binding proteinaccording to claim 70, wherein said binding protein has a greater halflife in vivo than the soluble counterpart of said binding protein. 77.The antibody construct according to claim 71, wherein said antibodyconstruct has a greater half life in vivo than the soluble counterpartof said antibody construct.
 78. The antibody conjugate according toclaim 72, wherein said antibody conjugate has a greater half life invivo than the soluble counterpart of said antibody conjugate.
 79. Thebinding protein according to claim 70, wherein said binding proteinretains biological activity.
 80. The antibody construct according toclaim 71, wherein said antibody construct retains biological activity.81. The antibody conjugate according to claim 72, wherein said antibodyconjugate retains biological activity.
 82. A binding protein describedin claim 1 produced according to a method comprising culturing a hostcell in culture medium under conditions sufficient to produce saidbinding protein wherein said host cell comprises a vector said vectorcomprising a nucleic acid encoding said binding protein.
 83. Acomposition for the release of a binding protein said compositioncomprising: (a) a formulation, wherein said formulation comprises acrystallized binding protein, according to claim 70, and an ingredient;and (b) at least one polymeric carrier.
 84. The composition according toclaim 83, wherein said polymeric carrier is a polymer selected from oneor more of the group consisting of: poly (acrylic acid), poly(cyanoacrylates), poly (amino acids), poly (anhydrides), poly(depsipeptide), poly (esters), poly (lactic acid), poly(lactic-co-glycolic acid) or PLGA, poly (b-hydroxybutryate), poly(caprolactone), poly (dioxanone); poly (ethylene glycol), poly((hydroxypropyl)methacrylamide, poly [(organo)phosphazene], poly (orthoesters), poly (vinyl alcohol), poly (vinylpyrrolidone), maleicanhydride-alkyl vinyl ether copolymers, pluronic polyols, albumin,alginate, cellulose and cellulose derivatives, collagen, fibrin,gelatin, hyaluronic acid, oligosaccharides, glycaminoglycans, sulfatedpolyeaccharides, blends and copolymers thereof.
 85. The compositionaccording to claim 83, wherein said ingredient is selected from thegroup consisting of albumin, sucrose, trehalose, lactitol, gelatin,hydroxypropyl-β-cyclodextrin, methoxypolyethylene glycol andpolyethylene glycol.
 86. A pharmaceutical composition comprising thebinding protein according to claim 1 or claim 70, and a pharmaceuticallyacceptable carrier.
 87. The pharmaceutical composition of claim 86wherein said pharmaceutically acceptable carrier functions as adjuvantuseful to increase the absorption, or dispersion of said bindingprotein.
 88. The pharmaceutical composition of claim 87 wherein saidadjuvant is hyaluronidase.
 89. The pharmaceutical composition of claim86 further comprising at least one additional therapeutic agent fortreating a disorder in which IL-12 activity is detrimental.
 90. Thepharmaceutical composition of claim 86 comprising an additional agent,wherein said additional agent is selected from the group consisting of:Therapeutic agent, imaging agent, cytotoxic agent, angiogenesisinhibitors; kinase inhibitors; co-stimulation molecule blockers;adhesion molecule blockers; anti-cytokine antibody or functionalfragment thereof, methotrexate; cyclosporin; rapamycin; FK506;detectable label or reporter; a TNF antagonist; an antirheumatic; amuscle relaxant, a narcotic, a non-steroid anti-inflammatory drug(NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, aneuromuscular blocker, an antimicrobial, an antipsoriatic, acorticosteriod, an anabolic steroid, an erythropoietin, an immunization,an immunoglobulin, an immunosuppressive, a growth hormone, a hormonereplacement drug, a radiopharmaceutical, an antidepressant, anantipsychotic, a stimulant, an asthma medication, a beta agonist, aninhaled steroid, an epinephrine or analog, a cytokine, and a cytokineantagonist.
 91. A method for reducing human IL-12 activity comprisingcontacting human IL-12 with the binding protein of claim 1 such thathuman IL-12 activity is reduced.
 92. The binding protein comprising anantigen binding domain according to claim 1, said binding proteincapable of binding the p40 subunit of human IL-12, wherein said bindingprotein has an on rate constant (Kon) to said target selected from thegroup consisting of: between 10²M⁻¹s⁻¹ to 10³M⁻¹s⁻¹; between 10³M⁻¹s⁻¹to 10⁴M⁻¹s⁻¹; between 10⁴M⁻¹s⁻¹ to 10⁵M⁻¹s⁻¹; and between 10⁵M⁻¹s⁻¹ to10⁶M⁻¹s⁻¹.
 93. The binding protein according to claim 92, where in thesaid binding protein has an on rate constant (Kon) to said targetselected from the group consisting of: at least about 1×10⁵M⁻¹s⁻¹, atleast about 1.2×10⁵M⁻¹s⁻¹, 3.2×10⁵M⁻¹s⁻¹, at least about 3.5×10⁵M⁻¹s⁻¹,at least about 4.8×10⁵M⁻¹s⁻¹, at least about 5.3×10⁵M⁻¹s⁻¹, at leastabout 7.4×10⁵M⁻¹s⁻¹, at least about 7.8×10⁵M⁻¹s⁻¹, at least about8.0×10⁵M⁻¹s⁻¹, at least about 1.3×10⁶M⁻¹s⁻¹, at least about1.6×10⁶M⁻¹s⁻¹, at least about 1.6×10⁶M⁻¹s⁻¹ and at least about1.7×10⁶M⁻¹s⁻¹.
 94. The binding protein comprising an antigen bindingdomain according to claim 1, said binding protein capable of binding thep40 subunit of human IL-12, wherein said binding protein has an off rateconstant (Koff) to said target selected from the group consisting of:10⁻³s⁻¹ to 10⁻⁴s⁻¹; of 10⁴s⁻¹ to 10⁻⁵s⁻¹; and of 10⁻⁵s⁻¹ to 10⁻⁶s⁻¹, asmeasured by surface plasmon resonance.
 95. The binding protein accordingto claim 94, wherein said binding protein has an off rate constant(Koff) to said target selected from the group consisting of: at mostabout 1×10⁻³s⁻¹, at most about 1.24×10⁻³s⁻¹, at most about 1.5×10⁻⁴s⁻¹;3×10⁴s⁻¹, at most about 1×10⁻⁵s⁻¹; 8×10⁻⁵s⁻¹, at most about 1×10⁻⁶s⁻¹and at most about 7.6×10⁻⁶s⁻¹, as measured by surface plasmon resonance.96. The binding protein comprising an antigen binding domain accordingto claim 1, said binding protein capable of binding the p40 subunit ofhuman IL-12, wherein said binding protein has a dissociation constant(K_(D)) to said target selected from the group consisting of: 10⁻⁷ M to10⁻⁸ M; of 10⁻⁸ M to 10⁻⁹ M; of 10⁻⁹ M to 10⁻¹⁰ M; of 10⁻¹⁰ to 10⁻¹¹ M;of 10⁻¹¹ M to 10⁻¹² M; and of 10⁻¹² to M 10⁻¹³ M.
 97. The bindingprotein according to claim 96, wherein said binding protein has adissociation constant (K_(D)) to said target selected from the groupconsisting of: at most about 1.3×10⁻⁹ M, at most about 2×10⁻¹⁰ M, atmost about 4×10⁻¹⁰ M; at most about 7.5×10⁻¹⁰ M, at most about7.6×10⁻¹⁰M, at most about 1×10⁻¹¹ M; at most about 2.4×10⁻¹¹ M and atmost about 4.6×10⁻¹¹M.
 98. The binding protein according to claim 96,wherein the binding protein is capable of neutralizing a target selectedfrom the group consisting of IL-12 and IL-23.
 99. The binding proteinaccording to claim 96, wherein said binding protein is selected from thegroup consisting of: an immunoglobulin molecule, a monoclonal antibody,a chimeric antibody, a CDR-grafted antibody, a humanized antibody, aFab, a Fab′, a F(ab′)2, a Fv, a disulfide linked Fv, a scFv, a diabody,a multispecific antibody, a dual specific antibody, and a bispecificantibody.
 100. The binding protein according to claim 99, wherein saidbinding protein is a humanized antibody.
 101. A pharmaceuticalcomposition comprising the antibody construct according to claim 60 orclaim 71, and a pharmaceutically acceptable carrier.
 102. Thepharmaceutical composition of claim 101 wherein said pharmaceuticallyacceptable carrier functions as adjuvant useful to increase theabsorption, or dispersion of said binding protein.
 103. Thepharmaceutical composition of claim 102 wherein said adjuvant ishyaluronidase.
 104. The pharmaceutical composition of claim 101 furthercomprising at least one additional therapeutic agent for treating adisorder in which IL-12 activity is detrimental.
 105. The pharmaceuticalcomposition of claim 101 comprising an additional agent, wherein saidadditional agent is selected from the group consisting of: Therapeuticagent, imaging agent, cytotoxic agent, angiogenesis inhibitors; kinaseinhibitors; co-stimulation molecule blockers; adhesion moleculeblockers; anti-cytokine antibody or functional fragment thereof,methotrexate; cyclosporin; rapamycin; FK506; detectable label orreporter; a TNF antagonist; an antirheumatic; a muscle relaxant, anarcotic, a non-steroid anti-inflammatory drug (NSAID), an analgesic, ananesthetic, a sedative, a local anesthetic, a neuromuscular blocker, anantimicrobial, an antipsoriatic, a corticosteriod, an anabolic steroid,an erythropoietin, an immunization, an immunoglobulin, animmunosuppressive, a growth hormone, a hormone replacement drug, aradiopharmaceutical, an antidepressant, an antipsychotic, a stimulant,an asthma medication, a beta agonist, an inhaled steroid, an epinephrineor analog, a cytokine, and a cytokine antagonist.
 106. A pharmaceuticalcomposition comprising the antibody conjugate according to claim 64 orclaim 72, and a pharmaceutically acceptable carrier.
 107. Thepharmaceutical composition of claim 106 wherein said pharmaceuticallyacceptable carrier functions as adjuvant useful to increase theabsorption, or dispersion of said binding protein.
 108. Thepharmaceutical composition of claim 107 wherein said adjuvant ishyaluronidase.
 109. The pharmaceutical composition of claim 106 furthercomprising at least one additional therapeutic agent for treating adisorder in which IL-12 activity is detrimental.
 110. The pharmaceuticalcomposition of claim 106 comprising an additional agent, wherein saidadditional agent is selected from the group consisting of: Therapeuticagent, imaging agent, cytotoxic agent, angiogenesis inhibitors; kinaseinhibitors; co-stimulation molecule blockers; adhesion moleculeblockers; anti-cytokine antibody or functional fragment thereof,methotrexate; cyclosporin; rapamycin; FK506; detectable label orreporter; a TNF antagonist; an antirheumatic; a muscle relaxant, anarcotic, a non-steroid anti-inflammatory drug (NSAID), an analgesic, ananesthetic, a sedative, a local anesthetic, a neuromuscular blocker, anantimicrobial, an antipsoriatic, a corticosteriod, an anabolic steroid,an erythropoietin, an immunization, an immunoglobulin, animmunosuppressive, a growth hormone, a hormone replacement drug, aradiopharmaceutical, an antidepressant, an antipsychotic, a stimulant,an asthma medication, a beta agonist, an inhaled steroid, an epinephrineor analog, a cytokine, and a cytokine antagonist.
 111. The bindingprotein according to claim 2, wherein said binding protein comprises atleast one variable domain having an amino acid sequence selected fromthe group consisting of: SEQ ID NO.:71 SEQ ID NO.:72 SEQ ID NO.:73 SEQID NO.:74 SEQ ID NO.:75 SEQ ID NO.:76 SEQ ID NO.:77 and SEQ ID NO.:78.


112. The binding protein according to claim 111 wherein said bindingprotein comprises two variable domains, wherein said two variabledomains have amino acid sequences selected from the group consisting of:SEQ ID NO.:71 & SEQ ID NO.:72, SEQ ID NO.:73 & SEQ ID NO.:74, SEQ IDNO.:75 & SEQ ID NO.:76, and SEQ ID NO.:77 & SEQ ID NO.:78.
 113. Thebinding protein according to claim 2, wherein said binding proteincomprises at least one variable domain having an amino acid sequenceselected from the group consisting of: SEQ ID NO.:88 SEQ ID NO.:89 SEQID NO.:90 SEQ ID NO.:91 SEQ ID NO.:104 SEQ ID NO.:105 SEQ ID NO.:106 SEQID NO.:107 SEQ ID NO.:108 and SEQ ID NO.:109.


114. The binding protein according to claim 113 wherein said bindingprotein comprises two variable domains, wherein said two variabledomains have amino acid sequences selected from the group consisting of:SEQ ID NO.:88 & SEQ ID NO.:89, SEQ ID NO.:90 & SEQ ID NO.:91, SEQ IDNO.:104 & SEQ ID NO.:105, SEQ ID NO.:106 & SEQ ID NO.:107, and SEQ IDNO.:108 & SEQ ID NO.:109.
 115. The binding protein according to claim 2,wherein the binding protein is capable of binding a target selected fromthe group consisting of IL-12 and IL-23.
 116. The binding proteinaccording to claim 2, wherein the binding protein is capable ofmodulating a biological function of a target selected from the groupconsisting of IL-12 and IL-23.
 117. The binding protein according toclaim 2, wherein the binding protein is capable of neutralizing a targetselected from the group consisting of IL-12 and IL-23.